The Concise Guide to Pharmacology 2019/20:Transporters by  et al.
                                                                    
University of Dundee
The Concise Guide to Pharmacology 2019/20
CGTP Collaborators; Alexander, Stephen P. H.; Kelly, Eamonn; Mathie, Alistair; Peters, John
A.; Veale, Emma L.
Published in:
British Journal of Pharmacology
DOI:
10.1111/bph.14753
Publication date:
2019
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
CGTP Collaborators, Alexander, S. P. H., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., ... Davies, J. A. (2019).
The Concise Guide to Pharmacology 2019/20: Transporters. British Journal of Pharmacology, 176 (S1), S397-
S493. https://doi.org/10.1111/bph.14753
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 07. Dec. 2019

S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters
Stephen PH Alexander1 , Eamonn Kelly2, Alistair Mathie3 , John A Peters4 , Emma L Veale3 ,
Jane F Armstrong5 , Elena Faccenda5 , Simon D Harding5 , Adam J Pawson5 , Joanna L Sharman5 ,
Christopher Southan5 , Jamie A Davies5 and CGTP Collaborators
1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK
2School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK
3Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue,
Chatham Maritime, Chatham, Kent, ME4 4TB, UK
4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK
5Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK
Abstract
The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human
drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org),
which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared
to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at
http://onlinelibrary.wiley.com/doi/10.1111/bph.14753. Transporters are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled re-
ceptors, ion channels, nuclear hormone receptors, catalytic receptors and enzymes. These are presented with nomenclature guidance and summary information on the best available pharmacological
tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to
mid-2019, and supersedes data presented in the 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the International
Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classiﬁcation (NC-IUPHAR), therefore, providing ofﬁcial IUPHAR classiﬁcation and nomenclature for human
drug targets, where appropriate.
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Overview: The majority of biological solutes are charged organic
or inorganic molecules. Cellular membranes are hydrophobic
and, therefore, effective barriers to separate them allowing the for-
mation of gradients, which can be exploited, for example, in the
generation of energy. Membrane transporters carry solutes across
cell membranes, which would otherwise be impermeable to them.
The energy required for active transport processes is obtained from
ATP turnover or by exploiting ion gradients.
ATP-driven transporters can be divided into three major classes: P-
type ATPases; F-type or V-type ATPases and ATP-binding cassette
transporters. The ﬁrst of these, P-type ATPases, aremultimeric pro-
teins, which transport (primarily) inorganic cations. The second,
F-type or V-type ATPases, are proton-coupled motors, which can
function either as transporters or as motors. Last, are ATP-binding
cassette transporters, heavily involved in drug disposition as well
as transporting endogenous solutes.
The second largest family of membrane proteins in the human
genome, after the G protein-coupled receptors, are the SLC so-
lute carrier family. Within the solute carrier family, there are a
great variety of solutes transported, from simple inorganic ions to
amino acids and sugars to relatively complex organic molecules
like haem. The solute carrier family includes 65 families of almost
400 members. Many of these overlap in terms of the solutes that
they carry. For example, amino acids accumulation is mediated
by members of the SLC1, SLC3/7, SLC6, SLC15, SLC16, SLC17,
SLC32, SLC36, SLC38 and SLC43 families. Further members of
the SLC superfamily regulate ion ﬂuxes at the plasma membrane,
or solute transport into and out of cellular organelles. Some SLC
familymembers remain orphan transporters, in asmuch as a phys-
iological function has yet to be dtermined. Within the SLC super-
family, there is an abundance in diversity of structure. Two fami-
lies (SLC3 and SLC7) only generate functional transporters as het-
eromeric partners, where one partner is a single TM domain pro-
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tein. Membrane topology predictions for other families suggest
3,4,6,7,8,9,10,11,12,13 or 14 TM domains. The SLC transporters
include members which function as antiports, where solute move-
ment in one direction is balanced by a solute moving in the reverse
direction. Symports allow concentration gradients of one solute to
allow co-transport of a second solute across a membrane. A third,
relatively small group are equilibrative transporters, which allow
solutes to travel across membranes down their concentration gra-
dients. A more complex family of transporters, the SLC27 fatty
acid transporters also express enzymatic function. Many of the
transporters also express electrogenic properties of ion channels.
Family structure
S399 ATP-binding cassette transporter family
S399 ABCA subfamily
S401 ABCB subfamily
S403 ABCC subfamily
S404 ABCD subfamily of peroxisomal ABC transporters
S405 ABCG subfamily
S406 F-type and V-type ATPases
S406 F-type ATPase
S407 V-type ATPase
S407 P-type ATPases
S407 Na+/K+-ATPases
S408 Ca2+-ATPases
S408 H /K -ATPases+ +
S408 Cu+-ATPases
S409 Phospholipid-transporting ATPases
S409 SLC superfamily of solute carriers
S410 SLC1 family of amino acid transporters
S410 Glutamate transporter subfamily
S412 Alanine/serine/cysteine transporter subfamily
S413 SLC2 family of hexose and sugar alcohol transporters
S413 Class I transporters
S414 Class II transporters
S415 Proton-coupled inositol transporter
S415 SLC3 and SLC7 families of heteromeric amino acid
transporters (HATs)
S415 SLC3 family
S416 SLC7 family
S417 SLC4 family of bicarbonate transporters
S417 Anion exchangers
S418 Sodium-dependent HCO3
- transporters
S418 SLC5 family of sodium-dependent glucose transporters
S419 Hexose transporter family
S420 Choline transporter
S421 Sodium iodide symporter, sodium-dependent
multivitamin transporter and sodium-coupled
monocarboxylate transporters
S422 Sodium myo-inositol cotransporter transporters
S423 SLC6 neurotransmitter transporter family
S423 Monoamine transporter subfamily
S424 GABA transporter subfamily
S425 Glycine transporter subfamily
S427 Neutral amino acid transporter subfamily
S428 SLC8 family of sodium/calcium exchangers
S429 SLC9 family of sodium/hydrogen exchangers
S429 SLC10 family of sodium-bile acid co-transporters
S431 SLC11 family of proton-coupled metal ion transporters
S431 SLC12 family of cation-coupled chloride transporters
S433 SLC13 family of sodium-dependent sulphate/carboxylate
transporters
S434 SLC14 family of facilitative urea transporters
S435 SLC15 family of peptide transporters
S437 SLC16 family of monocarboxylate transporters
S438 SLC17 phosphate and organic anion transporter family
S438 Type I sodium-phosphate co-transporters
S439 Sialic acid transporter
S439 Vesicular glutamate transporters (VGLUTs)
S440 Vesicular nucleotide transporter
S440 SLC18 family of vesicular amine transporters
S442 SLC19 family of vitamin transporters
S443 SLC20 family of sodium-dependent phosphate
transporters
S443 SLC22 family of organic cation and anion transporters
S444 Organic cation transporters (OCT)
S445 Organic zwitterions/cation transporters (OCTN)
S446 Organic anion transporters (OATs)
S446 Urate transporter
– Orphan or poorly characterized
SLC22 family members
S447 Atypical SLC22B subfamily
S448 SLC23 family of ascorbic acid transporters
S449 SLC24 family of sodium/potassium/calcium exchangers
S450 SLC25 family of mitochondrial transporters
S450 Mitochondrial di- and tri-carboxylic acid
transporter subfamily
S451 Mitochondrial amino acid transporter subfamily
S452 Mitochondrial phosphate transporters
S452 Mitochondrial nucleotide transporter subfamily
S453 Mitochondrial uncoupling proteins
S454 Miscellaneous SLC25 mitochondrial transporters
S454 SLC26 family of anion exchangers
S454 Selective sulphate transporters
S455 Chloride/bicarbonate exchangers
S455 Anion channels
S456 Other SLC26 anion exchangers
S457 SLC27 family of fatty acid transporters
S458 SLC28 and SLC29 families of nucleoside transporters
S458 SLC28 family
S459 SLC29 family
S461 SLC30 zinc transporter family
S461 SLC31 family of copper transporters
S462 SLC32 vesicular inhibitory amino acid transporter
S463 SLC33 acetylCoA transporter
S464 SLC34 family of sodium phosphate co-transporters
S465 SLC35 family of nucleotide sugar transporters
S466 SLC36 family of proton-coupled amino acid transporters
S468 SLC37 family of phosphosugar/phosphate exchangers
S468 SLC38 family of sodium-dependent neutral
amino acid transporters
S469 System A-like transporters
S469 System N-like transporters
S470 Orphan SLC38 transporters
S470 SLC39 family of metal ion transporters
S471 SLC40 iron transporter
S472 SLC41 family of divalent cation transporters
S473 SLC42 family of Rhesus glycoprotein ammonium
transporters
S473 SLC43 family of large neutral amino acid transporters
S474 SLC44 choline transporter-like family
S475 SLC45 family of putative sugar transporters
S475 SLC46 family of folate transporters
S477 SLC47 family of multidrug and toxin extrusion
transporters
S477 SLC48 heme transporter
S478 SLC49 family of FLVCR-related heme transporters
S479 SLC50 sugar transporter
S479 SLC51 family of steroid-derived molecule transporters
S480 SLC52 family of riboﬂavin transporters
S481 SLC53 Phosphate carriers
S481 SLC54 Mitochondrial pyruvate carriers
S482 SLC55 Mitochondrial cation/proton exchangers
S482 SLC56 Sideroﬂexins
S483 SLC57 NiPA-like magnesium transporter family
S483 SLC58 MagT-like magnesium transporter family
S484 SLC59 Sodium-dependent lysophosphatidylcholine
symporter family
S484 SLC60 Glucose transporters
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S485 SLC61 Molybdate transporter family
S485 SLC62 Pyrophosphate transporters
S486 SLC63 Sphingosine-phosphate transporters
S486 SLC64 Golgi Ca2+/H+ exchangers
S487 SLC65 NPC-type cholesterol transporters
S488 SLCO family of organic anion transporting polypeptides
ATP-binding cassette transporter family
Transporters → ATP-binding cassette transporter family
Overview: ATP-binding cassette transporters are ubiquitous
membrane proteins characterized by active ATP-dependent move-
ment of a range of substrates, including ions, lipids, peptides,
steroids. Individual subunits are typically made up of two groups
of 6TM-spanning domains, with two nucleotide-binding domains
(NBD). Themajority of eukaryotic ABC transporters are ‘full’ trans-
porters incorporating both TM and NBD entities. Some ABCs, no-
tably the ABCD and ABCG families are half-transporters with only
a single membrane spanning domain and one NBD, and are only
functional as homo- or heterodimers. Eukaryotic ABC transporters
convey substrates from the cytoplasm, either out of the cell or into
intracellular organelles. Their role in the efﬂux of exogenous com-
pounds, notably chemotherapeutic agents, has led to considerable
interest.
ABCA subfamily
Transporters → ATP-binding cassette transporter family → ABCA subfamily
Overview: To date, 12 members of the human ABCA subfamily are identiﬁed. They share a high degree of sequence conservation and have been mostly related with lipid trafﬁcking in a wide range
of body locations. Mutations in some of these genes have been described to cause severe hereditary diseases related with lipid transport, such as fatal surfactant deﬁciency or harlequin ichthyosis. In
addition, most of them are hypothesized to participate in the subcellular sequestration of drugs, thereby being responsible for the resistance of several carcinoma cell lines against drug treatment [8].
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Nomenclature ABCA1 ABCA3 ABCA4
Common abbreviation ABC1, CERP ABC3, ABCC ABCR
HGNC, UniProt ABCA1, O95477 ABCA3, Q99758 ABCA4, P78363
Selective ligands bihelical apoA-I mimetic peptide 5A (Binding) [567] – –
Selective inhibitors probucol [195, 676] – –
Comments – Loss-of-function mutations are associated with pulmonary
surfactant deﬁciency
Retinal-speciﬁc transporter of N-retinylPE; loss-of-function
mutations are associated with childhood-onset Stargardt
disease, a juvenile onset macular degenerative disease. The
earlier onset disease is often associated with the more severe
and deleterious ABCA4 variants [216].
ABCA4 facilitates the clearance of all-trans-retinal from
photoreceptor disc membranes following photoexcitation.
ABCA4 can also transport
N-11-cis-retinylidene-phosphatidylethanolamine, the
Schiff-base adduct of 11-cis-retinal; loss of function mutation
cause a buildup of lipofuscin, atrophy of the central retina,
and severe progressive loss in vision [512].
Nomenclature ABCA5 ABCA6 ABCA7 ABCA12
HGNC, UniProt ABCA5, Q8WWZ7 ABCA6, Q8N139 ABCA7, Q8IZY2 ABCA12, Q86UK0
Comments ABCA5 is a lysosomal protein whose loss of
function compromises integrity of lysosomes
and leads to intra-endolysosomal
accumulation of cholesterol. It has recently
been associated with Congenital Generalized
Hypertrichosis Terminalis (CGHT), a hair
overgrowth syndrome, in a patient with a
mutation in ABCA5 that signiﬁcantly decreased
its expression [147].
A recent genome wide association study
identiﬁed an ABCA6 variant associated with
cholesterol levels [636].
Genome wide association studies identify
ABCA7 variants as associated with Alzheimer’s
Disease [294].
Reported to play a role in skin ceramide
formation [727]. A recent study shows that
ABCA12 expression also impacts cholesterol
efﬂux from macrophages. ABCA12 is
postulated to associate with ABCA1 and LXR
beta, and stabilize expression of ABCA1.
ABCA12 deﬁciency causes decreased
expression of Abca1, Abcg1 and Nr1h2 [215].
Comments: A number of structural analogues are not found in man: Abca14 (ENSMUSG00000062017); Abca15 (ENSMUSG00000054746); Abca16 (ENSMUSG00000051900) and Abca17
(ENSMUSG00000035435).
Searchable database: http://www.guidetopharmacology.org/index.jsp ABCA subfamily S400
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14753/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology (2019) 176, S397–S493
ABCB subfamily
Transporters → ATP-binding cassette transporter family → ABCB subfamily
Overview: The ABCB subfamily is composed of four full transporters and two half transporters. This is the only human subfamily to have both half and full types of transporters. ABCB1 was discovered
as a protein overexpressed in certain drug resistant tumor cells. It is expressed primarily in the blood brain barrier and liver and is thought to be involved in protecting cells from toxins. Cells that
overexpress this protein exhibit multi-drug resistance [142].
Nomenclature ABCB1 ABCB2 ABCB3
Common abbreviation MDR1, PGP1 TAP1 TAP2
HGNC, UniProt ABCB1, P08183 TAP1, Q03518 TAP2, Q03519
Comments Responsible for the cellular export of many therapeutic drugs. The mouse and rat have two
Abcb1 genes (gene names; Abcb1a and Abcb1b) while the human has only the one gene,
ABCB1.
Endoplasmic reticulum peptide transporter is a hetero-dimer composed of the two
half-transporters, TAP1 (ABCB2) and TAP2 (ABCB3). The transporter shuttles peptides into
the endoplasmic reticulum where they are loaded onto major histocompatibility complex
class I (MHCI) molecules via the macromoldecular peptide-loading complex and are
eventually presented at the cell surface, attributing to TAP an important role in the adaptive
immune response [568].
Nomenclature ABCB4 ABCB5 ABCB6
Common abbreviation PGY3 – MTABC3
HGNC, UniProt ABCB4, P21439 ABCB5, Q2M3G0 ABCB6, Q9NP58
Comments Transports phosphatidylcholine from intracellular to
extracellular face of the hepatocyte canalicular membrane
[484]. Heterozygous ABCB4 variants contribute to mild
cholestatic phenotypes, while homozygous deﬁciency leads
to Progressive Intrahepatic Familial Cholestasis (PFIC) Type
3, and increased risk of cholesterol gallstones [291].
A drug efﬂux transporter that has been shown to identify
cancer stem-like cells in diverse human malignancies, and is
also identiﬁed as a limbal stem cell that is required for
corneal development and repair [377, 670].
Putative mitochondrial porphyrin transporter [374]; other
subcellular localizations are possible, such as the plasma
membrane, as a speciﬁc determinant of the Langereis blood
group system [285]. Loss of Abcb6 expression in mice leads
to decreased expression and activity of CYP450 [103].
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Nomenclature ABCB7 ABCB8 ABCB9
Common abbreviation ABC7 MABC1 TAPL
HGNC, UniProt ABCB7, O75027 ABCB8, Q9NUT2 ABCB9, Q9NP78
Comments Mitochondrial; reportedly essential for haematopoiesis
[501]. Deletion studies in mice demonstrate that Abcb7 is
essential in mammals and substantiate a role for
mitochondria in cytosolic Fe-S cluster assembly [502].
Mitochondrial; suggested to play a role in chemoresistance
of melanoma [177]. Cardiac speciﬁc deletion of Abcb8 leads
to cardiomyopathy and accumulation of mitochondrial iron,
and is thus thought to modulate mitochondrial iron export
[305].
A homodimeric transport complex that translocates cytosolic
peptides into the lumen of lysosome for degradation [145].
Nomenclature ABCB10 ABCB11
Common abbreviation MTABC2 ABC16
HGNC, UniProt ABCB10, Q9NRK6 ABCB11, O95342
Ligands – glycochenodeoxycholic acid (Binding) (pKi 5.2) [89]
Comments Mitochondrial location; the ﬁrst human ABC transporter to have a crystal structure reported
[575]. ABCB10 is important in early steps of heme synthesis in the heart and is required for
normal red blood cell development [45, 606].
Loss-of-function mutations are associated with progressive familial intrahepatic cholestasis
type 2 [590]. ATP-dependent transport of bile acids into the conﬁnes of the canalicular
space by ABCB11 (BSEP) generates an osmotic gradient and thereby, bile ﬂow. Mutations in
BSEP that decrease its function or expression cause Progressive Familial Cholestasis Type 2
(PFIC2), which in severe cases, can be fatal in the absence of a liver transplant. Drugs that
inhibit BSEP function with IC50 values less than 25 μM [450] or decrease its expression
[228] can cause Drug-Induced Liver Injury (DILI) in the form of cholestatic liver injury.
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ABCC subfamily
Transporters → ATP-binding cassette transporter family → ABCC subfamily
Overview: Subfamily ABCC contains thirteen members and nine of these transporters are referred to as Multidrug Resistance Proteins (MRPs). MRP proteins are found throughout nature and mediate
many important functions. They are known to be involved in ion transport, toxin secretion, and signal transduction [142].
Nomenclature ABCC1 ABCC2 ABCC3
Common abbreviation MRP1 MRP2, cMOAT MRP3
HGNC, UniProt ABCC1, P33527 ABCC2, Q92887 ABCC3, O15438
Inhibitors WP814 (pKi 7.2) [507] PAK-104P (pKi 5.4) [111] –
Comments Exhibits a broad substrate speciﬁcity [37], including LTC4
(Km 97 nM [394]) and estradiol-17β-glucuronide [595].
Loss-of-function mutations are associated with
Dubin-Johnson syndrome, in which plasma levels of
conjugated bilirubin are elevated (OMIM: 237500).
Transports conjugates of glutathione, sulfate or glucuronide
[67]
Nomenclature ABCC4 ABCC5 ABCC6
Common abbreviation MRP4 MRP5 MRP6
HGNC, UniProt ABCC4, O15439 ABCC5, O15440 ABCC6, O95255
Inhibitors estradiol disulfate (pIC50 6.7) [702] compound 2 (pKi 7.2) [541], sildenaﬁl (pKi 5.9) [541] –
Comments Although reported to facilitate cellular cyclic nucleotide
export, this role has been questioned [67]; reported to
export prostaglandins in a manner sensitive to NSAIDS [523]
Although reported to facilitate cellular cyclic nucleotide
export, this role has been questioned [67]
Loss-of-function mutations in ABCC6 are associated with
pseudoxanthoma elasticum (OMIM: 264800).
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Nomenclature ATP-binding cassette, sub-family C (CFTR/MRP), member 8 ABCC9 ABCC11
Systematic nomenclature ABCC8 – –
Common abbreviation SUR1 SUR2 MRP8
HGNC, UniProt ABCC8, Q09428 ABCC9, O60706 ABCC11, Q96J66
Selective inhibitors repaglinide (pIC50 7) [680] – –
Comments The sulfonyurea drugs (acetohexamide, tolbutamide and
glibenclamide) appear to bind sulfonylurea receptors and it
has been shown experimentally that tritiated glibenclamide
can be used to pull out a 140 kDa protein identiﬁed as
SUR1 (now known as ABCC8) [522]. SUR2 (ABCC9) has
also been identiﬁed [307]. However, this is not the full
mechanism of action and the functional channel has been
characterised as a hetero-octamer formed by four SUR and
four Kir6.2 subunits, with the Kir6.2 subunits forming the
core ion pore and the SUR subunits providing the
regulatory properties [440]. Co-expression of Kir6.2 with
SUR1, reconstitutes the ATP-dependent K+ conductivity
inhibited by the sulfonyureas [307].
Associated with familial atrial ﬁbrillation, Cantu syndrome
and familial isolated dilated cardiomyopathy.
Single nucleotide polymorphisms distinguish wet vs. dry
earwax (OMIM: 117800); an association between earwax
allele and breast cancer risk is reported in Japanese but not
European populations.
Comments: ABCC7 (also known as CFTR, a 12TM ABC
transporter-type protein, is a cAMP-regulated epithelial cell mem-
brane Cl- channel involved in normal ﬂuid transport across var-
ious epithelia and can be viewed in the Chloride channels sec-
tion of the Guide. ABCC8 (ENSG00000006071, also known as
SUR1, sulfonylurea receptor 1) and ABCC9 (ENSG00000069431,
also known as SUR2, sulfonylurea receptor 2) are unusual in that
they lack transport capacity but regulate the activity of particu-
lar K+ channels (Kir6.1-6.2), conferring nucleotide sensitivity to
these channels to generate the canonical KATP channels. ABCC13
(ENSG00000155288) is a possible pseudogene.
ABCD subfamily of peroxisomal ABC transporters
Transporters → ATP-binding cassette transporter family → ABCD subfamily of peroxisomal ABC transporters
Overview: Peroxisomes are indispensable organelles in higher eukaryotes. They are essential for the oxidation of a wide variety of metabolites, which include: saturated, monounsaturated and
polyunsaturated fatty acids, branched-chain fatty acids, bile acids and dicarboxylic acids [348]. However, the peroxisomal membrane forms an impermeable barrier to these metabolites. The mammalian
peroxisomal membrane harbours three ATP-binding cassette (ABC) half-transporters, which act as homo- and/or heterodimers to transport these metabolites across the peroxisomal membrane.
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Nomenclature ABCD1 ABCD2 ABCD3
Common abbreviation ALDP ALDR PMP70
HGNC, UniProt ABCD1, P33897 ABCD2, Q9UBJ2 ABCD3, P28288
Comments Transports coenzyme A esters of very long chain fatty acids
[637, 638]. Loss-of-function mutations in ABCD1 (mutation
registry held by the Adrenoleukodystrophy database;
https://adrenoleukodystrophy.info/) result in
adrenoleukodystrophy (OMIM: 300100) [347].
In vitro experiments indicate that ABCD2 has overlapping
substrate speciﬁcity with ABCD1 towards saturated and
monounsaturated very long-chain fatty acids, albeit at much
lower speciﬁcity. ABCD2 has afﬁnity for the polyunsaturated
fatty acids C22:6-CoA and C24:6-CoA. However, in vivo
proof for its true function is still lacking. No disease has yet
been linked to a deﬁciency of ABCD2.
Transports long-chain dicarboxylic acids, branched-chain
fatty acids and C27 bile acids DHC-CoA and THC-CoA [198].
In mitochondrial fatty acid deﬁcient cells and mice, ABCD3
accepts medium and long-chain fatty acids
Comments: ABCD4 (ENSG00000119688, also known as PMP69, PXMP1-L or P70R) is located at the lysosome and is involved in the transport of vitamin B12 (cobalamin) from lysosomes into the
cytosol [122].
ABCG subfamily
Transporters → ATP-binding cassette transporter family → ABCG subfamily
Overview: This family of ’half-transporters’ act as homo- or heterodimers; particularly ABCG5 and ABCG8 are thought to be obligate heterodimers. The ABCG5/ABCG heterodimer sterol transporter
structure has been determined [389], suggesting an extensive intracellular nucleotide binding domain linked to the transmembrane domains by a fold in the primary sequence. The functional ABCG2
transporter appears to be a homodimer with structural similarities to the ABCG5/ABCG8 heterodimer [609].
Nomenclature ABCG1 ABCG2 ABCG4 ABCG5 ABCG8
Common abbreviation ABC8 ABCP – – –
HGNC, UniProt ABCG1, P45844 ABCG2, Q9UNQ0 ABCG4, Q9H172 ABCG5, Q9H222 ABCG8, Q9H221
Inhibitors – cyclosporin A (pKi 6.3) [486] – – –
Comments Transports sterols and choline
phospholipids [351]
Exhibits a broad substrate
speciﬁcity, including urate and
haem, as well as multiple synthetic
compounds [351].
Putative functional dependence on
ABCG1
The ABCG5/ABCG8 heterodimer
transports phytosterols and
cholesterol [389]. Loss-of-function
mutations in ABCG5 or ABCG8 are
associated with sitosterolemia
(OMIM: 210250).
The ABCG5/ABCG8 heterodimer
transports phytosterols and
cholesterol [389]. Loss-of-function
mutations in ABCG5 or ABCG8 are
associated with sitosterolemia
(OMIM: 210250).
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Comments on ATP-binding cassette transporter family:
A further group of ABC transporter-like proteins have been iden-
tiﬁed to lack membrane spanning regions and are not believed
to be functional transporters, but appear to have a role in protein
translation [110, 490]: ABCE1 (P61221, also known as OABP or 2’-
5’ oligoadenylate-binding protein); ABCF1 (Q8NE71, also known
as ABC50 or TNF-α-stimulated ABC protein); ABCF2 (Q9UG63,
also known as iron-inhibited ABC transporter 2) and ABCF3
(Q9NUQ8).
Further reading on ATP-binding cassette transporter family
Baker A et al. (2015) Peroxisomal ABC transporters: functions and mechanism. Biochem. Soc. Trans.
43: 959-65 [PMID:26517910]
Beis K. (2015) Structural basis for the mechanism of ABC transporters. Biochem. Soc. Trans. 43:
889-93 [PMID:26517899]
Chen Z et al. (2016) Mammalian drug efﬂux transporters of the ATP binding cassette (ABC) family
in multidrug resistance: A review of the past decade. Cancer Lett. 370: 153-64 [PMID:26499806]
Kemp S et al. (2011) Mammalian peroxisomal ABC transporters: from endogenous substrates to
pathology and clinical signiﬁcance. Br. J. Pharmacol. 164: 1753-66 [PMID:21488864]
Kerr ID et al. (2011) The ABCG family of membrane-associated transporters: you don’t have to be
big to be mighty. Br. J. Pharmacol. 164: 1767-79 [PMID:21175590]
Kloudova A et al. (2017) The Role of Oxysterols in Human Cancer. Trends Endocrinol. Metab. 28:
485-496 [PMID:28410994]
López-Marqués RL et al. (2015) Structure and mechanism of ATP-dependent phospholipid trans-
porters. Biochim. Biophys. Acta 1850: 461-475 [PMID:24746984]
Neul C et al. (2016) Impact of MembraneDrug Transporters on Resistance to Small-Molecule Tyrosine
Kinase Inhibitors. Trends Pharmacol. Sci. 37: 904-932 [PMID:27659854]
Peña-Solórzano D et al. (2017) ABCG2/BCRP: Speciﬁc and Nonspeciﬁc Modulators. Med Res Rev 37:
987-1050 [PMID:28005280]
Robey RW et al. (2018) Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev
Cancer 18: 452-464 [https://www.ncbi.nlm.nih.gov/pubmed/29643473]
Vauthier V et al. (2017) Targeted pharmacotherapies for defective ABC transporters. Biochem.
Pharmacol. 136: 1-11 [PMID:28245962]
F-type and V-type ATPases
Transporters → F-type and V-type ATPases
Overview: The F-type (ATP synthase) and the V-type (vacuolar
or vesicular proton pump) ATPases, although having distinct sub-
cellular locations and roles, exhibit marked similarities in subunit
structure and mechanism. They are both composed of a ‘soluble’
complex (termed F1 or V1) and a membrane complex (Fo or Vo).
Within each ATPase complex, the two individual sectors appear to
function as connected opposing rotary motors, coupling catalysis
of ATP synthesis or hydrolysis to proton transport. Both the F-
type and V-type ATPases have been assigned enzyme commission
number E.C. 3.6.3.14
F-type ATPase
Transporters → F-type and V-type ATPases → F-type ATPase
Overview: The F-type ATPase, also known as ATP synthase
or ATP phosphohydrolase (H+-transporting), is a mitochondrial
membrane-associated multimeric complex consisting of two do-
mains, an F0 channel domain in the membrane and an F1 do-
main extending into the lumen. Proton transport across the in-
nermitochondrial membrane is used to drive the synthesis of ATP,
although it is also possible for the enzyme to function as an AT-
Pase. The ATP5O subunit (oligomycin sensitivity-conferring pro-
tein, OSCP, (P48047)), acts as a connector between F1 and F0 mo-
tors.
The F1 motor, responsible for ATP turnover, has the subunit com-
position α3β3γδ.
The F0 motor, responsible for ion translocation, is complex in
mammals, with probably nine subunits centring on A, B, and C
subunits in the membrane, together with D, E, F2, F6, G2 and 8
subunits. Multiple pseudogenes for the F0 motor proteins have
been deﬁned in the human genome.
Information on members of this family may be found in the online database.
Searchable database: http://www.guidetopharmacology.org/index.jsp F-type ATPase S406
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V-type ATPase
Transporters → F-type and V-type ATPases → V-type ATPase
Overview: The V-type ATPase is most prominently associated with lysosomes in mammals, but also appears to be expressed on the plasma membrane and neuronal synaptic vesicles.
The V1 motor, responsible for ATP turnover, has eight subunits with a composition of A-H.
TheV0 motor, responsible for ion translocation, has six subunits (a-e).
Information on members of this family may be found in the online database.
Further reading on F-type and V-type ATPases
Brandt K et al. (2015) Hybrid rotors in F1F(o) ATP synthases: subunit composition, distribution, and
physiological signiﬁcance. Biol. Chem. 396: 1031-42 [PMID:25838297]
Krah A. (2015) Linking structural features from mitochondrial and bacterial F-type ATP synthases
to their distinct mechanisms of ATPase inhibition. Prog. Biophys. Mol. Biol. 119: 94-102
[PMID:26140992]
Marshansky V et al. (2014) Eukaryotic V-ATPase: novel structural ﬁndings and functional insights.
Biochim. Biophys. Acta 1837: 857-79 [PMID:24508215]
Noji H et al. (2017) Catalytic robustness and torque generation of the F_1-ATPase. Biophys Rev 9:
103-118 [PMID:28424741]
Okuno D et al. (2013) Single-molecule analysis of the rotation of F_1-ATPase under high hydrostatic
pressure. Biophys. J. 105: 1635-42 [PMID:24094404]
P-type ATPases
Transporters → P-type ATPases
Overview: Phosphorylation-type ATPases (EC 3.6.3.-) are associ-
ated with membranes and the transport of ions or phospholipids.
Characteristics of the family are the transient phosphorylation of
the transporters at an aspartate residue and the interconversion
between E1 and E2 conformations in the activity cycle of the trans-
porters, taken to represent ‘half-channels’ facing the cytoplasm
and extracellular/luminal side of the membrane, respectively.
Sequence analysis across multiple species allows the deﬁnition of
ﬁve subfamilies, P1-P5. The P1 subfamily includes heavy metal
pumps, such as the copper ATPases. The P2 subfamily includes
calcium, sodium/potassium and proton/potassium pumps. The
P4 and P5 subfamilies include putative phospholipid ﬂippases.
Na+/K+-ATPases
Transporters → P-type ATPases → Na+/K+-ATPases
Overview: The cell-surface Na+/K+-ATPase is an integral mem-
brane protein which regulates the membrane potential of the cell
by maintaining gradients of Na+ and K+ ions across the plasma
membrane, also making a small, direct contribution to membrane
potential, particularly in cardiac cells. For every molecule of ATP
hydrolysed, the Na+/K+-ATPase extrudes three Na+ ions and im-
ports two K+ ions. The active transporter is a heteromultimer with
incompletely deﬁned stoichiometry, possibly as tetramers of het-
erodimers, each consisting of one of four large, ten TM domain
catalytic α subunits and one of three smaller, single TM domain
glycoprotein β-subunits. Additional protein partners known as
FXYD proteins (e.g. FXYD2, P54710) appear to associate with and
regulate the activity of the pump.
Information on members of this family may be found in the online database.
Comments: Na+/K+-ATPases are inhibited by ouabain and cardiac glycosides, such as digoxin, as well as potentially endogenous cardiotonic steroids [34].
Searchable database: http://www.guidetopharmacology.org/index.jsp S407
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Na+/K+-ATPases
Ca2+-ATPases
Transporters → P-type ATPases → Ca2+-ATPases
Overview: The sarcoplasmic/endoplasmic reticulum Ca2+-
ATPase (SERCA) is an intracellular membrane-associated pump
for sequestering calcium from the cytosol into intracellular or-
ganelles, usually associated with the recovery phase following ex-
citation of muscle and nerves.
The plasmamembrane Ca2+-ATPase (PMCA) is a cell-surface pump
for extruding calcium from the cytosol, usually associated with the
recovery phase following excitation of cells. The active pump is
a homodimer, each subunit of which is made up of ten TM seg-
ments, with cytosolic C- and N-termini and two large intracellular
loops.
Secretory pathway Ca2+-ATPases (SPCA) allow accumulation of
calcium and manganese in the Golgi apparatus.
Information on members of this family may be found in the online database.
Comments: The fungal toxin ochratoxin A has been described to activate SERCA in kidney microsomes [116]. Cyclopiazonic acid [564], thapsigargin [414] and BHQ are widely employed to block SERCA.
Thapsigargin has also been described to block the TRPV1 vanilloid receptor [629].
The stoichiometry of ﬂux through the PMCA differs from SERCA, with the PMCA transporting 1 Ca2+ while SERCA transports 2 Ca2+.
Loss-of-function mutations in SPCA1 appear to underlie Hailey-Hailey disease [299].
H+/K+-ATPases
Transporters → P-type ATPases → H+/K+-ATPases
Overview: The H+/K+ ATPase is a heterodimeric protein, made up of α and β subunits. The α subunit has 10 TM domains and exhibits catalytic and pore functions, while the β subunit has a single
TM domain, which appears to be required for intracellular trafﬁcking and stabilising the α subunit. The ATP4A and ATP4B subunits are expressed together, while the ATP12A subunit is suggested to be
expressed with the β1 (ATP1B1) subunit of the Na+/K+-ATPase [495].
Information on members of this family may be found in the online database.
Comments: The gastric H+/K+-ATPase is inhibited by proton pump inhibitors used for treating excessive gastric acid secretion, including dexlansoprazole and a metabolite of esomeprazole.
Cu+-ATPases
Transporters → P-type ATPases → Cu+-ATPases
Overview: Copper-transporting ATPases convey copper ions across cell-surface and intracellular membranes. They consist of eight TM domains and associate with multiple copper chaperone proteins
(e.g. ATOX1, O00244).
Information on members of this family may be found in the online database.
Searchable database: http://www.guidetopharmacology.org/index.jsp Cu -ATPases S408+
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Phospholipid-transporting ATPases
Transporters → P-type ATPases → Phospholipid-transporting ATPases
Overview: These transporters are thought to translocate the aminophospholipids phosphatidylserine and phosphatidylethanolamine from one side of the phospholipid bilayer to the other to generate
asymmetric membranes. They are also proposed to be involved in the generation of vesicles from intracellular and cell-surface membranes.
Information on members of this family may be found in the online database.
Comments: Loss-of-functionmutations in ATP8B1 are associated
with type I familial intrahepatic cholestasis.
A further series of structurally-related proteins have been iden-
tiﬁed in the human genome, with as yet undeﬁned function,
including ATP13A1 (Q9HD20), ATP13A2 (Q9NQ11), ATP13A3
(Q9H7F0), ATP13A4 (Q4VNC1) and ATP13A5 (Q4VNC0).
Further reading on P-type ATPases
Aperia A et al. (2016) Na+-K+-ATPase, a new class of plasma membrane receptors. Am. J. Physiol., Cell
Physiol. 310: C491-5 [PMID:26791490]
Brini M et al. (2017) The plasma membrane calcium pumps: focus on the role in (neuro)pathology.
Biochem. Biophys. Res. Commun. 483: 1116-1124 [PMID:27480928]
Bruce JIE. (2018) Metabolic regulation of the PMCA: Role in cell death and survival. Cell Calcium 69:
28-36 [PMID:28625348]
Diederich M et al. (2017) Cardiac glycosides: From molecular targets to immunogenic cell death.
Biochem. Pharmacol. 125: 1-11 [PMID:27553475]
Dubois C et al. (2016) The calcium-signaling toolkit: Updates needed. Biochim. Biophys. Acta 1863:
1337-43 [PMID:26658643]
Krebs J. (2015) The plethora of PMCA isoforms: Alternative splicing and differential expression.
Biochim. Biophys. Acta 1853: 2018-24 [PMID:25535949]
Little R et al. (2016) Plasma membrane calcium ATPases (PMCAs) as potential targets for the treat-
ment of essential hypertension. Pharmacol. Ther. 159: 23-34 [PMID:26820758]
López-Marqués RL et al. (2015) Structure and mechanism of ATP-dependent phospholipid trans-
porters. Biochim. Biophys. Acta 1850: 461-475 [PMID:24746984]
Migocka M. (2015) Copper-transporting ATPases: The evolutionarily conserved machineries for bal-
ancing copper in living systems. IUBMB Life 67: 737-45 [PMID:26422816]
Padányi R et al. (2016)Multifaceted plasmamembrane Ca(2+) pumps: From structure to intracellular
Ca(2+) handling and cancer. Biochim. Biophys. Acta 1863: 1351-63 [PMID:26707182]
Pomorski TG et al. (2016) Lipid somersaults: Uncovering the mechanisms of protein-mediated lipid
ﬂipping. Prog. Lipid Res. 64: 69-84 [PMID:27528189]
Retamales-Ortega R et al. (2016) P2C-Type ATPases and Their Regulation. Mol. Neurobiol. 53: 1343-54
[PMID:25631710]
Tadini-Buoninsegni F et al. (2017) Mechanisms of charge transfer in human copper ATPases ATP7A
and ATP7B. IUBMB Life 69: 218-225 [PMID:28164426]
SLC superfamily of solute carriers
Transporters → SLC superfamily of solute carriers
Overview: The SLC superfamily of solute carriers is the second
largest family of membrane proteins after G protein-coupled re-
ceptors, but with a great deal fewer therapeutic drugs that exploit
them. As with the ABC transporters, however, they play a major
role in drug disposition and so can be hugely inﬂuential in deter-
mining the clinical efﬁcacy of particular drugs.
48 families are identiﬁed on the basis of sequence similarities, but
many of them overlap in terms of the solutes that they carry. For
example, amino acid accumulation is mediated bymembers of the
SLC1, SLC3/7, SLC6, SLC15, SLC16, SLC17, SLC32, SLC36, SLC38
and SLC43. Further members of the SLC superfamily regulate ion
ﬂuxes at the plasma membrane, or solute transport into and out
of cellular organelles.
Within the SLC superfamily, there is an abundance in diversity of
structure. Two families (SLC3 and SLC7) only generate functional
transporters as heteromeric partners, where one partner is a sin-
gle TM domain protein. Membrane topology predictions for other
families suggest 3, 4 6, 7, 8, 9, 10, 11, 12, 13, or 14 TM domains.
Functionally, members may be divided into those dependent on
gradients of ions (particularly sodium, chloride or protons), ex-
change of solutes or simple equilibrative gating. For many mem-
bers, the stoichiometry of transport is not yet established. Fur-
thermore, one family of transporters also possess enzymatic activ-
ity (SLC27), while many members function as ion channels (e.g.
SLC1A7/EAAT5), which increases the complexity of function of
the SLC superfamily.
Searchable database: http://www.guidetopharmacology.org/index.jsp SLC superfamily of solute carriers S409
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SLC1 family of amino acid transporters
Transporters → SLC superfamily of solute carriers → SLC1 family of amino acid transporters
Overview: The SLC1 family of sodium dependent transporters includes the plasma membrane located glutamate transporters and the neutral amino acid transporters ASCT1 and ASCT2 [11, 46, 338,
339, 487].
Glutamate transporter subfamily
Transporters → SLC superfamily of solute carriers → SLC1 family of amino acid transporters → Glutamate transporter subfamily
Overview: Glutamate transporters present the unusual structural
motif of 8TM segments and 2 re-entrant loops [262]. The crystal
structure of a glutamate transporter homologue (GltPh) from Py-
rococcus horikoshii supports this topology and indicates that the
transporter assembles as a trimer, where each monomer is a func-
tional unit capable of substrate permeation [68, 526, 696] re-
viewed by [329]). This structural data is in agreementwith the pro-
posed quaternary structure for EAAT2 [232] and several functional
studies that propose themonomer is the functional unit [257, 366,
385, 539]. Recent evidence suggests that EAAT3 and EAAT4 may
assemble as heterotrimers [467]. The activity of glutamate trans-
porters located upon both neurones (predominantly EAAT3, 4 and
5) and glia (predominantly EAAT 1 and 2) serves, dependent upon
their location, to regulate excitatory neurotransmission, maintain
low ambient extracellular concentrations of glutamate (protecting
against excitotoxicity) and provide glutamate for metabolism in-
cluding the glutamate-glutamine cycle. The Na+/K+-ATPase that
maintains the ion gradients that drive transport has been demon-
strated to co-assemble with EAAT1 and EAAT2 [533]. Recent ev-
idence supports altered glutamate transport and novel roles in
brain for splice variants of EAAT1 and EAAT2 [231, 386]. Three pa-
tients with dicarboxylic aminoaciduria (DA) were recently found
to have loss-of-function mutations in EAAT3 [35]. DA is charac-
terized by excessive excretion of the acidic amino acids glutamate
and aspartate and EAAT3 is the predominant glutamate/aspartate
transporter in the kidney. Enhanced expression of EAAT2 result-
ing from administration of β-lactam antibiotics (e.g. ceftriaxone) is
neuroprotective and occurs through NF-κB-mediated EAAT2 pro-
moter activation [226, 390, 536] reviewed by [353]). PPARγ acti-
vation (e.g. by rosiglitazone) also leads to enhanced expression
of EAAT though promoter activation [532]. In addition, several
translational activators of EAAT2 have recently been described
[125] along with treatments that increase the surface expression of
EAAT2 (e.g. [384, 726]), or prevent its down-regulation (e.g. [248]).
A thermodynamically uncoupled Cl- ﬂux, activated by Na+ and
glutamate [259, 339, 419] (Na+ and aspartate in the case of GltPh
[538]), is sufﬁciently large, in the instances of EAAT4 and EAAT5,
to inﬂuence neuronal excitability [621, 648]. Indeed, it has re-
cently been suggested that the primary function of EAAT5 is as a
slow anion channel gated by glutamate, rather than a glutamate
transporter [220].
Searchable database: http://www.guidetopharmacology.org/index.jsp Glutamate transporter subfamily S410
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14753/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology (2019) 176, S397–S493
Nomenclature Excitatory amino acid transporter 1 Excitatory amino acid transporter 2 Excitatory amino acid transporter 3 Excitatory amino acid transporter 4 Excitatory amino acid transporter 5
Systematic nomenclature SLC1A3 SLC1A2 SLC1A1 SLC1A6 SLC1A7
Common abbreviation EAAT1 EAAT2 EAAT3 EAAT4 EAAT5
HGNC, UniProt SLC1A3, P43003 SLC1A2, P43004 SLC1A1, P43005 SLC1A6, P48664 SLC1A7, O00341
Substrates DL-threo-β-hydroxyaspartate (Ki
5.8×10−5M) [571], D-aspartic acid,
L-trans-2,4-pyrolidine
dicarboxylate
D-aspartic acid,
DL-threo-β-hydroxyaspartate,
L-trans-2,4-pyrolidine
dicarboxylate [367]
L-trans-2,4-pyrolidine
dicarboxylate,
DL-threo-β-hydroxyaspartate,
D-aspartic acid
D-aspartic acid,
DL-threo-β-hydroxyaspartate,
L-trans-2,4-pyrolidine
dicarboxylate
D-aspartic acid,
L-trans-2,4-pyrolidine
dicarboxylate,
DL-threo-β-hydroxyaspartate
Endogenous substrates L-aspartic acid, L-glutamic acid L-glutamic acid, L-aspartic acid L-aspartic acid, L-cysteine [706],
L-glutamic acid
L-glutamic acid, L-aspartic acid L-aspartic acid, L-glutamic acid
Stoichiometry Probably 3 Na+: 1 H+ : 1
glutamate (in): 1 K+ (out)
3 Na+: 1 H+ : 1 glutamate (in): 1
K+ (out) [396]
3 Na+: 1 H+ : 1 glutamate (in): 1
K+ (out) [705]
Probably 3 Na+: 1 H+ : 1
glutamate (in): 1 K+(out)
Probably 3 Na+: 1 H+ : 1
glutamate (in): 1 K+ (out)
Inhibitors UCPH-101 (membrane potential
assay) (pIC50 6.9) [326], DL-TBOA
(pKB 5) [571]
WAY-213613 (pIC50 7.1) [167],
DL-TBOA (pKB 6.9) [571],
SYM2081 (pKB 5.5) [640],
dihydrokainate (pKB 5),
threo-3-methylglutamate (pKB
4.7) [640]
NBI-59159 (pIC50 7.1) [165],
L-β-BA ([3H]D-aspartate uptake
assay) (pKi 6.1) [186], DL-TBOA
(pIC50 5.1) [573]
DL-TBOA (pKi 5.4) [570],
threo-3-methylglutamate (pKi 4.3)
[176]
DL-TBOA (pKi 5.5) [570]
Labelled ligands [3H]ETB-TBOA (Binding) (pKd 7.8)
[572] – Rat, [3H]D-aspartic acid,
[3H]L-aspartic acid, [3H]SYM2081
[3H]ETB-TBOA (Binding) (pKd 7.8)
[572] – Rat, [3H]D-aspartic acid,
[3H]L-aspartic acid, [3H]SYM2081
[3H]ETB-TBOA (Binding) (pKd 6.5)
[572] – Rat, [3H]D-aspartic acid,
[3H]L-aspartic acid
[3H]ETB-TBOA (Binding) (pKd 7.9)
[572] – Rat, [3H]D-aspartic acid,
[3H]L-aspartic acid
[3H]ETB-TBOA (Binding) (pKd 7.6)
[572] – Rat, [3H]D-aspartic acid,
[3H]L-aspartic acid
Comments: The KB (or Ki) values reported, unless indicated oth-
erwise, are derived from transporter currents mediated by EAATs
expressed in voltage-clamped Xenopus laevis oocytes [176, 570,
571, 640]. KB (or Ki) values derived in uptake assays are generally
higher (e.g. [571]). In addition to acting as a poorly transportable
inhibitor of EAAT2, (2S,4R)-4-methylglutamate, also known as
SYM2081, is a competitive substrate for EAAT1 (KM = 54μM; [300,
640]) and additionally is a potent kainate receptor agonist [715]
which renders the compound unsuitable for autoradiographic lo-
calisation of EAATs [24]. Similarly, at concentrations that inhibit
EAAT2, dihydrokainate binds to kainate receptors [571]. WAY-855
and WAY-213613 are both non-substrate inhibitors with a prefer-
ence for EAAT2 over EAAT3 and EAAT1 [166, 167]. NBI-59159
is a non-substrate inhibitor with modest selectivity for EAAT3
over EAAT1 (>10-fold) and EAAT2 (5-fold) [126, 164]. Analo-
gously, L-β-threo-benzyl-aspartate (L-β-BA) is a competitive non-
substrate inhibitor that preferentially blocks EAAT3 versus EAAT1,
or EAAT2 [186]. [3H]SYM2081 demonstrates low afﬁnity binding
(KD ∼= 6.0 μM) to EAAT1 and EAAT2 in rat brain homogenates
[25] and EAAT1 in murine astrocyte membranes [23], whereas
[3H]ETB-TBOA binds with high afﬁnity to all EAATs other than
EAAT3 [572]. The novel isoxazole derivative (-)-HIP-A may in-
teract at the same site as TBOA and preferentially inhibit reverse
transport of glutamate [124]. Threo-3-methylglutamate induces
substrate-like currents at EAAT4, but does not elicit heteroex-
change of [3H]-aspartate in synaptosome preparations, inconsis-
tent with the behaviour of a substrate inhibitor [176]. Parawixin 1,
a compound isolated from the venom from the spider Parawixia
bistriata is a selective enhancer of the glutamate uptake through
EAAT2 but not through EAAT1 or EAAT3 [207, 208]. In addition
to the agents listed in the table, DL-threo-β-hydroxyaspartate and
L-trans-2,4-pyrolidine dicarboxylate act as non-selective compet-
itive substrate inhibitors of all EAATs. Zn2+ and arachidonic acid
are putative endogenous modulators of EAATs with actions that
differ across transporter subtypes (reviewed by [639]).
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Alanine/serine/cysteine transporter subfamily
Transporters → SLC superfamily of solute carriers → SLC1 family of amino acid transporters → Alanine/serine/cysteine transporter subfamily
Overview: ASC transporters mediate Na+-dependent exchange of small neutral amino acids such as Ala, Ser, Cys and Thr and their structure is predicted to be similar to that of the glutamate transporters
[27, 634]. ASCT1 and ASCT2 also exhibit thermodynamically uncoupled chloride channel activity associated with substrate transport [79, 704]. Whereas EAATs counter-transport K+ (see above) ASCTs
do not and their function is independent of the intracellular concentration of K+ [704].
Nomenclature Alanine/serine/cysteine transporter 1 Alanine/serine/cysteine transporter 2
Systematic nomenclature SLC1A4 SLC1A5
Common abbreviation ASCT1 ASCT2
HGNC, UniProt SLC1A4, P43007 SLC1A5, Q15758
Endogenous substrates L-cysteine > L-alanine = L-serine > L-threonine L-alanine = L-serine = L-cysteine (low Vmax) = L-threonine = L-glutamine = L-asparagine 
L-methionine ∼= glycine ∼= L-leucine > L-valine > L-glutamic acid (enhanced at low pH)
Stoichiometry 1 Na+: 1 amino acid (in): 1 Na+: 1 amino acid (out); (homo-, or hetero-exchange; [705]) 1 Na+: 1 amino acid (in): 1 Na+: 1 amino acid (out); (homo-, or hetero-exchange; [77])
Inhibitors – p-nitrophenyl glutamyl anilide (pKi 4.3) [187] – Rat, benzylcysteine (pKi 3.1) [258],
benzylserine (pKi 3) [258]
Comments: The substrate speciﬁcity of ASCT1 may extend to L-proline and trans-4-hydroxy-proline [499]. At low pH (5.5) both ASCT1 and ASCT2 are able to exchange acidic amino acids such as
L-cysteate and glutamate [605, 634]. In addition to the inhibitors tabulated above, HgCl2, methylmercury and mersalyl, at low micromolar concentrations, non-competitively inhibit ASCT2 by covalent
modiﬁciation of cysteine residues [480].
Further reading on SLC1 family of amino acid transporters
Beart PM et al. (2007) Transporters for L-glutamate: an update on their molecular pharmacology and
pathological involvement. Br. J. Pharmacol. 150: 5-17 [PMID:17088867]
Bjrn-Yoshimoto WE et al. (2016) The importance of the excitatory amino acid transporter 3 (EAAT3).
Neurochem. Int. 98: 4-18 [PMID:27233497]
Fahlke C et al. (2016) Molecular physiology of EAAT anion channels. Pﬂugers Arch. 468: 491-502
[PMID:26687113]
Fontana AC. (2015) Current approaches to enhance glutamate transporter function and expression.
J. Neurochem. 134: 982-1007 [PMID:26096891]
Grewer C et al. (2014) SLC1 glutamate transporters. Pﬂugers Arch. 466: 3-24 [PMID:24240778]
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SLC2 family of hexose and sugar alcohol transporters
Transporters → SLC superfamily of solute carriers → SLC2 family of hexose and sugar alcohol transporters
Overview: The SLC2 family transports D-glucose, D-fructose, inositol (e.g. myo-inositol) and related hexoses. Three classes of glucose transporter can be identiﬁed, separating GLUT1-4 and 14, GLUT6,
8, 10 and 12; and GLUT5, 7, 9 and 11. Modelling suggests a 12 TM membrane topology, with intracellular termini, with functional transporters acting as homodimers or homotetramers.
Class I transporters
Transporters → SLC superfamily of solute carriers → SLC2 family of hexose and sugar alcohol transporters → Class I transporters
Overview: Class I transporters are able to transport D-glucose, but not D-fructose, in the direction of the concentration gradient and may be inhibited non-selectively by phloretin and cytochalasin B.
GLUT1 is the major glucose transporter in brain, placenta and erythrocytes, GLUT2 is found in the pancreas, liver and kidneys, GLUT3 is neuronal and placental, while GLUT4 is the insulin-responsive
transporter found in skeletal muscle, heart and adipose tissue. GLUT14 appears to result from gene duplication of GLUT3 and is expressed in the testes [678].
Nomenclature Glucose transporter 1 Glucose transporter 2 Glucose transporter 3 Glucose transporter 4 Glucose transporter 14
Systematic nomenclature SLC2A1 SLC2A2 SLC2A3 SLC2A4 SLC2A14
Common abbreviation GLUT1 GLUT2 GLUT3 GLUT4 GLUT14
HGNC, UniProt SLC2A1, P11166 SLC2A2, P11168 SLC2A3, P11169 SLC2A4, P14672 SLC2A14, Q8TDB8
Substrates D-glucosamine (D-glucose =
D-glucosamine) [631],
dehydroascorbic acid [55], D-glucose
(D-glucose = D-glucosamine) [631]
D-glucosamine (D-glucosamine >
D-glucose) [631], D-glucose
(D-glucosamine > D-glucose) [631]
D-glucose D-glucosamine (D-glucosamine ≥
D-glucose) [631], D-glucose
(D-glucosamine ≥ D-glucose) [631]
–
Labelled ligands [3H]2-deoxyglucose [3H]2-deoxyglucose [3H]2-deoxyglucose [3H]2-deoxyglucose –
Comments GLUT1 is a class I facilitative sugar
transporter. GLUT1 functions to
maintain basal glucose import which
is required for cellular respiration.
– – – –
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Class II transporters
Transporters → SLC superfamily of solute carriers → SLC2 family of hexose and sugar alcohol transporters → Class II transporters
Overview: Class II transporters transport D-fructose and appear to be insensitive to cytochalasin B. Class II transporters appear to be predominantly intracellularly located.
Nomenclature Glucose transporter 5 Glucose transporter 7 Glucose transporter 9
Systematic nomenclature SLC2A5 SLC2A7 SLC2A9
Common abbreviation GLUT5 GLUT7 GLUT9
HGNC, UniProt SLC2A5, P22732 SLC2A7, Q6PXP3 SLC2A9, Q9NRM0
Substrates D-fructose (D-fructose > D-glucose) [83], D-glucose (D-fructose > D-glucose) [83] D-fructose [104], D-glucose [104] D-fructose [94], uric acid [94]
Nomenclature Glucose transporter 11 Glucose transporter 6 Glucose transporter 8 Glucose transporter 10 Glucose transporter 12
Systematic nomenclature SLC2A11 SLC2A6 SLC2A8 SLC2A10 SLC2A12
Common abbreviation GLUT11 GLUT6 GLUT8 GLUT10 GLUT12
HGNC, UniProt SLC2A11, Q9BYW1 SLC2A6, Q9UGQ3 SLC2A8, Q9NY64 SLC2A10, O95528 SLC2A12, Q8TD20
Substrates D-fructose [426], D-glucose [156] – D-glucose [303] dehydroascorbic acid [392],
D-glucose [392]
D-glucose [530]
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Proton-coupled inositol transporter
Transporters → SLC superfamily of solute carriers → SLC2 family of hexose and sugar alcohol transporters → Proton-coupled inositol transporter
Overview: Proton-coupled inositol transporters are expressed predominantly in the brain and can be inhibited by phloretin and cytochalasin B [631].
Nomenclature Proton myo-inositol cotransporter
Systematic nomenclature SLC2A13
Common abbreviation HMIT
HGNC, UniProt SLC2A13, Q96QE2
Substrates D-chiro-inositol [631], myo-inositol [631], scyllo-inositol [631], muco-inositol [631]
Stoichiometry 1 H+ : 1 inositol (in) [150]
Further reading on SLC2 family of hexose and sugar alcohol transporters
Augustin R. (2010) The protein family of glucose transport facilitators: It’s not only about glucose
after all. IUBMB Life 62: 315-33 [PMID:20209635]
Klip A et al. (2014) Signal transduction meets vesicle trafﬁc: the software and hardware of GLUT4
translocation. Am. J. Physiol., Cell Physiol. 306: C879-86 [PMID:24598362]
Leney SE et al. (2009) Themolecular basis of insulin-stimulated glucose uptake: signalling, trafﬁcking
and potential drug targets. J. Endocrinol. 203: 1-18 [PMID:19389739]
Mueckler M et al. (2013) The SLC2 (GLUT) family of membrane transporters. Mol. Aspects Med. 34:
121-38 [PMID:23506862]
Uldry M et al. (2004) The SLC2 family of facilitated hexose and polyol transporters. Pﬂugers Arch.
447: 480-9 [PMID:12750891]
SLC3 and SLC7 families of heteromeric amino acid transporters (HATs)
Transporters → SLC superfamily of solute carriers → SLC3 and SLC7 families of heteromeric amino acid transporters (HATs)
Overview: The SLC3 and SLC7 families combine to generate functional transporters, where the subunit composition is a disulphide-linked combination of a heavy chain (SLC3 family) with a light chain
(SLC7 family).
SLC3 family
Transporters → SLC superfamily of solute carriers → SLC3 and SLC7 families of heteromeric amino acid transporters (HATs) → SLC3 family
Overview: SLC3 family members are single TM proteins with extensive glycosylation of the exterior C-terminus, which heterodimerize with SLC7 family members in the endoplasmic reticulum and
assist in the plasma membrane localization of the transporter.
Information on members of this family may be found in the online database.
Searchable database: http://www.guidetopharmacology.org/index.jsp SLC3 family S415
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SLC7 family
Transporters → SLC superfamily of solute carriers → SLC3 and SLC7 families of heteromeric amino acid transporters (HATs) → SLC7 family
Overview: SLC7 family members may be divided into two major groups: cationic amino acid transporters (CATs) and glycoprotein-associated amino acid transporters (gpaATs).
Cationic amino acid transporters are 14 TM proteins, which mediate pH- and sodium-independent transport of cationic amino acids (system y+), apparently as an exchange mechanism. These transporters
are sensitive to inhibition by N-ethylmaleimide.
Nomenclature High afﬁnity cationic amino acid
transporter 1
Low afﬁnity cationic amino acid
transporter 2
Cationic amino acid transporter 3 L-type amino acid transporter 1 L-type amino acid transporter 2
Systematic nomenclature SLC7A1 SLC7A2 SLC7A3 SLC7A5 SLC7A8
Common abbreviation CAT1 CAT2 CAT3 LAT1 LAT2
HGNC, UniProt SLC7A1, P30825 SLC7A2, P52569 SLC7A3, Q8WY07 SLC7A5, Q01650 SLC7A8, Q9UHI5
Substrates L-ornithine, L-arginine, L-lysine,
L-histidine
L-ornithine, L-arginine, L-lysine,
L-histidine
L-ornithine, L-arginine, L-lysine – –
Selective inhibitors – – – KYT-0353 [476] –
Nomenclature y+L amino acid transporter 1 y+L amino acid transporter 2 b0,+-type amino acid
transporter 1
Asc-type amino acid
transporter 1
Cystine/glutamate transporter AGT1
Systematic nomenclature SLC7A7 SLC7A6 SLC7A9 SLC7A10 SLC7A11 SLC7A13
Common abbreviation y+LAT1 y+LAT2 b0,+AT Asc-1 xCT –
HGNC, UniProt SLC7A7, Q9UM01 SLC7A6, Q92536 SLC7A9, P82251 SLC7A10, Q9NS82 SLC7A11, Q9UPY5 SLC7A13, Q8TCU3
Inhibitors – – – – quisqualate (pIC50 5.3) [188] –
Comments: CAT4 appears to be non-functional in heterologous
expression [672], while SLC7A14 has yet to be characterized.
Glycoprotein-associated amino acid transporters are 12 TM pro-
teins, which heterodimerize with members of the SLC3 family to
act as cell-surface amino acid exchangers.
Heterodimers between 4F2hc and LAT1 or LAT2 generate sodium-
independent system L transporters. LAT1 transports large neutral
amino acids including branched-chain and aromatic amino acids
as well as miglustat, whereas LAT2 transports most of the neutral
amino acids.
Heterodimers between 4F2hc and y+LAT1 or y+LAT2 generate
transporters similar to the system y+L , which transport cationic
(L-arginine, L-lysine, L-ornithine) amino acids independent
of sodium and neutral (L-leucine, L-isoleucine, L-methionine,
L-glutamine) amino acids in a partially sodium-dependent man-
ner. These transporters are N-ethylmaleimide-insensitive. Het-
erodimers between rBAT and b0,+AT appear to mediate sodium-
independent system b0,+ transport of most of the neutral
amino acids and cationic amino acids (L-arginine, L-lysine and
L-ornithine).
Asc-1 appears to heterodimerize with 4F2hc to allow the trans-
port of small neutral amino acids (such as L-alanine, L-serine,
L-threonine, L-glutamine and glycine), as well as D-serine, in a
sodium-independent manner.
xCT generates a heterodimer with 4F2hc for a system x-e-c
transporter that mediates the sodium-independent exchange of
L-cystine and L-glutamic acid.
AGT has been conjugated with SLC3 members as fusion proteins
to generate functional transporters, but the identity of a native
heterodimer has yet to be ascertained.
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Further reading on SLC3 and SLC7 families of heteromeric amino acid transporters (HATs)
Bhutia YD et al. (2015) Amino Acid transporters in cancer and their relevance to "glutamine addic-
tion": novel targets for the design of a new class of anticancer drugs. Cancer Res. 75: 1782-8
[PMID:25855379]
Fotiadis D et al. (2013) The SLC3 and SLC7 families of amino acid transporters. Mol. Aspects Med.
34: 139-58 [PMID:23506863]
Palacín M et al. (2004) The ancillary proteins of HATs: SLC3 family of amino acid transporters.
Pﬂugers Arch. 447: 490-4 [PMID:14770309]
Palacín M et al. (2005) The genetics of heteromeric amino acid transporters. Physiology (Bethesda) 20:
112-24 [PMID:15772300]
Verrey F et al. (2004) CATs and HATs: the SLC7 family of amino acid transporters. Pﬂugers Arch. 447:
532-42 [PMID:14770310]
SLC4 family of bicarbonate transporters
Transporters → SLC superfamily of solute carriers → SLC4 family of bicarbonate transporters
Overview: Together with the SLC26 family, the SLC4 family of
transporters subserve anion exchange, principally of chloride and
bicarbonate (HCO3-), but also carbonate and hydrogen sulphate
(HSO4-). SLC4 family members regulate bicarbonate ﬂuxes as part
of carbon dioxide movement, chyme neutralization and reabsorp-
tion in the kidney.
Within the family, subgroups of transporters are identiﬁable: the
electroneutral sodium-independent Cl-/HCO3
- transporters (AE1,
AE2 and AE3), the electrogenic sodium-dependent HCO3- trans-
porters (NBCe1 and NBCe2) and the electroneutral HCO3
- trans-
porters (NBCn1 and NBCn2). Topographical information derives
mainly from study of AE1, abundant in erythrocytes, which sug-
gests a dimeric or tetrameric arrangement, with subunits made up
of 13 TM domains and re-entrant loops at TM9/10 and TM11/12.
The N terminus exhibits sites for interaction with multiple pro-
teins, including glycolytic enzymes, haemoglobin and cytoskele-
tal elements.
Anion exchangers
Transporters → SLC superfamily of solute carriers → SLC4 family of bicarbonate transporters → Anion exchangers
Nomenclature Anion exchange protein 1 Anion exchange protein 2 Anion exchange protein 3 Anion exchange protein 4
Systematic nomenclature SLC4A1 SLC4A2 SLC4A3 SLC4A9
Common abbreviation AE1 AE2 AE3 AE4
HGNC, UniProt SLC4A1, P02730 SLC4A2, P04920 SLC4A3, P48751 SLC4A9, Q96Q91
Endogenous substrates HCO3-, Cl- Cl-, HCO3- Cl-, HCO3- –
Stoichiometry 1 Cl- (in) : 1 HCO3- (out) 1 Cl- (in) : 1 HCO3- (out) 1 Cl- (in) : 1 HCO3- (out) –
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Sodium-dependent HCO3- transporters
Transporters → SLC superfamily of solute carriers → SLC4 family of bicarbonate transporters → Sodium-dependent HCO3- transporters
Nomenclature Electrogenic sodium
bicarbonate cotransporter 1
Electrogenic sodium
bicarbonate cotransporter 4
Electroneutral sodium
bicarbonate cotransporter 1
Electroneutral sodium
bicarbonate cotransporter 2
NBCBE NaBC1
Systematic nomenclature SLC4A4 SLC4A5 SLC4A7 SLC4A10 SLC4A8 SLC4A11
Common abbreviation NBCe1 NBCe2 NBCn1 NBCn2 NDCBE BTR1
HGNC, UniProt SLC4A4, Q9Y6R1 SLC4A5, Q9BY07 SLC4A7, Q9Y6M7 SLC4A10, Q6U841 SLC4A8, Q2Y0W8 SLC4A11, Q8NBS3
Endogenous substrates NaHCO3- NaHCO3- NaHCO3- NaHCO3- NaHCO3-, Cl- Cl-, NaHCO3-
Stoichiometry 1 Na+ : 2/3 HCO3- (out) or 1
Na+ : CO32*
1 Na+ : 2/3 HCO3- (out) or 1
Na+ : CO32*
1 Na+ : 1 HCO3- (out) or 1
Na+ : CO32*
1 Na+ : 1 HCO3- (out) or 1 Na
: CO32*
1 Na+ : 2HCO3- (in) : 1 Cl-
(out)
–
Further reading on SLC4 family of bicarbonate transporters
Majumdar D et al. (2010) Na-coupled bicarbonate transporters of the solute carrier 4 family in the
nervous system: function, localization, and relevance to neurologic function. Neuroscience 171:
951-72 [PMID:20884330]
Parker MD et al. (2013) The divergence, actions, roles, and relatives of sodium-coupled bicarbonate
transporters. Physiol. Rev. 93: 803-959 [PMID:23589833]
Reithmeier RA et al. (2016) Band 3, the human red cell chloride/bicarbonate anion exchanger (AE1,
SLC4A1), in a structural context. Biochim. Biophys. Acta 1858: 1507-32 [PMID:27058983]
Romero MF et al. (2013) The SLC4 family of bicarbonate (HCO_3−) transporters. Mol. Aspects Med.
34: 159-82 [PMID:23506864]
Thornell IM et al. (2015) Regulators of Slc4 bicarbonate transporter activity. Front Physiol 6: 166
[PMID:26124722]
SLC5 family of sodium-dependent glucose transporters
Transporters → SLC superfamily of solute carriers → SLC5 family of sodium-dependent glucose transporters
Overview: The SLC5 family of sodium-dependent glucose transporters includes, in mammals, the Na+/substrate co-transporters for glucose (e.g. choline), D-glucose, monocarboxylates, myo-inositol and
I- [200, 224, 674, 675]. Members of the SLC5 and SLC6 families, along with other unrelated Na+ cotransporters (i.e. Mhp1 and BetP), share a common structural core that contains an inverted repeat of
5TM α-helical domains [2].
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Hexose transporter family
Transporters → SLC superfamily of solute carriers → SLC5 family of sodium-dependent glucose transporters → Hexose transporter family
Overview: Detailed characterisation of members of the hexose
transporter family is limited to SGLT1, 2 and 3, which are all in-
hibited in a competitive manner by phlorizin, a natural dihydro-
choline glucoside, that exhibits modest selectivity towards SGLT2
(see [674] for an extensive review). SGLT1 is predominantly ex-
pressed in the small intestine, mediating the absorption of glucose
(e.g. D-glucose), but also occurs in the brain, heart and in the late
proximal straight tubule of the kidney. The expression of SGLT2
is almost exclusively restricted to the early proximal convoluted
tubule of the kidney, where it is largely responsible for the renal
reabsorption of glucose. SGLT3 is not a transporter but instead
acts as a glucosensor generating an inwardly directed ﬂux of Na+
that causes membrane depolarization [153].
Nomenclature Sodium/glucose cotransporter 1 Sodium/glucose cotransporter 2 Low afﬁnity sodium-glucose
cotransporter
Sodium/glucose cotransporter 4 Sodium/glucose cotransporter 5
Systematic nomenclature SLC5A1 SLC5A2 SLC5A4 SLC5A9 SLC5A10
Common abbreviation SGLT1 SGLT2 SGLT3 SGLT4 SGLT5
HGNC, UniProt SLC5A1, P13866 SLC5A2, P31639 SLC5A4, Q9NY91 SLC5A9, Q2M3M2 SLC5A10, A0PJK1
Substrates D-galactose [650], α-MDG [650],
D-glucose [650]
α-MDG, D-glucose D-glucose [650],
1-deoxynojirimycin-1-sulfonic acid
[650], N-ethyl-1-deoxynojirimycin
[650], miglustat [650], miglitol
[650], 1-deoxynojirimycin [650]
D-glucose, D-mannose, α-MDG D-galactose, D-glucose
Stoichiometry 2 Na+ : 1 glucose [340] 1 Na+ : 1 glucose [301] – – –
Selective inhibitors mizagliﬂozin (pKi 7.6) [311] dapagliﬂozin (pIC50 9.3) [343] – – –
Comments – – SGLT3 acts as a glucosensor. – –
Comments: Recognition and transport of substrate by SGLTs re-
quires that the sugar is a pyranose. De-oxyglucose derivatives have
reduced afﬁnity for SGLT1, but the replacement of the sugar equa-
torial hydroxyl group by ﬂuorine at some positions, excepting C2
and C3, is tolerated (see [674] for a detailed quantiﬁcation). Al-
though SGLT1 and SGLT2 have been described as high- and low-
afﬁnity sodium glucose co-transporters, respectively, recent work
suggests that they have a similar afﬁnity for glucose under phys-
iological conditions [301]. Selective blockers of SGLT2, and thus
blocking 50% of renal glucose reabsorption, are in development
for the treatment of diabetes (e.g. [100]).
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Choline transporter
Transporters → SLC superfamily of solute carriers → SLC5 family of sodium-dependent glucose transporters → Choline transporter
Overview: The high afﬁnity, hemicholinium-3-sensitive, choline
transporter (CHT) is expressed mainly in cholinergic neurones on
nerve cell terminals and synaptic vesicles (keratinocytes being an
additional location). In autonomic neurones, expression of CHT
requires an activity-dependent retrograde signal from postsynap-
tic neurones [375]. Through recapture of choline generated by the
hydrolysis of ACh by acetylcholinesterase, CHT serves tomaintain
acetylcholine synthesis within the presynaptic terminal [200]. Ho-
mozygous mice engineered to lack CHT die within one hour of
birth as a result of hypoxia arising from failure of transmission at
the neuromuscular junction of the skeletal muscles that support
respiration [199]. A low afﬁnity choline uptake mechanism that
remains to be identiﬁed at the molecular level may involve multi-
ple transporters. In addition, a family of choline transporter-like
(CTL) proteins, (which are members of the SLC44 family) with
weak Na+ dependence have been described [622].
Nomenclature CHT
Systematic nomenclature SLC5A7
HGNC, UniProt SLC5A7, Q9GZV3
Substrates triethylcholine
Endogenous substrates choline
Stoichiometry Na+ : choline (variable stoichimetry); modulated by extracellular Cl- [322]
Selective inhibitors hemicholinium-3 (pKi 7–8) [478]
Labelled ligands [3H]hemicholinium-3 (pKd 8.2–8.4)
Comments: Ki and KD values for hemicholinium-3 listed in the table are for human CHT expressed in Xenopus laevis oocytes [479], or COS-7 cells [22]. Hemicholinium mustard is a substrate for CHT
that causes covalent modiﬁcation and irreversible inactivation of the transporter. Several exogenous substances (e.g. triethylcholine) that are substrates for CHT act as precursors to cholinergic false
transmitters.
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Sodium iodide symporter, sodium-dependent multivitamin
transporter and sodium-coupled monocarboxylate transporters
Transporters → SLC superfamily of solute carriers → SLC5 family of sodium-dependent glucose transporters → Sodium iodide symporter, sodium-dependent multivitamin transporter and
sodium-coupled monocarboxylate transporters
Overview: The sodium-iodide symporter (NIS) is an iodide trans-
porter found principally in the thyroid gland where it mediates
the accumulation of I- within thyrocytes. Transport of I- by NIS
from the blood across the basolateral membrane followed by api-
cal efﬂux into the colloidal lumen, mediated at least in part by
pendrin (SLC22A4), and most likely not SMCT1 (SLC5A8) as once
thought, provides the I- required for the synthesis of the thyroid
hormones triiodothyronine (triiodothyronine) and thyroxine (T4)
[59]. NIS is also expressed in the salivary glands, gastric mucosa,
intestinal enterocytes and lactating breast. NIS mediates I- ab-
sorption in the intestine and I- secretion into the milk. SMVT is
expressed on the apical membrane of intestinal enterocytes and
colonocytes and is the main system responsible for biotin (vi-
tamin H) and pantothenic acid (vitamin B5) uptake in humans
[544]. SMVT located in kidney proximal tubule epithelial cells
mediates the reabsorption of biotin and pantothenic acid. SMCT1
(SLC5A8), which transports a wide range of monocarboxylates, is
expressed in the apical membrane of epithelia of the small in-
testine, colon, kidney, brain neurones and the retinal pigment
epithelium [224]. SMCT2 (SLC5A12) also localises to the apical
membrane of kidney, intestine, and colon, but in the brain and
retina is restricted to astrocytes andMüller cells, respectively [224].
SMCT1 is a high-afﬁnity transporter whereas SMCT2 is a low-
afﬁnity transporter. The physiological substrates for SMCT1 and
SMCT2 are lactate (L-lactic acid and D-lactic acid), pyruvic acid,
propanoic acid, and nicotinic acid in non-colonic tissues such as
the kidney. SMCT1 is also likely to be the principal transporter for
the absorption of nicotinic acid (vitamin B3) in the intestine and
kidney [246]. In the small intestine and colon, the physiological
substrates for these transporters are nicotinic acid and the short-
chain fatty acids acetic acid, propanoic acid, and butyric acid that
are produced by bacterial fermentation of dietary ﬁber [447]. In
the kidney, SMCT2 is responsible for the bulk absorption of lactate
because of its low-afﬁnity/high-capacity nature. Absence of both
transporters in the kidney leads to massive excretion of lactate in
urine and consequently drastic decrease in the circulating levels
of lactate in blood [615]. SMCT1 also functions as a tumour sup-
pressor in the colon as well as in various other non-colonic tissues
[225]. The tumour-suppressive function of SMCT1 is based on its
ability to transport pyruvic acid, an inhibitor of histone deacety-
lases, into cells in non-colonic tissues [616]; in the colon, the abil-
ity of SMCT1 to transport butyric acid and propanoic acid, also in-
hibitors of histone deacetylases, underlies the tumour-suppressive
function of this transporter [224, 225, 271]. The ability of SMCT1
to promote histone acetylase inhibition through accumulation of
butyric acid and propanoic acid in immune cells is also respon-
sible for suppression of dendritic cell development in the colon
[579].
Nomenclature NIS SMVT SMCT1 SMCT2
Systematic nomenclature SLC5A5 SLC5A6 SLC5A8 SLC5A12
HGNC, UniProt SLC5A5, Q92911 SLC5A6, Q9Y289 SLC5A8, Q8N695 SLC5A12, Q1EHB4
Substrates ClO4-, SCN-, I-, NO3-, pertechnetate lipoic acid [139], pantothenic acid
[139], I- [139], biotin [139]
propanoic acid, 3-bromopyruvate, pyroglutamic acid,
nicotinic acid, D-lactic acid, β-D-hydroxybutyric acid,
L-lactic acid, salicylic acid, dichloroacetate, butyric acid,
α-ketoisocaproate, pyruvic acid, acetoacetic acid,
benzoate, γ-hydroxybutyric acid,
2-oxothiazolidine-4-carboxylate, acetic acid,
β-L-hydroxybutyric acid, 5-aminosalicylate
pyruvic acid, L-lactic acid, nicotinic acid
Stoichiometry 2Na+ : 1 I- [185]; 1Na+ : 1 ClO4- [157] 2Na+ : 1 biotin (or pantothenic acid)
[506]
2Na+ : 1 monocarboxylate [120] –
Inhibitors – – fenoprofen (pIC50 4.6) [319], ibuprofen (pIC50 4.2)
[319], ketoprofen (pIC50 3.9) [319]
–
Comments: I-, ClO4-, thiocyanate and NO3- are competitive substrate inhibitors of NIS [157]. Lipoic acid appears to act as a competitive substrate inhibitor of SMVT [654] and the anticonvulsant drugs
primidone and carbamazepine competitively block the transport of biotin by brush border vesicles prepared from human intestine [545].
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Sodium ionide symporter, sodium-dependent multivitamin
Sodium myo-inositol cotransporter transporters
Transporters → SLC superfamily of solute carriers → SLC5 family of sodium-dependent glucose transporters → Sodium myo-inositol cotransporter transporters
Overview: Three different mammalian myo-inositol cotrans-
porters are currently known; two are the Na+-coupled SMIT1 and
SMIT2 tabulated below and the third is proton-coupled HMIT
(SLC2A13). SMIT1 and SMIT2 have a widespread and overlap-
ping tissue location but in polarized cells, such as the Madin-
Darby canine kidney cell line, they segregate to the basolateral
and apical membranes, respectively [58]. In the nephron, SMIT1
mediatesmyo-inositol uptake as a ‘compatible osmolyte’ when in-
ner medullary tubules are exposed to increases in extracellular os-
molality, whilst SMIT2 mediates the reabsorption of myo-inositol
from the ﬁltrate. In some species (e.g. rat, but not rabbit) apically
located SMIT2 is responsible for the uptake of myo-inositol from
the intestinal lumen [21].
Nomenclature SMIT SGLT6
Systematic nomenclature SLC5A3 SLC5A11
Common abbreviation SMIT1 SMIT2
HGNC, UniProt SLC5A3, P53794 SLC5A11, Q8WWX8
Substrates myo-inositol, scyllo-inositol > L-fucose > L-xylose > L-glucose, D-glucose, α-MDG >
D-galactose, D-fucose > D-xylose [273]
myo-inositol = D-chiro-inositol> D-glucose > D-xylose > L-xylose [121]
Stoichiometry 2 Na+ :1 myo-inositol [273] 2 Na+ :1 myo-inositol [70]
Inhibitors phlorizin [121] phlorizin (pKi 4.1) [121]
Comments: The data tabulated are those for dog SMIT1 and rabbit SMIT2. SMIT2 transports D-chiro-inositol, but SMIT1 does not. In addition, whereas SMIT1 transports both D-xylose and L-xylose
and D-fucose and L-fucose, SMIT2 transports only the D-isomers of these sugars [121, 273]. Thus the substrate speciﬁcities of SMIT1 (for L-fucose) and SMIT2 (for D-chiro-inositol) allow discrimination
between the two SMITs. Human SMIT2 appears not to transport glucose [402].
Further reading on SLC5 family of sodium-dependent glucose transporters
DeFronzo RA et al. (2017) Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.
Nat Rev Nephrol 13: 11-26 [PMID:27941935]
Koepsell H. (2017) The Na+-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment
of diabetes and cancer. Pharmacol. Ther. 170: 148-165 [PMID:27773781]
Lehmann A et al. (2016) Intestinal SGLT1 inmetabolic health and disease. Am. J. Physiol. Gastrointest.
Liver Physiol. 310: G887-98 [PMID:27012770]
Wright EM. (2013) Glucose transport families SLC5 and SLC50. Mol. Aspects Med. 34: 183-96
[PMID:23506865]
Wright EM et al. (2011) Biology of human sodium glucose transporters. Physiol. Rev. 91: 733-94
[PMID:21527736]
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SLC6 neurotransmitter transporter family
Transporters → SLC superfamily of solute carriers → SLC6 neurotransmitter transporter family
Overview: Members of the solute carrier family 6 (SLC6) of
sodium- and (sometimes chloride-) dependent neurotransmitter
transporters [80, 106, 376] are primarily plasma membrane lo-
cated and may be divided into four subfamilies that transport
monoamines, GABA, glycine and neutral amino acids, plus the
related bacterial NSS transporters [546]. The members of this su-
perfamily share a structural motif of 10 TM segments that has
been observed in crystal structures of the NSS bacterial homolog
LeuTAa, a Na
+-dependent amino acid transporter from Aquiﬂex ae-
olicus [687] and in several other transporter families structurally
related to LeuT [209].
Monoamine transporter subfamily
Transporters → SLC superfamily of solute carriers → SLC6 neurotransmitter transporter family → Monoamine transporter subfamily
Overview: Monoamine neurotransmission is limited by perisynaptic transporters. Presynapticmonoamine transporters allow recycling of synaptically released noradrenaline, dopamine and 5-hydroxytryptamine.
Nomenclature NET DAT SERT
Systematic nomenclature SLC6A2 SLC6A3 SLC6A4
HGNC, UniProt SLC6A2, P23975 SLC6A3, Q01959 SLC6A4, P31645
Substrates MPP+, methamphetamine, amphetamine MPP+, methamphetamine, amphetamine MDMA, p-chloroamphetamine
Endogenous substrates dopamine, (-)-adrenaline, (-)-noradrenaline dopamine, (-)-adrenaline, (-)-noradrenaline 5-hydroxytryptamine
Stoichiometry 1 noradrenaline: 1 Na+:1 Cl- [266] 1 dopamine: 1˘2 Na+: 1 Cl- [265] 1 5-HT:1 Na+:1 Cl- (in), + 1 K+ (out) [603]
Inhibitors H05 (pKi 8.2) [682] – Rat – H05 (pKi 8.3) [682] – Rat
Sub/family-selective inhibitors sibutramine (pKi 5.2) [31] sibutramine (pKi 6.3) [31] sibutramine (pKi 6) [31]
Selective inhibitors mazindol (pKi 8.9), protriptyline (pIC50 8.8) [449],
nisoxetine (pKi 8.4), protriptyline (pKi 8.2) [404],
nomifensine (pKi 8.1), reboxetine (pKi 8) [673]
mazindol (pKi 8), WIN35428 (pKi 7.9) [524], GBR12935
(pKi 7.6), dexmethylphenidate (pKi 7.6) [381],
methylphenidate (pIC50 7.1) [214]
clomipramine (pKi 9.7) [608], paroxetine (pKi 9.6) [608],
clomipramine (pKd 9.6) [608], sertraline (pKi 9.1),
escitalopram (pIC50 9) [535], dapoxetine (pIC50 8.9)
[233], ﬂuvoxamine (pKd 8.7) [608], ﬂuoxetine (pKi 8.5)
[608], citalopram (pKi 8.4) [49]
Labelled ligands [3H]mazindol (Inhibitor) (pKd 9.3) [514] – Rat,
[3H]nisoxetine (Inhibitor) (pKd 8.4)
[3H]GBR12935 (Inhibitor) (pKd 8.5) [508],
[3H]WIN35428 (Inhibitor) (pKd 8) [508]
[3H]paroxetine (Inhibitor) (pKd 9.7), [
3H]citalopram
(Inhibitor) (pKd 8.3)
Comments: [125I]RTI55 labels all three monoamine transporters (NET, DAT and SERT) with afﬁnities between 0.5 and 5 nM. Cocaine is an inhibitor of all three transporters with pKi values between 6.5
and 7.2. Potential alternative splicing sites in non-coding regions of SERT and NET have been identiﬁed. A bacterial homologue of SERT shows allosteric modulation by selected anti-depressants [580].
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GABA transporter subfamily
Transporters → SLC superfamily of solute carriers → SLC6 neurotransmitter transporter family → GABA transporter subfamily
Overview: The activity of GABA-transporters located predomi-
nantly upon neurones (GAT-1), glia (GAT-3) or both (GAT-2, BGT-
1) serves to terminate phasic GABA-ergic transmission, maintain
low ambient extracellular concentrations of GABA, and recycle
GABA for reuse by neurones. Nonetheless, ambient concentra-
tions of GABA are sufﬁcient to sustain tonic inhibition mediated
by high afﬁnity GABAA receptors in certain neuronal populations
[566]. GAT1 is the predominant GABA transporter in the brain and
occurs primarily upon the terminals of presynaptic neurones and
to a much lesser extent upon distal astocytic processes that are in
proximity to axons terminals. GAT3 resides predominantly on dis-
tal astrocytic terminals that are close to the GABAergic synapse. By
contrast, BGT1 occupies an extrasynaptic location possibly along
with GAT2 which has limited expression in the brain [422]. TauT
is a high afﬁnity taurine transporter involved in osmotic balance
that occurs in the brain and non-neuronal tissues, such as the kid-
ney, brush border membrane of the intestine and blood brain bar-
rier [106, 279]. CT1, which transports creatine, has a ubiquitous
expression pattern, often co-localizing with creatine kinase [106].
Nomenclature GAT1 GAT2 GAT3 BGT1 TauT CT1
Systematic nomenclature SLC6A1 SLC6A13 SLC6A11 SLC6A12 SLC6A6 SLC6A8
HGNC, UniProt SLC6A1, P30531 SLC6A13, Q9NSD5 SLC6A11, P48066 SLC6A12, P48065 SLC6A6, P31641 SLC6A8, P48029
Substrates nipecotic acid, guvacine nipecotic acid, guvacine guvacine, nipecotic acid – – –
Endogenous substrates GABA β-alanine, GABA β-alanine, GABA GABA, betaine β-alanine, taurine, GABA
[15]
creatine
Stoichiometry 2Na+: 1Cl-: 1GABA 2Na+: 1Cl-:1GABA ≥ 2Na+: 2 Cl-: 1GABA 3Na+: 1 (or 2) Cl-: 1GABA 2Na+: 1Cl-: 1 taurine Probably 2Na+: 1Cl-: 1
creatine
Selective inhibitors NNC-711 (pIC50 7.4) [66],
tiagabine (pIC50 7.2) [66],
SKF89976A (pIC50 6.9)
[149], CI-966 (pIC50 6.6)
[66], (R/S) EF-1500 (pIC50
4.9–5.7), (R)-EF-1520 (pIC50
5.1–5.4), LU32-176B (pIC50
5.4) [667] – Mouse,
(S)-EF-1520 (pIC50 3.6–3.9)
SNAP-5114 (pIC50 4.7) [65]
– Rat
SNAP-5114 (pIC50 5.2) [65] NNC052090 (pKi 5.9) [618]
– Mouse, (R/S) EF-1500
(pIC50 4.9), (R)-EF-1520
(pIC50 3.7–4.7), (S)-EF-1520
(pIC50 3.6–4.5), LU32-176B
(pIC50 4) [667] – Mouse
– –
Labelled ligands [3H]tiagabine (Inhibitor) – – – – –
Comments: The IC50 values for GAT1-4 reported in the table re-
ﬂect the range reported in the literature from studies of both hu-
man and mouse transporters. There is a tendency towards lower
IC50 values for the human orthologue [380]. SNAP-5114 is only
weakly selective for GAT 2 and GAT3, with IC50 values in the
range 22 to >30 μM at GAT1 and BGT1, whereas NNC052090
has at least an order of magnitude selectivity for BGT1 [see
[119, 562] for reviews]. Compound (R)-4d is a recently described
compound that displays 20-fold selectivity for GAT3 over GAT1
[218]. In addition to the inhibitors listed, deramciclane is a
moderately potent, though non-selective, inhibitor of all cloned
GABA transporters (IC50 = 26-46 μM; [148]). Diaryloxime and
diarylvinyl ether derivatives of nipecotic acid and guvacine that
potently inhibit the uptake of [3H]GABA into rat synaptosomes
have been described [359]. Several derivatives of exo-THPO (e.g.
N-methyl-exo-THPO and N-acetyloxyethyl-exo-THPO) demon-
strate selectivity as blockers of astroglial, versus neuronal, up-
take of GABA [see [119, 561] for reviews]. GAT3 is inhibited by
physiologically relevant concentrations of Zn2+ [123]. Taut trans-
ports GABA, but with low afﬁnity, but CT1 does not, although
it can be engineered to do so by mutagenesis guided by LeuT
as a structural template [155]. Although inhibitors of creatine
transport by CT1 (e.g. β-guanidinopropionic acid, cyclocreatine,
guanidinoethane sulfonic acid) are known (e.g. [131]) they insuf-
ﬁciently characterized to be included in the table.
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Glycine transporter subfamily
Transporters → SLC superfamily of solute carriers → SLC6 neurotransmitter transporter family → Glycine transporter subfamily
Overview: Two gene products, GlyT1 and GlyT2, are known that
give rise to transporters that are predominantly located on glia and
neurones, respectively. Five variants of GlyT1 (a,b,c,d & e) differ-
ing in their N- and C-termini are generated by alternative pro-
moter usage and splicing, and three splice variants of GlyT2 (a,b
& c) have also been identiﬁed (see [51, 189, 242, 594] for reviews).
GlyT1 transporter isoforms expressed in glia surrounding gluta-
matergic synapses regulate synaptic glycine concentrations in-
ﬂuencing NMDA receptor-mediated neurotransmission [50, 219],
but also are important, in early neonatal life, for regulating glycine
concentrations at inhibitory glycinergic synapses [243]. Homozy-
gous mice engineered to totally lack GlyT1 exhibit severe respi-
ratory and motor deﬁciencies due to hyperactive glycinergic sig-
nalling and die within the ﬁrst postnatal day [243, 624]. Dis-
ruption of GlyT1 restricted to forebrain neurones is associated
with enhancement of EPSCs mediated by NMDA receptors and
behaviours that are suggestive of a promnesic action [695]. GlyT2
transporters localised on the axons and boutons of glycinergic
neurones appear crucial for efﬁcient transmitter loading of synap-
tic vesicles but may not be essential for the termination of in-
hibitory neurotransmission [244, 537]. Mice in which GlyT2 has
been deleted develop a fatal hyperekplexia phenotype during the
second postnatal week [244] and mutations in the human gene
encoding GlyT2 (SLC6A5) have been identiﬁed in patients with
hyperekplexia (reviewed by [281]). ATB0+ (SLC6A14) is a trans-
porter for numerous dipolar and cationic amino acids and thus
has a much broader substrate speciﬁcity than the glycine trans-
porters alongside which it is grouped on the basis of structural
similarity [106]. ATB0+ is expressed in various peripheral tissues
[106]. By contrast PROT (SLC6A7), which is expressed only in
brain in association with a subset of excitatory nerve terminals,
shows speciﬁcity for the transport of L-proline.
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Nomenclature GlyT1 GlyT2 ATB0,+ PROT
Systematic nomenclature SLC6A9 SLC6A5 SLC6A14 SLC6A7
HGNC, UniProt SLC6A9, P48067 SLC6A5, Q9Y345 SLC6A14, Q9UN76 SLC6A7, Q99884
Substrates – – BCH, zwitterionic or cationic NOS inhibitors
[284], 1-methyltryptophan [345],
valganciclovir [632]
–
Endogenous substrates sarcosine, glycine glycine β-alanine [13, 15]
L-isoleucine > L-leucine, L-methionine >
L-phenylalanine > L-tryptophan > L-valine
> L-serine [581]
L-proline
Stoichiometry 2 Na+: 1 Cl-: 1 glycine 3 Na+: 1 Cl-: 1 glycine 2-3 Na+: 1 Cl-: 1 amino acid [581] Probably 2 Na+: 1 Cl-: 1 L-proline
Inhibitors PF-03463275 (pKi 7.9) [411] bitopertin (pEC50 <4.5) [498] – –
Selective inhibitors (R)-NFPS (pIC50 8.5–9.1), SSR-103800
(pIC50 8.7) [69], N-methyl-SSR504734
(pIC50 8.6), LY2365109 (pIC50 7.8),
GSK931145 (pIC50 7.6), bitopertin (pEC50
7.5) [498]
Org 25543 (pIC50 7.8) [95], ALX 1393,
ALX 1405
α-methyl-D,L-tryptophan (pIC50 3.6) [345] compound 58 (pIC50 7.7) [724], LP-403812
(pIC50 7) [698]
Labelled ligands [3H](R)-NPTS (Binding) (pKd 9) [410],
[3H]GSK931145 (Binding) (pKd 8.8) [287],
[35S]ACPPB (Binding) (pKd 8.7) [703],
[3H]SB-733993 (Binding) (pKd 8.7) [287],
[3H]N-methyl-SSR504734 (pKd 8.1–8.5),
[3H]NFPS (pKd 7.7–8.2)
– – –
Comments – N-Oleoyl-L-carnitine (0.3μM, [91]) and and
N-arachidonoylglycine (IC50 5-8 μM, [668])
have been described as potential
endogenous selective GlyT2 inhibitors
– –
Comments: Sarcosine is a selective transportable inhibitor of
GlyT1 and also a weak agonist at the glycine binding site of the
NMDA receptor [707], but has no effect on GlyT2. This differ-
ence has been attributed to a single glycine residue in TM6 (ser-
ine residue in GlyT2) [641]. Inhibition of GLYT1 by the sarco-
sine derivatives NFPS, NPTS and Org 24598 is non-competitive
[424, 436]. IC50 values for Org 24598 reported in the literature
vary, most likely due to differences in assay conditions [74, 424].
The tricyclic antidepressant amoxapine weakly inhibits GlyT2
(IC50 92 μM) with approximately 10-fold selectivity over GlyT1
[473]. The endogenous lipids arachidonic acid and anandamide
exert opposing effects upon GlyT1a, inhibiting (IC50 2 μM)
and potentiating (EC50 13 μM) transport currents, respectively
[491]. N-arachidonyl-glycine, N-arachidonyl-γ-aminobutyric acid
and N-arachidonyl-D-alanine have been described as endogenous
non-competitive inhibitors of GlyT2a, but not GlyT1b [170, 327,
668]. Protons [30] and Zn2+ [332] act as non-competitive in-
hibitors of GlyT1b, with IC50 values of 100 nM and 10 μM respec-
tively, but neither ion affects GlyT2 (reviewed by [639]). Glycine
transport by GLYT1 is inhibited by Li+, whereas GLYT2 transport
is stimulated (both in the presence of Na+) [509].
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Neutral amino acid transporter subfamily
Transporters → SLC superfamily of solute carriers → SLC6 neurotransmitter transporter family → Neutral amino acid transporter subfamily
Overview: Certain members of neutral amino acid transport family are expressed upon the apical surface of epithelial cells and are important for the absorption of amino acids from the duodenum,
jejunum and ileum and their reabsorption within the proximal tubule of the nephron (i.e. B0AT1 (SLC6A19), SLC6A18, SLC6A20). Others may function as transporters for neurotransmitters or their
precursors (i.e. B0AT2, SLC6A17) [81]. B0AT1 has been proposed as a drug target to treat phenylketonuria [47].
Nomenclature B0AT1 B0AT2 B0AT3 NTT5 NTT4 SIT1
Systematic nomenclature SLC6A19 SLC6A15 SLC6A18 SLC6A16 SLC6A17 SLC6A20
HGNC, UniProt SLC6A19, Q695T7 SLC6A15, Q9H2J7 SLC6A18, Q96N87 SLC6A16, Q9GZN6 SLC6A17, Q9H1V8 SLC6A20, Q9NP91
Endogenous substrates L-leucine, L-methionine,
L-isoleucine, L-valine >
L-asparagine,
L-phenylalanine, L-alanine,
L-serine > L-threonine,
glycine, L-proline [80]
L-proline > L-alanine,
L-valine, L-methionine,
L-leucine > L-isoleucine,
L-threonine, L-asparagine,
L-serine, L-phenylalanine >
glycine [80]
L-alanine, glycine >
L-methionine,
L-phenylalanine, L-leucine,
L-histidine, L-glutamine
[643]
– L-leucine, L-methionine,
L-proline > L-cysteine,
L-alanine, L-glutamine,
L-serine > L-histidine,
glycine [700]
L-proline
Stoichiometry 1 Na+: 1 amino acid [90] 1 Na+: 1 amino acid [78] Na+- and Cl- -dependent
transport [578]
– Na+-dependent,
Cl--independent transport
[700]
2 Na+: 1 Cl-: 1 imino acid
[76]
Inhibitors cinromide (pIC50 6.4) [134],
nimesulide (pIC50 4.6) [500]
– Rat, benzatropine (pIC50
4.4) [112]
– – – – –
Selective inhibitors – loratadine (pIC50 5.4) [130] – – – –
Comments Mutations in B0AT1 are
associated with Hartnup
disorder
– SLC6A18 is a functional
transporter in mouse, but
not in humans.
– – –
Further reading on SLC6 neurotransmitter transporter family
Bermingham DP et al. (2016) Kinase-dependent Regulation of Monoamine Neurotransmitter Trans-
porters. Pharmacol. Rev. 68: 888-953 [PMID:27591044]
Bröer S et al. (2012) The solute carrier 6 family of transporters. Br. J. Pharmacol. 167: 256-78
[PMID:22519513]
Joncquel-Chevalier Curt M et al. (2015) Creatine biosynthesis and transport in health and disease.
Biochimie 119: 146-65 [PMID:26542286]
Lohr KM et al. (2017) Membrane transporters as mediators of synaptic dopamine dynamics: impli-
cations for disease. Eur. J. Neurosci. 45: 20-33 [PMID:27520881]
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SLC8 family of sodium/calcium exchangers
Transporters → SLC superfamily of solute carriers → SLC8 family of sodium/calcium exchangers
Overview: The sodium/calcium exchangers (NCX) use the extra-
cellular sodium concentration to facilitate the extrusion of cal-
cium out of the cell. Alongside the plasma membrane Ca2+-
ATPase (PMCA) and sarcoplasmic/endoplasmic reticulum Ca2+-
ATPase (SERCA), as well as the sodium/potassium/calcium ex-
changers (NKCX, SLC24 family), NCX allow recovery of intracel-
lular calcium back to basal levels after cellular stimulation. When
intracellular sodium ion levels rise, for example, following de-
polarisation, these transporters can operate in the reverse direc-
tion to allow calcium inﬂux and sodium efﬂux, as an electrogenic
mechanism. Structural modelling suggests the presence of 9 TM
segments, with a large intracellular loop between the ﬁfth and
sixth TM segments.
Nomenclature Sodium/calcium exchanger 1 Sodium/calcium exchanger 2 Sodium/calcium exchanger 3
Systematic nomenclature SLC8A1 SLC8A2 SLC8A3
Common abbreviation NCX1 NCX2 NCX3
HGNC, UniProt SLC8A1, P32418 SLC8A2, Q9UPR5 SLC8A3, P57103
Stoichiometry 3 Na+ (in) : 1 Ca2+ (out) or 4 Na+ (in) : 1 Ca2+ (out) [158];
Reverse mode 1 Ca2+ (in): 1 Na+ (out)
– –
Selective inhibitors – – YM-244769 (pIC50 7.7) [323]
Comments: Although subtype-selective inhibitors of NCX function are not widely available, 3,4-dichlorobenzamil and CBDMB act as non-selective NCX inhibitors, while SEA0400, KB-R7943, SN6, and
ORM-10103 [331] act to inhibit NCX function with varying degrees of selectivity. BED is a selective NCX3 inhibitor [563] and and YM-244769 inhibits NCX3 preferentially over other isoforms [323, 688].
Further reading on SLC8 family of sodium/calcium exchangers
Giladi M et al. (2016) Structure-Functional Basis of Ion Transport in Sodium-Calcium Exchanger
(NCX) Proteins. Int J Mol Sci 17: [PMID:27879668]
Khananshvili D. (2013) The SLC8 gene family of sodium-calcium exchangers (NCX) - structure, func-
tion, and regulation in health and disease. Mol. Aspects Med. 34: 220-35 [PMID:23506867]
Sekler I. (2015) Standing of giants shoulders the story of the mitochondrial Na(+)Ca(2+) exchanger.
Biochem. Biophys. Res. Commun. 460: 50-2 [PMID:25998733]
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SLC9 family of sodium/hydrogen exchangers
Transporters → SLC superfamily of solute carriers → SLC9 family of sodium/hydrogen exchangers
Overview: Sodium/hydrogen exchangers or sodium/proton an-
tiports are a family of transporters that maintain cellular pH by
utilising the sodium gradient across the plasma membrane to ex-
trude protons produced by metabolism, in a stoichiometry of 1
Na+ (in) : 1 H+ (out). Several isoforms, NHE6, NHE7, NHE8 and
NHE9 appear to locate on intracellular membranes [448, 457, 472].
Li+ and NH4+, but not K+, ions may also be transported by some
isoforms. Modelling of the topology of these transporters indi-
cates 12 TM regions with an extended intracellular C-terminus
containing multiple regulatory sites.
NHE1 is considered to be a ubiquitously-expressed ‘housekeeping’
transporter. NHE3 is highly expressed in the intestine and kid-
neys and regulate sodium movements in those tissues. NHE10 is
present in sperm [653] and osteoclasts [391]; gene disruption re-
sults in infertile male mice [653].
Information on members of this family may be found in the online database.
Comments: Analogues of the non-selective cation transport inhibitor amiloride appear to inhibit NHE function through competitive inhibition of the extracellular Na+ binding site. The more selective
amiloride analogues MPA and ethylisopropylamiloride exhibit a rank order of afﬁnity of inhibition of NHE1 > NHE2 > NHE3 [127, 625, 626].
Further reading on SLC9 family of sodium/hydrogen exchangers
Donowitz M et al. (2013) SLC9/NHE gene family, a plasma membrane and organellar family of
Na+/H+ exchangers. Mol. Aspects Med. 34: 236-51 [PMID:23506868]
Kato A et al. (2011) Regulation of electroneutral NaCl absorption by the small intestine. Annu. Rev.
Physiol. 73: 261-81 [PMID:21054167]
Ohgaki R et al. (2011) Organellar Na+/H+ exchangers: novel players in organelle pH regulation and
their emerging functions. Biochemistry 50: 443-50 [PMID:21171650]
Parker MD et al. (2015) Na+-H+ exchanger-1 (NHE1) regulation in kidney proximal tubule. Cell. Mol.
Life Sci. 72: 2061-74 [PMID:25680790]
Rufﬁn VA et al. (2014) Intracellular pH regulation by acid-base transporters in mammalian neurons.
Front Physiol 5: 43 [PMID:24592239]
SLC10 family of sodium-bile acid co-transporters
Transporters → SLC superfamily of solute carriers → SLC10 family of sodium-bile acid co-transporters
Overview: The SLC10 family transport bile acids, sulphated
solutes, and other xenobiotics in a sodium-dependent manner.
The founding members, SLC10A1 (NTCP) and SLC10A2 (ASBT)
function, along with members of the ABC transporter family
(MDR1/ABCB1, BSEP/ABCB11 andMRP2/ABCC2) and the organic
solute transporter obligate heterodimer OSTα:OSTβ (SLC51), to
maintain the enterohepatic circulation of bile acids [138, 357].
SLC10A6 (SOAT) functions as a sodium-dependent transporter
of sulphated solutes including sulfphated steroids and bile acids
[234, 236]. Transport function has not yet been demonstrated
for the 4 remaining members of the SLC10 family, SLC10A3 (P3),
SLC10A4 (P4), SLC10A5 (P5), and SLC10A7 (P7), and the iden-
tity of their endogenous substrates remain unknown [201, 236,
241, 649]. Members of the SLC10 family are predicted to have
seven transmembrane domains with an extracellular N-terminus
and cytoplasmic C-terminus [42, 274].
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Nomenclature Sodium/bile acid and sulphated solute cotransporter 1 Sodium/bile acid and sulphated solute cotransporter 2 Sodium/bile acid and sulphated solute cotransporter 6
Systematic nomenclature SLC10A1 SLC10A2 SLC10A6
Common abbreviation NTCP ASBT SOAT
HGNC, UniProt SLC10A1, Q14973 SLC10A2, Q12908 SLC10A6, Q3KNW5
Substrates – glycodeoxycholic acid > glycoursodeoxycholic acid,
glycochenodeoxycholic acid > taurocholic acid >
cholic acid [129]
pregnenolone sulphate [234], estrone-3-sulphate,
dehydroepiandrosterone sulphate [236],
taurolithocholic acid-3-sulphate
Endogenous substrates dehydroepiandrosterone sulphate [129, 201, 430],
estrone-3-sulphate, iodothyronine sulphates [649]
tauroursodeoxycholic acid, taurocholic acid,
taurochenodeoxycholic acid > glycocholic acid >
cholic acid [430]
– –
Stoichiometry 2 Na+: 1 bile acid [42, 234] >1 Na+: 1 bile acid [129, 662] –
Inhibitors (-)-propranolol (pIC50 8.2) [355], cyclosporin A (pIC50 6)
[355], (+)-propranolol (pIC50 5.3) [355], cyclosporin A (pKi
5.1) [159], irbesartan (pKi 4.9) [159]
elobixibat (pIC50 8.9) [237], SC-435 (pIC50 8.8) [54],
264W94 (pIC50 7.3) [620, 679]
–
Labelled ligands – [3H]taurocholic acid [129] –
Comments – Chenodeoxycholyl-N-nitrobenzoxadiazol-lysine is a
ﬂuorescent bile acid analogue used as a probe [662].
–
Comments: Heterologously expressed SLC10A4 [235] or SLC10A7 [241] failed to exhibit signiﬁcant transport of taurocholic acid, pregnenolone sulphate, dehydroepiandrosterone sulphate or choline.
SLC10A4 has recently been suggested to associate with neuronal vesicles [84].
Further reading on SLC10 family of sodium-bile acid co-transporters
Anwer MS et al. (2014) Sodium-dependent bile salt transporters of the SLC10A transporter family:
more than solute transporters. Pﬂugers Arch. 466: 77-89 [PMID:24196564]
Claro da Silva T et al. (2013) The solute carrier family 10 (SLC10): beyond bile acid transport. Mol.
Aspects Med. 34: 252-69 [PMID:23506869]
Dawson PA. (2017) Roles of Ileal ASBT and OSTα-OSTβ in Regulating Bile Acid Signaling. Dig Dis 35:
261-266 [PMID:28249269]
Zwicker BL et al. (2013) Transport and biological activities of bile acids. Int. J. Biochem. Cell Biol. 45:
1389-98 [PMID:23603607]
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SLC11 family of proton-coupled metal ion transporters
Transporters → SLC superfamily of solute carriers → SLC11 family of proton-coupled metal ion transporters
Overview: The family of proton-coupled metal ion trans-
porters are responsible for movements of divalent cations, par-
ticularly ferrous and manganese ions, across the cell membrane
(SLC11A2/DMT1) and across endosomal (SLC11A2/DMT1) or
lysosomal/phagosomal membranes (SLC11A1/NRAMP1), depen-
dent on proton transport. Both proteins appear to have 12 TM re-
gions and cytoplasmic N- and C- termini. NRAMP1 is involved in
antimicrobial action in macrophages, although its precise mech-
anism is undeﬁned. Facilitated diffusion of divalent cations into
phagosomes may increase intravesicular free radicals to damage
the pathogen. Alternatively, export of divalent cations from the
phagosome may deprive the pathogen of essential enzyme cofac-
tors. SLC11A2/DMT1 is more widely expressed and appears to
assist in divalent cation assimilation from the diet, as well as in
phagocytotic cells.
Nomenclature NRAMP1 DMT1
Systematic nomenclature SLC11A1 SLC11A2
HGNC, UniProt SLC11A1, P49279 SLC11A2, P49281
Endogenous substrates Fe2+, Mn2+ Cu2+, Co2+, Cd2+, Fe2+, Mn2+
Stoichiometry 1 H+ : 1 Fe2+ (out) or 1 Fe2+ (in) : 1 H+ (out) 1 H+ : 1 Fe2+ (out) [269]
Inhibitors – compound 6b (pIC50 7.1) [710]
Comments: Loss-of-functionmutations in NRAMP1 are associated with increased susceptibility tomicrobial infection (OMIM: 607948). Loss-of-functionmutations inDMT1 are associated withmicrocytic
anemia (OMIM: 206100).
Further reading on SLC11 family of proton-coupled metal ion transporters
Codazzi F et al. (2015) Iron entry in neurons and astrocytes: a link with synaptic activity. Front Mol
Neurosci 8: 18 [PMID:26089776]
Montalbetti N et al. (2013) Mammalian iron transporters: families SLC11 and SLC40. Mol. Aspects
Med. 34: 270-87 [PMID:23506870]
Wessling-Resnick M. (2015) Nramp1 and Other Transporters Involved in Metal Withholding during
Infection. J. Biol. Chem. 290: 18984-90 [PMID:26055722]
Zheng W et al. (2012) Regulation of brain iron and copper homeostasis by brain barrier systems:
implication in neurodegenerative diseases. Pharmacol. Ther. 133: 177-88 [PMID:22115751]
SLC12 family of cation-coupled chloride transporters
Transporters → SLC superfamily of solute carriers → SLC12 family of cation-coupled chloride transporters
Overview: The SLC12 family of chloride transporters contribute
to ion ﬂuxes across a variety of tissues, particularly in the kidney
and choroid plexus of the brain. Within this family, further sub-
families are identiﬁable: NKCC1, NKCC2 and NCC constitute a
group of therapeutically-relevant transporters, targets for loop and
thiazide diuretics. These 12 TM proteins exhibit cytoplasmic ter-
mini and an extended extracellular loop at TM7/8 and are kidney-
speciﬁc (NKCC2 and NCC) or show a more widespread distribu-
tion (NKCC1). A second family, the K-Cl co-transporters are also
12 TM domain proteins with cytoplasmic termini, but with an ex-
tended extracellular loop at TM 5/6. CCC6 exhibits structural sim-
ilarities with the K-Cl co-transporters, while CCC9 is divergent,
with 11 TM domains and a cytoplasmic N-terminus and extracel-
lular C-terminus.
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Nomenclature Kidney-speciﬁc Na-K-Cl symporter Basolateral Na-K-Cl symporter Na-Cl symporter K-Cl cotransporter 1 K-Cl cotransporter 2
Systematic nomenclature SLC12A1 SLC12A2 SLC12A3 SLC12A4 SLC12A5
Common abbreviation NKCC2 NKCC1 NCC KCC1 KCC2
HGNC, UniProt SLC12A1, Q13621 SLC12A2, P55011 SLC12A3, P55017 SLC12A4, Q9UP95 SLC12A5, Q9H2X9
Stoichiometry 1 Na+ : 1 K+ : 2 Cl- (in) 1 Na+ : 1 K+ : 2 Cl- (in) 1 Na+ : 1 Cl- (in) 1 K+ : 1 Cl- (out) 1 K+ : 1 Cl- (out)
Inhibitors bumetanide (pIC50 6.5) [280],
piretanide (pIC50 6) [280],
furosemide (pIC50 5.2) [280]
piretanide (pIC50 5.6) [280],
bumetanide (pIC50 5.6) [280],
furosemide (pIC50 5.1) [280]
chlorothiazide, cyclothiazide,
hydrochlorothiazide, metolazone
DIOA VU0240551 (pIC50 6.2) [143],
DIOA
Nomenclature K-Cl cotransporter 3 K-Cl cotransporter 4 Cation-chloride cotransporter 9
Systematic nomenclature SLC12A6 SLC12A7 SLC12A8
Common abbreviation KCC3 KCC4 CCC9
HGNC, UniProt SLC12A6, Q9UHW9 SLC12A7, Q9Y666 SLC12A8, A0AV02
Substrates – – L-glutamic acid, spermine, L-aspartic acid, spermidine
Stoichiometry 1 K+ : 1 Cl- (out) 1 K+ : 1 Cl- (out) Unknown
Inhibitors DIOA DIOA –
Comments – – In mouse studies Slc12a8 has been shown to transport the nicotinamide adenine dinucleotide (NAD+) precursor, nicotinamide
mononucleotide (NMN) in to cells, and administration of NMN produces anti-ageing effects in vivo [261].
Comments: DIOA is able to differentiate KCC isoforms from NKCC and NCC transporters, but also inhibits CFTR [321].
Further reading on SLC12 family of cation-coupled chloride transporters
Arroyo JP et al. (2013) The SLC12 family of electroneutral cation-coupled chloride cotransporters.
Mol. Aspects Med. 34: 288-98 [PMID:23506871]
Bachmann S et al. (2017) Regulation of renal Na-(K)-Cl cotransporters by vasopressin. Pﬂugers Arch.
469: 889-897 [PMID:28577072]
Bazúa-Valenti S et al. (2016) Physiological role of SLC12 familymembers in the kidney. Am. J. Physiol.
Renal Physiol. 311: F131-44 [PMID:27097893]
Huang X et al. (2016) Everything we always wanted to know about furosemide but were afraid to
ask. Am. J. Physiol. Renal Physiol. 310: F958-71 [PMID:26911852]
Kahle KT et al. (2015) K-Cl cotransporters, cell volume homeostasis, and neurological disease. Trends
Mol Med 21: 513-23 [PMID:26142773]
Martín-Aragón Baudel MA et al. (2017) Chloride co-transporters as possible therapeutic targets for
stroke. J. Neurochem. 140: 195-209 [PMID:27861901]
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SLC13 family of sodium-dependent sulphate/carboxylate transporters
Transporters → SLC superfamily of solute carriers → SLC13 family of sodium-dependent sulphate/carboxylate transporters
Overview: Within the SLC13 family, two groups of transporters may be differentiated on the basis of the substrates transported: NaS1 and NaS2 convey sulphate, while NaC1-3 transport carboxylates.
NaS1 and NaS2 transporters are made up of 13 TM domains, with an intracellular N terminus and are electrogenic with physiological roles in the intestine, kidney and placenta. NaC1, NaC2 and NaC3
are made up of 11 TM domains with an intracellular N terminus and are electrogenic, with physiological roles in the kidney and liver.
Nomenclature Na+/sulfate cotransporter Na+/dicarboxylate cotransporter 1 Na+/dicarboxylate cotransporter 3 Na+/sulfate cotransporter Na+/citrate cotransporter
Systematic nomenclature SLC13A1 SLC13A2 SLC13A3 SLC13A4 SLC13A5
Common abbreviation NaS1 NaC1 NaC3 NaS2 NaC2
HGNC, UniProt SLC13A1, Q9BZW2 SLC13A2, Q13183 SLC13A3, Q8WWT9 SLC13A4, Q9UKG4 SLC13A5, Q86YT5
Endogenous substrates SeO42-, SO42-, S2O32- citric acid, succinic acid citric acid, succinic acid SO42- citric acid, pyruvic acid
Stoichiometry 3 Na+ : 1 SO42- (in) 3 Na+ : 1 dicarboxylate2- (in) Unknown 3 Na+ : SO42- (in) Unknown
Further reading on SLC13 family of sodium-dependent sulphate/carboxylate transporters
Bergeron MJ et al. (2013) SLC13 family of Na+-coupled di- and tri-carboxylate/sulfate transporters.
Mol. Aspects Med. 34: 299-312 [PMID:23506872]
Markovich D. (2014) Na+-sulfate cotransporter SLC13A1. Pﬂugers Arch. 466: 131-7 [PMID:24193406]
Pajor AM. (2014) Sodium-coupled dicarboxylate and citrate transporters from the SLC13 family.
Pﬂugers Arch. 466: 119-30 [PMID:24114175]
Searchable database: http://www.guidetopharmacology.org/index.jsp SLC13 family of sodium-dependent sulphate/ S433
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14753/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology (2019) 176, S397–S493
carboxylate transporters
SLC14 family of facilitative urea transporters
Transporters → SLC superfamily of solute carriers → SLC14 family of facilitative urea transporters
Overview: As a product of protein catabolism, urea is moved
around the body and through the kidneys for excretion. Although
there is experimental evidence for concentrative urea transporters,
these have not been deﬁned at the molecular level. The SLC14
family are facilitative transporters, allowing urea movement down
its concentration gradient. Multiple splice variants of these trans-
porters have been identiﬁed; for UT-A transporters, in particular,
there is evidence for cell-speciﬁc expression of these variants with
functional impact [589]. Topographical modelling suggests that
the majority of the variants of SLC14 transporters have 10 TM do-
mains, with a glycosylated extracellular loop at TM5/6, and intra-
cellular C- and N-termini. The UT-A1 splice variant, exceptionally,
has 20 TMdomains, equivalent to a combination of theUT-A2 and
UT-A3 splice variants.
Nomenclature Erythrocyte urea transporter Kidney urea transporter
Systematic nomenclature SLC14A1 SLC14A2
Common abbreviation UT-B UT-A
HGNC, UniProt SLC14A1, Q13336 SLC14A2, Q15849
Substrates acetamide [711], acrylamide [711], methylurea [711] –
Endogenous substrates ammonium carbonate [711], urea [711], formamide [711] urea [420]
Stoichiometry Equilibrative Equilibrative
Inhibitors compound 1a (pIC50 ∼8) [406], compound 1a (pIC50 7.6) [406] – Mouse –
Further reading on SLC14 family of facilitative urea transporters
Esteva-Font C et al. (2015) Urea transporter proteins as targets for small-molecule diuretics. Nat Rev
Nephrol 11: 113-23 [PMID:25488859]
LeMoine CM et al. (2015) Evolution of urea transporters in vertebrates: adaptation to urea’s multiple
roles and metabolic sources. J. Exp. Biol. 218: 1936-1945 [PMID:26085670]
Pannabecker TL. (2013) Comparative physiology and architecture associated with the mammalian
urine concentrating mechanism: role of inner medullary water and urea transport pathways in
the rodentmedulla. Am. J. Physiol. Regul. Integr. Comp. Physiol. 304: R488-503 [PMID:23364530]
Shayakul C et al. (2013) The urea transporter family (SLC14): physiological, pathological and struc-
tural aspects. Mol. Aspects Med. 34: 313-22 [PMID:23506873]
Stewart G. (2011) The emerging physiological roles of the SLC14A family of urea transporters. Br. J.
Pharmacol. 164: 1780-92 [PMID:21449978]
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SLC15 family of peptide transporters
Transporters → SLC superfamily of solute carriers → SLC15 family of peptide transporters
Overview: The Solute Carrier 15 (SLC15) family of peptide
transporters, alias H+-coupled oligopeptide cotransporter family,
is a group of membrane transporters known for their key role
in the cellular uptake of di- and tripeptides (di/tripeptides). Of
its members, SLC15A1 (PEPT1) chieﬂy mediates intestinal ab-
sorption of luminal di/tripeptides from overall dietary protein
digestion, SLC15A2 (PEPT2) mainly allows renal tubular reup-
take of di/tripeptides from ultraﬁltration and brain-to-blood ef-
ﬂux of di/tripeptides in the choroid plexus, SLC15A3 (PHT2) and
SLC15A4 (PHT1) interact with both di/tripeptides and histidine,
e.g. in certain immune cells, and SLC15A5 has unknown phys-
iological function. In addition, the SLC15 family of peptide
transporters variably interacts with a very large number of pep-
tidomimetics and peptide-like drugs. It is conceivable, based on
the currently acknowledged structural and functional differences,
to divide the SLC15 family of peptide transporters into two sub-
families.
Nomenclature Peptide transporter 1 Peptide transporter 2
Systematic nomenclature SLC15A1 SLC15A2
Common abbreviation PEPT1 PEPT2
HGNC, UniProt SLC15A1, P46059 SLC15A2, Q16348
Substrates fMet-Leu-Phe [88, 102, 432, 433, 677], His-Leu-lopinavir [425], D-Ala-Lys-AMCA [245,
260, 372, 599], β-Ala-Lys-AMCA [3, 324, 372], alafosfalin [462], muramyl dipeptide [318,
645]
muramyl dipeptide [297, 592], β-Ala-Lys-AMCA [3, 152, 372, 531, 540, 592, 722, 723],
D-Ala-Lys-AMCA [372, 599, 663], γ-iE-DAP [592, 597], alafosfalin [462]
Endogenous substrates protons, dipeptides [169], 5-aminolevulinic acid [16, 53, 169, 312, 461, 549], tripeptides
[169]
dipeptides, protons, tripeptides, 5-aminolevulinic acid [169, 312, 681]
Stoichiometry Transport is electrogenic and involves a variable proton-to-substrate stoichiometry for
uptake of neutral and mono- or polyvalently charged peptides, as well as 5-aminolevulic
acid.
Transport is electrogenic and involves a variable proton-to-substrate stoichiometry for
uptake of neutral and mono- or polyvalently charged peptides, as well as 5-aminolevulic
acid.
Inhibitors Lys[Z(NO2)]-Val (pKi 5.7) [360], 4-AMBA (pKi 5.5) [135, 431], Lys[Z(NO2)]-Pro (pKi
5–5.3) [362]
Lys[Z(NO2)]-Lys[Z(NO2)] (pKi 8) [57, 617], Lys[Z(NO2)]-Pro
Labelled ligands [11C]GlySar [444], [14C]GlySar [6, 40, 56, 221, 222, 223, 312, 361, 362, 363, 413, 425,
556, 604, 612, 613, 614], [3H]GlySar [12, 87, 118, 128, 278, 325, 399, 483, 549, 599]
[11C]GlySar [453], [14C]GlySar [217, 221, 222, 223, 298, 312, 361, 363, 405, 413, 556,
612, 614], [3H]GlySar [399, 412, 483, 550, 583, 599]
Comments A variety of dipeptides and drugs interact with PEPT1, including carnosine [288], D-Phe-Ala
[169, 362], D-Phe-Gln [16], 5-aminolevulinic acid [461, 475, 529], nateglinide [614],
glibenclamide [556], valacyclovir [39, 40, 53, 270], cefadroxil [664], cephalexin [221] and
penicillin G (benzylpenicillin) [53], as detected using [3H] and [14C] radio-labelled probes.
Other high-afﬁnity (non-transported) inhibitors: Lys[Z(NO2)]-Val (Ki 2 μM) [360, 362],
Lys[Z(NO2)]-Pro (Ki 3-7 μM) [360, 362]; other low-afﬁnity, (non-transported) inhibitors:
4-AMBA (Ki 3 mM) [16, 135, 431]. Like PEPT1, PEPT2 interact with dipeptides and drugs
including carnosine [681], D-Phe-Ala [169, 617], 5-aminolevulinic acid [169, 312, 461,
475, 529], nateglinide [614], glibenclamide [556], cefadroxil [475], cephalexin [221] and
penicillin G (benzylpenicillin) [475].
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Nomenclature Peptide transporter 3 Peptide transporter 4
Systematic nomenclature SLC15A3 SLC15A4
Common abbreviation PHT2 PHT1
HGNC, UniProt SLC15A3, Q8IY34 SLC15A4, Q8N697
Substrates MDP-rhodamine [456], muramyl dipeptide [456, 660], Tri-DAP [660] His-Leu-lopinavir [425], Tri-DAP [388, 554, 584], C12-iE-DAP [388], glycyl-sarcosine [52,
298, 584, 599], muramyl dipeptide [456, 584], valacyclovir [52], MDP-rhodamine [297,
456]
Endogenous substrates L-histidine [548], dipeptides, tripeptides, protons L-histidine [52, 365, 425, 658, 689], carnosine [52, 689]
Stoichiometry PHT2 has not been analyzed systematically with respect to driving force, mode of
transport, and substrate speciﬁcity. The pH dependence observed for transport of histidine
[548] and the model peptides used, i.e., carnosine [548] and histidyl-leucine [548],
suggest a similar mode of operation as PEPT1 and PEPT2 proteins.
PHT1 has not been analyzed systematically with respect to driving force, mode of
transport, and substrate speciﬁcity. The pH dependence observed for transport of histidine
[52, 365, 425, 658, 689] and the model peptide used, i.e., carnosine [52, 689], suggest a
similar mode of operation as PEPT1 and PEPT2 proteins.
Labelled ligands [14C]histidine [548] [14C]histidine (Binding) [658, 659, 689], [3H]histidine [52, 425, 599, 658]
Comments PHT2 interacts with [3H]carnosine [548]. Other PHT1 ligands include [3H]histidine [52, 425, 599, 658], d3-L-histidine [584],
[3H]carnosine [52, 689] [14C]GlySar [298], [3H]GlySar [52, 599] and [3H]valacyclovir [52].
Comments: The members of the SLC15 family of peptide
transporters are particularly promiscuous in the transport of
di/tripeptides, and D-amino acid containing peptides are also
transported. While SLC15A3 and SLC15A4 transport histi-
dine, none of them transport tetrapeptides. In addition, many
molecules, among which beta-lactam antibiotics, angiotensin-
converting enzyme inhibitors and sartans, variably interact
with the SLC15 family transporters. Known substrates include
cefadroxil, valacyclovir, 5-aminolevulinic acid, L-Dopa prodrugs,
gemcitabine prodrugs, ﬂoxuridine prodrugs, Maillard reaction
products, JBP485, zanamivir, oseltamivir prodrugs, doxorubicin
prodrugs, polymyxins, and didanosine prodrugs. Frequently used
pharmaceutical excipients such as Tween® 20, Tween® 80, Solu-
tol® HS 15 and Cremophor EL® strongly inhibit cellular uptake
of Gly-Sar by SLC15A1 and/or SLC15A2 [483].
There is evidence to suggest the existence of a ﬁfth member of
this transporter family, SLC15A5 (A6NIM6; ENSG00000188991),
but to date there is no established biological function or reported
pharmacology for this protein [585].
Further reading on SLC15 family of peptide transporters
Anderson CM et al. (2010) Hijacking solute carriers for proton-coupled drug transport. Physiology
(Bethesda) 25: 364-77 [PMID:21186281]
Brandsch M. (2013) Drug transport via the intestinal peptide transporter PepT1. Curr Opin Pharmacol
13: 881-7 [PMID:24007794]
Brandsch M. (2009) Transport of drugs by proton-coupled peptide transporters: pearls and pitfalls.
Expert Opin Drug Metab Toxicol 5: 887-905 [PMID:19519280]
Fredriksson R et al. (2008) The solute carrier (SLC) complement of the human genome: phylogenetic
classiﬁcation reveals four major families. FEBS Lett. 582: 3811-6 [PMID:18948099]
Newstead S. (2015) Molecular insights into proton coupled peptide transport in the PTR family of
oligopeptide transporters. Biochim. Biophys. Acta 1850: 488-499 [PMID:24859687]
Newstead S. (2017) Recent advances in understanding proton coupled peptide transport via the POT
family. Curr. Opin. Struct. Biol. 45: 17-24 [PMID:27865112]
Newstead S. (2011) Towards a structural understanding of drug and peptide transport within the
proton-dependent oligopeptide transporter (POT) family. Biochem. Soc. Trans. 39: 1353-8
[PMID:21936814]
Smith DE et al. (2013) Proton-coupled oligopeptide transporter family SLC15: physiological, phar-
macological and pathological implications. Mol. Aspects Med. 34: 323-36 [PMID:23506874]
Thwaites DT et al. (2007) H+-coupled nutrient, micronutrient and drug transporters in the mam-
malian small intestine. Exp. Physiol. 92: 603-19 [PMID:17468205]
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SLC16 family of monocarboxylate transporters
Transporters → SLC superfamily of solute carriers → SLC16 family of monocarboxylate transporters
Overview: Members of the SLC16 family may be divided into subfamilies on the basis of substrate selectivities, particularly lactate (e.g. L-lactic acid), pyruvic acid and ketone bodies, as well as aromatic
amino acids. Topology modelling suggests 12 TM domains, with intracellular termini and an extended loop at TM 6/7.
The proton-coupledmonocarboxylate transporters (monocarboxylate transporters 1, 4, 2 and 3) allow transport of the products of cellular metabolism, principally lactate (e.g. L-lactic acid) and pyruvic acid.
Nomenclature Monocarboxylate
transporter 1
Monocarboxylate
transporter 2
Monocarboxylate
transporter 3
Monocarboxylate
transporter 4
Monocarboxylate
transporter 6
Monocarboxylate
transporter 8
Monocarboxylate
transporter 10
Systematic nomenclature SLC16A1 SLC16A7 SLC16A8 SLC16A3 SLC16A5 SLC16A2 SLC16A10
Common abbreviation MCT1 MCT2 MCT3 MCT4 MCT6 MCT8 TAT1
HGNC, UniProt SLC16A1, P53985 SLC16A7, O60669 SLC16A8, O95907 SLC16A3, O15427 SLC16A5, O15375 SLC16A2, P36021 SLC16A10, Q8TF71
Substrates γ-hydroxybutyric acid
[657]
– – – – – –
Endogenous substrates pyruvic acid,
L-lactic acid,
β-D-hydroxybutyric acid
pyruvic acid,
L-lactic acid
L-lactic acid pyruvic acid,
L-lactic acid
– triiodothyronine [213],
T4 [213]
L-tryptophan,
L-phenylalanine,
levodopa, L-tyrosine
Stoichiometry 1 H+ : 1
monocarboxylate- (out)
1 H+ : 1
monocarboxylate- (out)
1 H+ : 1
monocarboxylate- (out)
1 H+ : 1
monocarboxylate- (out)
Unknown Unknown Unknown
Inhibitors compound 30
(Compound 30 is a
channel blocker.) (pKi
8.3) [268]
7ACC2 (pIC50 8) [162] – – – – –
Comments – – – – MCT6 has been
reported to transport
bumetanide, but not
short chain fatty acids
[451].
– –
Comments: MCT1 and MCT2, but not MCT3 and MCT4, are inhibited by CHC, which also inhibits members of the mitochondrial transporter family, SLC25.
MCT5-MCT7, MCT9 and MCT11-14 are regarded as orphan transporters.
Further reading on SLC16 family of monocarboxylate transporters
Bernal J et al. (2015) Thyroid hormone transporters-functions and clinical implications. Nat Rev
Endocrinol 11: 406-417 [PMID:25942657]
Halestrap AP. (2013) The SLC16 gene family - structure, role and regulation in health and disease.
Mol. Aspects Med. 34: 337-49 [PMID:23506875]
Jones RS et al. (2016) Monocarboxylate Transporters: Therapeutic Targets and Prognostic Factors in
Disease. Clin. Pharmacol. Ther. 100: 454-463 [PMID:27351344]
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SLC17 phosphate and organic anion transporter family
Transporters → SLC superfamily of solute carriers → SLC17 phosphate and organic anion transporter family
Overview: The SLC17 family are sometimes referred to as Type I sodium-phosphate co-transporters, alongside Type II (SLC34 family) and Type III (SLC20 family) transporters. Within the SLC17 family,
however, further subgroups of organic anion transporters may be deﬁned, allowing the accumulation of sialic acid in the endoplasmic reticulum and glutamate (e.g. L-glutamic acid) or nucleotides in
synaptic and secretory vesicles. Topology modelling suggests 12 TM domains.
Type I sodium-phosphate co-transporters
Transporters → SLC superfamily of solute carriers → SLC17 phosphate and organic anion transporter family → Type I sodium-phosphate co-transporters
Overview: Type I sodium-phosphate co-transporters are expressed in the kidney and intestine.
Nomenclature Sodium/phosphate cotransporter 1 Sodium/phosphate cotransporter 3 Sodium/phosphate cotransporter 4 Sodium/phosphate cotransporter homolog
Systematic nomenclature SLC17A1 SLC17A2 SLC17A3 SLC17A4
Common abbreviation NPT1 NPT3 NPT4 –
HGNC, UniProt SLC17A1, Q14916 SLC17A2, O00624 SLC17A3, O00476 SLC17A4, Q9Y2C5
Substrates probenecid [86], penicillin G [86], Cl- [306],
organic acids [306], uric acid [306],
phosphate [306]
– – –
Stoichiometry Unknown Unknown Unknown Unknown
Searchable database: http://www.guidetopharmacology.org/index.jsp Type I sodium-phosphate co-transporters S438
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14753/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology (2019) 176, S397–S493
Sialic acid transporter
Transporters → SLC superfamily of solute carriers → SLC17 phosphate and organic anion transporter family → Sialic acid transporter
Overview: The sialic acid transporter is expressed on both lysosomes and synaptic vesicles, where it appears to allow export of sialic acid and accumulation of acidic amino acids, respectively [446],
driven by proton gradients. In lysosomes, degradation of glycoproteins generates amino acids and sugar residues, which are metabolized further following export from the lysosome.
Nomenclature Sialin
Systematic nomenclature SLC17A5
Common abbreviation AST
HGNC, UniProt SLC17A5, Q9NRA2
Endogenous substrates L-lactic acid, gluconate (out), L-glutamic acid (in) [446], glucuronic acid, L-aspartic acid [446], sialic acid
Stoichiometry 1 H+ : 1 sialic acid (out)
Comments: Loss-of-function mutations in sialin are associated with Salla disease (OMIM: 604369), an autosomal recessive neurodegenerative disorder associated with sialic acid storage disease [647].
Vesicular glutamate transporters (VGLUTs)
Transporters → SLC superfamily of solute carriers → SLC17 phosphate and organic anion transporter family → Vesicular glutamate transporters (VGLUTs)
Overview: Vesicular glutamate transporters (VGLUTs) allow accumulation of glutamate into synaptic vesicles, as well as secretory vesicles in endocrine tissues. The roles of VGLUTs in kidney and liver
are unclear. These transporters appear to utilize the proton gradient and also express a chloride conductance [48].
Nomenclature Vesicular glutamate transporter 1 Vesicular glutamate transporter 2 Vesicular glutamate transporter 3
Systematic nomenclature SLC17A7 SLC17A6 SLC17A8
Common abbreviation VGLUT1 VGLUT2 VGLUT3
HGNC, UniProt SLC17A7, Q9P2U7 SLC17A6, Q9P2U8 SLC17A8, Q8NDX2
Endogenous substrates L-glutamic acid > D-glutamic acid L-glutamic acid > D-glutamic acid L-glutamic acid > D-glutamic acid
Stoichiometry Unknown Unknown Unknown
Comments: Endogenous ketoacids produced during fasting have been proposed to regulate VGLUT function through blocking chloride ion-mediated allosteric enhancement of transporter function
[333].
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Vesicular nucleotide transporter
Transporters → SLC superfamily of solute carriers → SLC17 phosphate and organic anion transporter family → Vesicular nucleotide transporter
Overview: The vesicular nucleotide transporter is the most recent member of the SLC17 family to have an assigned function. Uptake of ATP was independent of pH, but dependent on chloride ions and
membrane potential [555].
Nomenclature Vesicular nucleotide transporter
Systematic nomenclature SLC17A9
Common abbreviation VNUT
HGNC, UniProt SLC17A9, Q9BYT1
Endogenous substrates guanosine 5’-diphosphate [555], guanosine-5’-triphosphate [555], ATP [555]
Stoichiometry Unknown
Selective inhibitors clodronic acid (pIC50 7.8) [346]
Comments: VGLUTs and VNUT can be inhibited by DIDS and evans blue dye.
Further reading on SLC17 phosphate and organic anion transporter family
Moriyama Y et al. (2017) Vesicular nucleotide transporter (VNUT): appearance of an actress on the
stage of purinergic signaling. Purinergic Signal. 13: 387-404 [PMID:28616712]
Omote H et al. (2016) Structure, Function, and Drug Interactions of Neurotransmitter Transporters
in the Postgenomic Era. Annu. Rev. Pharmacol. Toxicol. 56: 385-402 [PMID:26514205]
Reimer RJ. (2013) SLC17: a functionally diverse family of organic anion transporters. Mol. Aspects
Med. 34: 350-9 [PMID:23506876]
Takamori S. (2016) Vesicular glutamate transporters as anion channels? Pﬂugers Arch. 468: 513-8
[PMID:26577586]
SLC18 family of vesicular amine transporters
Transporters → SLC superfamily of solute carriers → SLC18 family of vesicular amine transporters
Overview: The vesicular amine transporters (VATs) are puta-
tive 12 TM domain proteins that function to transport singly
positively charged amine neurotransmitters and hormones from
the cytoplasm and concentrate them within secretory vesicles.
They function as amine/proton antiporters driven by secondary
active transport utilizing the proton gradient established by a
multi-subunit vacuolar ATPase that acidiﬁes secretory vesicles (re-
viewed by [174]). The vesicular acetylcholine transporter (VAChT;
[184]) localizes to cholinergic neurons, but non-neuronal expres-
sion has also been claimed [558]. Vesicular monoamine trans-
porter 1 (VMAT1, [182]) is mainly expressed in peripheral neu-
roendocrine cells, but most likely not in the CNS, whereas VMAT2
[183] distributes between both central and peripheral sympathetic
monoaminergic neurones [175]. The vescular polyamine trans-
porter (VPAT) is highly expressed in the lungs and placenta, with
moderate expression in brain and testis, and with low expression
in heart and skeletal muscle [290]. VPAT mediates vesicular accu-
mulation of polyamines in mast cells [602].
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Nomenclature Vesicular monoamine transporter 1 Vesicular monoamine transporter 2 Vesicular acetylcholine transporter
Systematic nomenclature SLC18A1 SLC18A2 SLC18A3
Common abbreviation VMAT1 VMAT2 VAChT
HGNC, UniProt SLC18A1, P54219 SLC18A2, Q05940 SLC18A3, Q16572
Substrates dexamfetamine (Ki 4.7×10−5M) [183], β-phenylethylamine
(Ki 3.4×10−5M) [183], fenﬂuramine (Ki 3.1×10−6M) [183],
MPP+ (Ki 6.9×10−5M) [183], MDMA (Ki 1.9×10−5M) [183]
β-phenylethylamine (Ki 3.7×10−6M) [183], dexamfetamine
(Ki 2.1×10−6M) [183], fenﬂuramine (Ki 5.1×10−6M) [183],
MPP+ (Ki 8.9×10−6M) [183], MDMA (Ki 6.9×10−6M) [183]
TPP+ [71], ethidium [71], N-methyl-pyridinium-2-aldoxime
[71],
N-(4’-pentanonyl)-4-(4”-dimethylamino-styryl)pyridinium
[71]
Endogenous substrates histamine (Ki 4.6×10−3M) [183], 5-hydroxytryptamine (Ki
1.4×10−6M) [183], dopamine (Ki 3.8×10−6M) [183],
(-)-noradrenaline (Ki 1.3×10−5M) [183], (-)-adrenaline (Ki
5.5×10−6M) [183]
histamine (Ki 1.4×10−4M) [183], dopamine (Ki
1.4×10−6M) [183], 5-hydroxytryptamine (Ki 9×10−7M)
[183], (-)-noradrenaline (Ki 3.4×10−6M) [183],
(-)-adrenaline (Ki 1.9×10−6M) [183]
acetylcholine (Ki 7.9×10−4M) [72, 352], choline (Ki
5×10−3M) [72, 352]
Stoichiometry 1 amine (in): 2H+ (out) 1 amine (in): 2H+ (out) 1 amine (in): 2H+ (out)
Inhibitors reserpine (pKi 7.5) [183], ketanserin (pKi 5.8) [183],
tetrabenazine (pKi 4.7) [183]
reserpine (pKi 7.9) [183], tetrabenazine (pKi 7) [183],
ketanserin (pKi 6.3) [183]
aminobenzovesamicol (pKi 10.9) [173], vesamicol (pKi 8.7)
[173]
Labelled ligands – [3H]TBZOH (Inhibitor) (pKd 8.2) [644], [
125I]iodovinyl-TBZ
(Inhibitor) (pKd 8.1) [378], [
11C]DTBZ (Inhibitor),
[125I]7-azido-8-iodoketanserine (Inhibitor) [577]
[3H]vesamicol (pKd 8.4) [644], [
123I]iodobenzovesamicol
Comments: pKi values for endogenous and synthetic substrate inhibitors of human VMAT1 and VMAT2 are for inhibition of [3H]5-HT uptake in transfected and permeabilised CV-1 cells as detailed
by [183]. In addition to the monoamines listed in the table, the trace amines tyramine and β-phenylethylamine are probable substrates for VMAT2 [175]. Probes listed in the table are those currently
employed; additional agents have been synthesized (e.g. [720]).
Further reading on SLC18 family of vesicular amine transporters
German CL et al. (2015) Regulation of the Dopamine and Vesicular Monoamine Transporters: Phar-
macological Targets and Implications for Disease. Pharmacol. Rev. 67: 1005-24 [PMID:26408528]
Lohr KM et al. (2017) Membrane transporters as mediators of synaptic dopamine dynamics: impli-
cations for disease. Eur. J. Neurosci. 45: 20-33 [PMID:27520881]
Omote H et al. (2016) Structure, Function, and Drug Interactions of Neurotransmitter Transporters
in the Postgenomic Era. Annu. Rev. Pharmacol. Toxicol. 56: 385-402 [PMID:26514205]
Sitte HH et al. (2015) Amphetamines, new psychoactive drugs and the monoamine transporter cycle.
Trends Pharmacol. Sci. 36: 41-50 [PMID:25542076]
Wimalasena K. (2011) Vesicular monoamine transporters: structure-function, pharmacology, and
medicinal chemistry. Med Res Rev 31: 483-519 [PMID:20135628]
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SLC19 family of vitamin transporters
Transporters → SLC superfamily of solute carriers → SLC19 family of vitamin transporters
Overview: The B vitamins folic acid and thiamine are transported across the cell membrane, particularly in the intestine, kidneys and placenta, using pH differences as driving forces. Topological
modelling suggests the transporters have 12 TM domains.
Nomenclature Reduced folate transporter 1 Thiamine transporter 1 Thiamine transporter 2
Systematic nomenclature SLC19A1 SLC19A2 SLC19A3
Common abbreviation FOLT ThTr1 ThTr2
HGNC, UniProt SLC19A1, P41440 SLC19A2, O60779 SLC19A3, Q9BZV2
Substrates N5-formyltetrahydrofolate, folinic acid, methotrexate,
folic acid [505]
– –
Endogenous substrates Other tetrahydrofolate-cofactors, Organic phosphates; in
particular, adenine nucleotides, tetrahydrofolic acid [505],
N5-methylfolate [505], thiamine monophosphate [712]
thiamine thiamine
Stoichiometry Folate (in) : organic phosphate (out), precise stoichiometry
unknown
A facilitative carrier not known to be coupled to an
inorganic or organic ion gradient
A facilitative carrier not known to be coupled to an
inorganic or organic ion gradient
Inhibitors compound 9 (pKi 6.6) [534], methotrexate (pKi 5.3) [534] – –
Labelled ligands [3H]folic acid [29], [3H]methotrexate [29] [3H]thiamine [168] [3H]thiamine [518]
Comments: Loss-of-function mutations in ThTr1 underlie thiamine-responsive megaloblastic anemia syndrome [151].
Further reading on SLC19 family of vitamin transporters
Matherly LH et al. (2014) The major facilitative folate transporters solute carrier 19A1 and solute
carrier 46A1: biology and role in antifolate chemotherapy of cancer. Drug Metab. Dispos. 42:
632-49 [PMID:24396145]
Zhao R et al. (2013) Folate and thiamine transporters mediated by facilitative carriers (SLC19A1-3
and SLC46A1) and folate receptors. Mol. Aspects Med. 34: 373-85 [PMID:23506878]
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SLC20 family of sodium-dependent phosphate transporters
Transporters → SLC superfamily of solute carriers → SLC20 family of sodium-dependent phosphate transporters
Overview: The SLC20 family is looked upon not only as ion transporters, but also as retroviral receptors. As ion transporters, they are sometimes referred to as Type III sodium-phosphate co-transporters,
alongside Type I (SLC17 family) and Type II (SLC34 family). PiTs are cell-surface transporters, composed of ten TM domains with extracellular C- and N-termini. PiT1 is a focus for dietary phosphate and
vitamin D regulation of parathyroid hormone secretion from the parathyroid gland. PiT2 appears to be involved in intestinal absorption of dietary phosphate.
Nomenclature Sodium-dependent phosphate transporter 1 Sodium-dependent phosphate transporter 2
Systematic nomenclature SLC20A1 SLC20A2
Common abbreviation PiT1 PiT2
HGNC, UniProt SLC20A1, Q8WUM9 SLC20A2, Q08357
Substrates AsO43- [519], phosphate [519] phosphate [519]
Stoichiometry >1 Na+ : 1 HPO42- (in) >1 Na+ : 1 HPO42- (in)
Further reading on SLC20 family of sodium-dependent phosphate transporters
Biber J et al. (2013) Phosphate transporters and their function. Annu. Rev. Physiol. 75: 535-50
[PMID:23398154]
Forster IC et al. (2013) Phosphate transporters of the SLC20 and SLC34 families. Mol. Aspects Med.
34: 386-95 [PMID:23506879]
Shobeiri N et al. (2014) Phosphate: an old bone molecule but new cardiovascular risk factor. Br J Clin
Pharmacol 77: 39-54 [PMID:23506202]
SLC22 family of organic cation and anion transporters
Transporters → SLC superfamily of solute carriers → SLC22 family of organic cation and anion transporters
Overview: The SLC22 family of transporters is mostly composed of non-selective transporters, which are expressed highly in liver, kidney and intestine, playing a major role in drug disposition. The
family may be divided into three subfamilies based on the nature of the substrate transported: organic cations (OCTs), organic anions (OATs) and organic zwiterrion/cations (OCTN). Membrane topology
is predicted to contain 12 TM domains with intracellular termini, and an extended extracellular loop at TM 1/2.
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Organic cation transporters (OCT)
Transporters → SLC superfamily of solute carriers → SLC22 family of organic cation and anion transporters → Organic cation transporters (OCT)
Overview: Organic cation transporters (OCT) are electrogenic, Na+-independent and reversible.
Nomenclature Organic cation transporter 1 Organic cation transporter 2 Organic cation transporter 3
Systematic nomenclature SLC22A1 SLC22A2 SLC22A3
Common abbreviation OCT1 OCT2 OCT3
HGNC, UniProt SLC22A1, O15245 SLC22A2, O15244 SLC22A3, O75751
Substrates MPP+, tetraethylammonium, desipramine, metformin
[576], aciclovir
MPP+ [247], pancuronium [247], tetraethylammonium
[247], tubocurarine [247], cisplatin [368], metformin [368]
MPP+, tetraethylammonium, quinidine, metformin [368]
Endogenous substrates PGF2α, choline, PGE2, 5-hydroxytryptamine PGE2 [356], dopamine [263], histamine [263] (-)-noradrenaline [719], 5-hydroxytryptamine [719],
dopamine [719]
Stoichiometry Unknown Unknown Unknown
Inhibitors clonidine (pKi 6.3) [708] decynium 22 (pKi 7) [247] disprocynium24 (pKi 7.8) [264]
Comments: Corticosterone and quinine are able to inhibit all three organic cation transporters.
Further reading on Organic cation transporters (OCT)
Koepsell H. (2013) The SLC22 family with transporters of organic cations, anions and zwitterions.
Mol. Aspects Med. 34: 413-35 [PMID:23506881]
Lozano E et al. (2013) Role of the plasma membrane transporter of organic cations OCT1 and its
genetic variants in modern liver pharmacology. Biomed Res Int 2013: 692071 [PMID:23984399]
Pelis RM et al. (2014) SLC22, SLC44, and SLC47 transporters–organic anion and cation transporters:
molecular and cellular properties. Curr Top Membr 73: 233-61 [PMID:24745985]
Yin J et al. (2016) Renal drug transporters and their signiﬁcance in drug-drug interactions. Acta
Pharm Sin B 6: 363-373 [PMID:27709005]
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Organic zwitterions/cation transporters (OCTN)
Transporters → SLC superfamily of solute carriers → SLC22 family of organic cation and anion transporters → Organic zwitterions/cation transporters (OCTN)
Overview: Organic zwitterions/cation transporters (OCTN) function as organic cation uniporters, organic cation/proton exchangers or sodium/L-carnitine co-transporters.
Nomenclature Organic cation/carnitine transporter 1 Organic cation/carnitine transporter 2 Carnitine transporter 2
Systematic nomenclature SLC22A4 SLC22A5 SLC22A16
Common abbreviation OCTN1 OCTN2 CT2
HGNC, UniProt SLC22A4, Q9H015 SLC22A5, O76082 SLC22A16, Q86VW1
Substrates verapamil, mepyramine, tetraethylammonium, MPP+ verapamil, tetraethylammonium, MPP+, mepyramine –
Endogenous substrates L-carnitine L-carnitine, acetyl-L-carnitine L-carnitine
Stoichiometry Unknown Unknown Unknown
Comments: Mutations in the SLC22A5 gene lead to primary carnitine deﬁciency [409].
Further reading on Organic zwitterions/cation transporters (OCTN)
Pochini L et al. (2013) OCTN cation transporters in health and disease: role as drug targets and assay
development. J Biomol Screen 18: 851-67 [PMID:23771822]
Tamai I. (2013) Pharmacological and pathophysiological roles of carnitine/organic cation trans-
porters (OCTNs: SLC22A4, SLC22A5 and Slc22a21). Biopharm Drug Dispos 34: 29-44
[PMID:22952014]
Yin J et al. (2016) Renal drug transporters and their signiﬁcance in drug-drug interactions. Acta
Pharm Sin B 6: 363-373 [PMID:27709005]
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Organic anion transporters (OATs)
Transporters → SLC superfamily of solute carriers → SLC22 family of organic cation and anion transporters → Organic anion transporters (OATs)
Overview: Organic anion transporters (OATs) are non-selective transporters prominent in the kidney, placenta and blood-brain barrier.
Nomenclature Organic anion transporter 1 Organic anion transporter 2 Organic anion transporter 3 Organic anion transporter 4 Organic anion transporter 5 Organic anion transporter 7
Systematic nomenclature SLC22A6 SLC22A7 SLC22A8 SLC22A11 SLC22A10 SLC22A9
Common abbreviation OAT1 OAT2 OAT3 – OAT5 OAT4
HGNC, UniProt SLC22A6, Q4U2R8 SLC22A7, Q9Y694 SLC22A8, Q8TCC7 SLC22A11, Q9NSA0 SLC22A10, Q63ZE4 SLC22A9, Q8IVM8
Substrates aminohippuric acid,
non-steroidal
anti-inﬂammatory drugs
aminohippuric acid, PGE2,
non-steroidal
anti-inﬂammatory drugs
uric acid [466],
estrone-3-sulphate [379],
aminohippuric acid [379],
cimetidine [379],
ochratoxin A [379]
uric acid [466],
dehydroepiandrosterone sulphate
[97], estrone-3-sulphate
[97], ochratoxin A [97]
ochratoxin A [697] –
Stoichiometry Unknown Unknown Unknown Unknown Unknown Unknown
Inhibitors probenecid (Inhibition of
urate transport by human
SCL22A6.) (pIC50 4.9) [304]
– – – – –
Further reading on Organic anion transporters (OATs)
Burckhardt G et al. (2011) In vitro and in vivo evidence of the importance of organic anion trans-
porters (OATs) in drug therapy. Handb Exp Pharmacol 29-104 [PMID:21103968]
Koepsell H. (2013) The SLC22 family with transporters of organic cations, anions and zwitterions.
Mol. Aspects Med. 34: 413-35 [PMID:23506881]
Shen H et al. (2017) Organic Anion Transporter 2: An Enigmatic Human Solute Carrier. Drug Metab.
Dispos. 45: 228-236 [PMID:27872146]
Yin J et al. (2016) Renal drug transporters and their signiﬁcance in drug-drug interactions. Acta
Pharm Sin B 6: 363-373 [PMID:27709005]
Urate transporter
Transporters → SLC superfamily of solute carriers → SLC22 family of organic cation and anion transporters → Urate transporter
Overview: URAT1, a member of the OAT (organic anion transporter) family, is an anion-exchanging uptake transporter localized to the apical (brush border) membrane of renal proximal tubular cells.
It is an anion exchanger that speciﬁcally reabsorbs uric acid from the proximal tubule in exchange for monovalent anions such as lactate, nicotinoate, acetoacetate, and hydroxybutyrate [181].
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Nomenclature Urate anion exchanger 1
Systematic nomenclature SLC22A12
Common abbreviation URAT1
HGNC, UniProt SLC22A12, Q96S37
Endogenous substrates uric acid [181], orotic acid [181]
Stoichiometry Unknown
Selective inhibitors suﬁnpyrazone (pIC50 4) [699]
Comments URAT1 is expressed in the proximal tubule of the kidney and regulates uric acid excretion from the body. Inhibitors of this transporter, such as losartan, ﬁnd clinical utility in managing
hyperuricemia in patients with gout [85, 275].
Further reading on Urate transporter
Nigam SK et al. (2018) The systems biology of uric acid transporters: the role of remote sensing and
signaling. Curr. Opin. Nephrol. Hypertens. 27: 305-313 [PMID:29847376]
Atypical SLC22B subfamily
Transporters → SLC superfamily of solute carriers → SLC22 family of organic cation and anion transporters → Atypical SLC22B subfamily
Overview: This family of transporters has previously been classiﬁed as part of the atypical major facilitator superfamily (MSF) protein superfamily [489, 492, 493, 520]. The atypical SLCs share sequence
similarities and phylogenetic ancestry with other SLCs, and they have historically been classiﬁed in to subfamilies (also referred to as atypical MFS transporter families (AMTF1-15)) based on phylogenetic,
sequence and structural analyses [492].
Nomenclature synaptic vesicle glycoprotein 2A
Systematic nomenclature SLC22B1
HGNC, UniProt SV2A, Q7L0J3
Substrates Galactose [421]
Inhibitors brivaracetam (pIC50 7) [349] – Rat, levetiracetam (pKi 5.8) [470] – Rat
Comments: There are three human synaptic vesicle glycoprotein 2 family members, SV2A, SV2B and SV2C. They have transmembrane transporter activity and can be classiﬁed in to the SLC superfamily
of solute carriers in subfamily SLC22, as SCL22B1, B2 and B3 respectively. SV2A (SCL22B1) has been identiﬁed as the brain binding-site for the antiepileptic drugs levetiracetam [358, 415] and brivaracetam
[465].
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Further reading on Atypical SLC22B subfamily
Löscher W et al. (2016) Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and
Beyond. CNS Drugs 30: 1055-1077 [PMID:27752944]
Mendoza-Torreblanca JG et al. (2013) Synaptic vesicle protein 2A: basic facts and role in synaptic
function. Eur. J. Neurosci. 38: 3529-39 [PMID:24102679]
Further reading on SLC22 family of organic cation and anion transporters
Burckhardt G. (2012) Drug transport by Organic Anion Transporters (OATs). Pharmacol. Ther. 136:
106-30 [PMID:22841915]
Hillgren KM et al. (2013) Emerging transporters of clinical importance: an update from the Interna-
tional Transporter Consortium. Clin. Pharmacol. Ther. 94: 52-63 [PMID:23588305]
International Transporter Consortium et al. (2010) Membrane transporters in drug development.
Nat Rev Drug Discov 9: 215-36 [PMID:20190787]
Koepsell H. (2013) The SLC22 family with transporters of organic cations, anions and zwitterions.
Mol. Aspects Med. 34: 413-35 [PMID:23506881]
Lozano E et al. (2018) Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition. J
Pers Med 8: [PMID:29659532]
Nigam SK. (2018) The SLC22 Transporter Family: A Paradigm for the Impact of Drug Transporters
on Metabolic Pathways, Signaling, and Disease. Annu. Rev. Pharmacol. Toxicol. 58: 663-687
[PMID:29309257]
Zamek-Gliszczynski MJ et al. (2018) Transporters in Drug Development: 2018 ITC Recommenda-
tions for Transporters of Emerging Clinical Importance. Clin. Pharmacol. Ther. 104: 890-899
[PMID:30091177]
SLC23 family of ascorbic acid transporters
Transporters → SLC superfamily of solute carriers → SLC23 family of ascorbic acid transporters
Overview: Predicted to be 12 TM segment proteins, members of this family transport the reduced form of ascorbic acid (while the oxidized form may be handled by members of the SLC2 family
(GLUT1/SLC2A1, GLUT3/SLC2A3 and GLUT4/SLC2A4). Phloretin is considered a non-selective inhibitor of these transporters, with an afﬁnity in the micromolar range.
Nomenclature Sodium-dependent vitamin C transporter 1 Sodium-dependent vitamin C transporter 2 Sodium-dependent vitamin C transporter 3
Systematic nomenclature SLC23A1 SLC23A2 SLC23A3
Common abbreviation SVCT1 SVCT2 SVCT3
HGNC, UniProt SLC23A1, Q9UHI7 SLC23A2, Q9UGH3 SLC23A3, Q6PIS1
Endogenous substrates L-ascorbic acid > D-ascorbic acid > dehydroascorbic acid
[628]
L-ascorbic acid > D-ascorbic acid > dehydroascorbic acid
[628]
–
Stoichiometry 2 Na+: 1 ascorbic acid (in) [628] 2 Na+: 1 ascorbic acid (in) [628] –
Inhibitors phloretin (pKi 4.2) [628] – –
Labelled ligands [14C]ascorbic acid (Binding) [417] [14C]ascorbic acid –
Comments – – SLC23A3 does not transport ascorbic acid and remains an
orphan transporter.
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Nomenclature Sodium-dependent nucleobase transporter
Systematic nomenclature SLC23A4
Common abbreviation SNBT1
HGNC, UniProt SLC23A4P, –
Substrates 5-ﬂuorouracil [685]
Endogenous substrates uracil > thymine > guanine, hypoxanthine > xanthine, uridine [685]
Stoichiometry 1 Na+ : 1 uracil (in) [685]
Comments SLC23A4/SNBT1 is found in rodents and non-human primates, but the sequence is truncated in the human genome and named as a pseudogene, SLC23A4P
Further reading on SLC23 family of ascorbic acid transporters
Bürzle M et al. (2013) The sodium-dependent ascorbic acid transporter family SLC23. Mol. Aspects
Med. 34: 436-54 [PMID:23506882]
May JM. (2011) The SLC23 family of ascorbate transporters: ensuring that you get and keep your
daily dose of vitamin C. Br. J. Pharmacol. 164: 1793-801 [PMID:21418192]
SLC24 family of sodium/potassium/calcium exchangers
Transporters → SLC superfamily of solute carriers → SLC24 family of sodium/potassium/calcium exchangers
Overview: The sodium/potassium/calcium exchange family of transporters utilize the extracellular sodium gradient to drive calcium and potassium co-transport out of the cell. As is the case for NCX
transporters (SLC8A family), NKCX transporters are thought to be bidirectional, with the possibility of calcium inﬂux following depolarization of the plasma membrane. Topological modeling suggests
the presence of 10 TM domains, with a large intracellular loop between the ﬁfth and sixth TM regions.
Nomenclature Sodium/potassium/calcium exchanger 1 Sodium/potassium/calcium exchanger 6
Systematic nomenclature SLC24A1 SLC24A6
Common abbreviation NKCX1 NKCX6
HGNC, UniProt SLC24A1, O60721 SLC8B1, Q6J4K2
Stoichiometry 4Na+:(1Ca2+ + 1K+) –
Comments: NKCX6 has been proposed to be the sole member of a CAX Na+/Ca2+ exchanger family, which may be the mitochondrial transporter responsible for calcium accumulation from the cytosol
[565].
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Further reading on SLC24 family of sodium/potassium/calcium exchangers
Schnetkamp PP. (2013) The SLC24 gene family of Na+/Ca2+-K+ exchangers: from sight and smell to
memory consolidation and skin pigmentation. Mol. Aspects Med. 34: 455-64 [PMID:23506883]
Schnetkamp PP et al. (2014) The SLC24 family of K+-dependent Na+-Ca2+ exchangers: structure-
function relationships. Curr Top Membr 73: 263-87 [PMID:24745986]
Sekler I. (2015) Standing of giants shoulders the story of the mitochondrial Na(+)Ca(2+) exchanger.
Biochem. Biophys. Res. Commun. 460: 50-2 [PMID:25998733]
SLC25 family of mitochondrial transporters
Transporters → SLC superfamily of solute carriers → SLC25 family of mitochondrial transporters
Overview: Mitochondrial transporters are nuclear-encoded proteins, which convey solutes across the inner mitochondrial membrane. Topological modelling suggests homodimeric transporters, each
with six TM segments and termini in the cytosol.
Mitochondrial di- and tri-carboxylic acid transporter subfamily
Transporters → SLC superfamily of solute carriers → SLC25 family of mitochondrial transporters → Mitochondrial di- and tri-carboxylic acid transporter subfamily
Overview: Mitochondrial di- and tri-carboxylic acid transporters are grouped on the basis of commonality of substrates and include the citrate transporter which facilitates citric acid export from the
mitochondria to allow the generation of oxalacetic acid and acetyl CoA through the action of ATP:citrate lyase.
Nomenclature Mitochondrial citrate transporter Mitochondrial dicarboxylate transporter Mitochondrial oxoglutarate carrier Mitochondrial oxodicarboxylate carrier
Systematic nomenclature SLC25A1 SLC25A10 SLC25A11 SLC25A21
Common abbreviation CIC DIC OGC ODC
HGNC, UniProt SLC25A1, P53007 SLC25A10, Q9UBX3 SLC25A11, Q02978 SLC25A21, Q9BQT8
Substrates phosphoenolpyruvic acid, malic acid,
citric acid
SO42-, phosphate, S2O32-, succinic acid,
malic acid
α-ketoglutaric acid, malic acid α-ketoglutaric acid, α-oxoadipic acid
Stoichiometry Malate2- (in) : H-citrate2- (out) PO34- (in) : malate2- (out) Malate2- (in) : oxoglutarate2- (out) Oxoadipate (in) : oxoglutarate (out)
Inhibitors 1,2,3-benzenetricarboxylic acid – – –
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Mitochondrial amino acid transporter subfamily
Transporters → SLC superfamily of solute carriers → SLC25 family of mitochondrial transporters → Mitochondrial amino acid transporter subfamily
Overview: Mitochondrial amino acid transporters can be subdivided on the basis of their substrates. Mitochondrial ornithine transporters play a role in the urea cycle by exchanging cytosolic ornithine
(L-ornithine and D-ornithine) for mitochondrial citrulline (L-citrulline and D-citrulline) in equimolar amounts. Further members of the family include transporters of S-adenosylmethionine and carnitine.
Nomenclature AGC1 AGC2 Mitochondrial
glutamate carrier 2
Mitochondrial
glutamate carrier 1
Mitochondrial ornithine
transporter 2
Mitochondrial ornithine
transporter 1
Carnitine/acylcarnitine
carrier
Systematic nomenclature SLC25A12 SLC25A13 SLC25A18 SLC25A22 SLC25A2 SLC25A15 SLC25A20
Common abbreviation – – GC2 GC1 ORC2 ORC1 CAC
HGNC, UniProt SLC25A12, O75746 SLC25A13, Q9UJS0 SLC25A18, Q9H1K4 SLC25A22, Q9H936 SLC25A2, Q9BXI2 SLC25A15, Q9Y619 SLC25A20, O43772
Substrates L-glutamic acid,
2-amino-3-
sulﬁnopropanoic acid,
L-aspartic acid
2-amino-3-
sulﬁnopropanoic acid,
L-glutamic acid,
L-aspartic acid
L-glutamic acid L-glutamic acid L-citrulline [202],
L-arginine [202],
L-lysine [202], D-lysine
[202], D-arginine [202],
D-citrulline [202],
D-ornithine [202],
L-ornithine [202],
D-histidine [202],
L-histidine [202]
L-lysine [202],
L-ornithine [202],
L-citrulline [202],
L-arginine [202]
–
Stoichiometry Aspartate : glutamate
H+ (bidirectional)
Aspartate : glutamate
H+ (bidirectional)
Glutamate : H+
(bidirectional)
Glutamate : H+
(bidirectional)
1 Ornithine (in) :1
citrulline : 1 H+ (out)
1 Ornithine (in) :1
citrulline : 1 H+ (out)
–
Comments – – – – – – Exchanges cytosolic
acylcarnitine for
mitochondrial carnitine
Comments: Both ornithine transporters are inhibited by the polyamine spermine [203]. Loss-of-functionmutations in these genes are associated with hyperornithinemia-hyperammonemia-homocitrullinuria.
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Mitochondrial phosphate transporters
Transporters → SLC superfamily of solute carriers → SLC25 family of mitochondrial transporters → Mitochondrial phosphate transporters
Overview: Mitochondrial phosphate transporters allow the import of inorganic phosphate for ATP production.
Nomenclature Mitochondrial phosphate carrier
Systematic nomenclature SLC25A3
Common abbreviation PHC
HGNC, UniProt SLC25A3, Q00325
Stoichiometry PO34- (in) : OH- (out) or PO34- : H+ (in)
Mitochondrial nucleotide transporter subfamily
Transporters → SLC superfamily of solute carriers → SLC25 family of mitochondrial transporters → Mitochondrial nucleotide transporter subfamily
Overview: Mitochondrial nucleotide transporters, deﬁned by structural similarlities, include the adenine nucleotide translocator family (SLC25A4, SLC25A5, SLC25A6 and SLC25A31), which under
conditions of aerobic metabolism, allow coupling between mitochondrial oxidative phosphorylation and cytosolic energy consumption by exchanging cytosolic ADP for mitochondrial ATP. Further
members of the mitochondrial nucleotide transporter subfamily convey diverse substrates including CoA, although not all members have had substrates identiﬁed.
Nomenclature Mitochondrial
adenine nucleotide
translocator 1
Mitochondrial
adenine nucleotide
translocator 2
Mitochondrial
adenine nucleotide
translocator 3
Mitochondrial
adenine nucleotide
translocator 4
Graves disease carrier Peroxisomal membrane
protein
Systematic nomenclature SLC25A4 SLC25A5 SLC25A6 SLC25A31 SLC25A16 SLC25A17
Common abbreviation ANT1 ANT2 ANT3 ANT4 GDC PMP34
HGNC, UniProt SLC25A4, P12235 SLC25A5, P05141 SLC25A6, P12236 SLC25A31, Q9H0C2 SLC25A16, P16260 SLC25A17, O43808
Substrates – – – – CoA and congeners ADP, ATP,
adenosine 5’-monophosphate
Stoichiometry ADP3- (in) : ATP4- (out) ADP3- (in) : ATP4- (out) ADP3- (in) : ATP4- (out) ADP3- (in) : ATP4- (out) CoA (in) ATP (in)
Inhibitors bongkrek acid,
carboxyatractyloside
– – – – –
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Nomenclature Deoxynucleotide carrier 1 S-Adenosylmethionine carrier Mitochondrial phosphate carrier 1 Mitochondrial phosphate carrier 2 Mitochondrial phosphate carrier 3
Systematic nomenclature SLC25A19 SLC25A26 SLC25A24 SLC25A23 SLC25A25
Common abbreviation DNC SAMC1 APC1 APC2 APC3
HGNC, UniProt SLC25A19, Q9HC21 SLC25A26, Q70HW3 SLC25A24, Q6NUK1 SLC25A23, Q9BV35 SLC25A25, Q6KCM7
Substrates Nucleotide Diphosphates (NDPs),
Deoxynucleotide Diphosphates
(dNDPs), Dideoxynucleotide
Triphosphates (ddNTPs),
Deoxynucleotide Triphosphates
(dNTPs)
S-adenosyl methionine – – –
Stoichiometry dNDP (in) : ATP (out) – – – –
Mitochondrial uncoupling proteins
Transporters → SLC superfamily of solute carriers → SLC25 family of mitochondrial transporters → Mitochondrial uncoupling proteins
Overview: Mitochondrial uncoupling proteins allow dissipation of the mitochondrial proton gradient associated with thermogenesis and regulation of radical formation.
Nomenclature Uncoupling protein 1 Uncoupling protein 2 Uncoupling protein 3 Uncoupling protein 4 Uncoupling protein 5 KMCP1
Systematic nomenclature SLC25A7 SLC25A8 SLC25A9 SLC25A27 SLC25A14 SLC25A30
Common abbreviation UCP1 UCP2 UCP3 UCP4 UCP5 –
HGNC, UniProt UCP1, P25874 UCP2, P55851 UCP3, P55916 SLC25A27, O95847 SLC25A14, O95258 SLC25A30, Q5SVS4
Stoichiometry H+ (in) H+ (in) H+ (in) H+ (in) H+ (in) –
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Miscellaneous SLC25 mitochondrial transporters
Transporters → SLC superfamily of solute carriers → SLC25 family of mitochondrial transporters → Miscellaneous SLC25 mitochondrial transporters
Overview: Many of the transporters identiﬁed below have yet to be assigned functions and are currently regarded as orphans.
Information on members of this family may be found in the online database.
Further reading on SLC25 family of mitochondrial transporters
Baffy G. (2017) Mitochondrial uncoupling in cancer cells: Liabilities and opportunities. Biochim.
Biophys. Acta 1858: 655-664 [PMID:28088333]
Bertholet AM et al. (2017) UCP1: A transporter for H+ and fatty acid anions. Biochimie 134: 28-34
[PMID:27984203]
Clémençon B et al. (2013) The mitochondrial ADP/ATP carrier (SLC25 family): pathological impli-
cations of its dysfunction. Mol. Aspects Med. 34: 485-93 [PMID:23506884]
Palmieri F. (2013) The mitochondrial transporter family SLC25: identiﬁcation, properties and phys-
iopathology. Mol. Aspects Med. 34: 465-84 [PMID:23266187]
Seifert EL et al. (2015) The mitochondrial phosphate carrier: Role in oxidative metabolism, cal-
cium handling and mitochondrial disease. Biochem. Biophys. Res. Commun. 464: 369-75
[PMID:26091567]
Taylor EB. (2017) Functional Properties of the Mitochondrial Carrier System. Trends Cell Biol. 27:
633-644 [PMID:28522206]
SLC26 family of anion exchangers
Transporters → SLC superfamily of solute carriers → SLC26 family of anion exchangers
Overview: Along with the SLC4 family, the SLC26 family acts to allow movement of monovalent and divalent anions across cell membranes. The predicted topology is of 10-14 TM domains with
intracellular C- and N-termini, probably existing as dimers. Within the family, subgroups may be identiﬁed on the basis of functional differences, which appear to function as anion exchangers and anion
channels (SLC26A7 and SLC26A9).
Selective sulphate transporters
Transporters → SLC superfamily of solute carriers → SLC26 family of anion exchangers → Selective sulphate transporters
Nomenclature Sat-1 DTDST
Systematic nomenclature SLC26A1 SLC26A2
HGNC, UniProt SLC26A1, Q9H2B4 SLC26A2, P50443
Substrates SO42-, oxalate SO42-
Stoichiometry SO42- (in) : anion (out) 1 SO42- (in) : 2 Cl- (out)
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Chloride/bicarbonate exchangers
Transporters → SLC superfamily of solute carriers → SLC26 family of anion exchangers → Chloride/bicarbonate exchangers
Nomenclature DRA Pendrin PAT-1
Systematic nomenclature SLC26A3 SLC26A4 SLC26A6
HGNC, UniProt SLC26A3, P40879 SLC26A4, O43511 SLC26A6, Q9BXS9
Substrates Cl- formate, HCO3-, OH-, I-, Cl- formate, oxalate, SO42-, OH-, Cl-, HCO3-, I-
Stoichiometry 2 Cl- (in) : 1 HCO3- (out) or 2 Cl- (in) : 1 OH- (out) Unknown 1 SO42- (in) : 2 HCO3- (out) or 1 Cl- (in) : 2 HCO3- (out)
Anion channels
Transporters → SLC superfamily of solute carriers → SLC26 family of anion exchangers → Anion channels
Nomenclature SLC26A7 SLC26A9
HGNC, UniProt SLC26A7, Q8TE54 SLC26A9, Q7LBE3
Substrates NO3-  Cl- = Br- = I- > SO42- = L-glutamic acid I- > Br- > NO3- > Cl- > L-glutamic acid
Functional Characteristics Voltage- and time-independent current, linear I-V relationship [354] Voltage- and time-independent current, linear I-V relationship [161]
Comments – SLC26A9 has been suggested to operate in two additional modes as a Cl--HCO3-
exchanger and as a Na+-anion cotransporter [99].
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Other SLC26 anion exchangers
Transporters → SLC superfamily of solute carriers → SLC26 family of anion exchangers → Other SLC26 anion exchangers
Nomenclature Prestin
Systematic nomenclature SLC26A5
HGNC, UniProt SLC26A5, P58743
Substrates HCO3- [443], Cl- [443]
Stoichiometry Unknown
Comments Prestin has been suggested to function as a molecular motor, rather than a transporter
Further reading on SLC26 family of anion exchangers
Alper SL et al. (2013) The SLC26 gene family of anion transporters and channels. Mol. Aspects Med.
34: 494-515 [PMID:23506885]
Kato A et al. (2011) Regulation of electroneutral NaCl absorption by the small intestine. Annu. Rev.
Physiol. 73: 261-81 [PMID:21054167]
Nofziger C et al. (2011) Pendrin function in airway epithelia. Cell. Physiol. Biochem. 28: 571-8
[PMID:22116372]
Soleimani M. (2013) SLC26 Cl-/HCO3- exchangers in the kidney: roles in health and disease. Kidney
Int. 84: 657-66 [PMID:23636174]
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SLC27 family of fatty acid transporters
Transporters → SLC superfamily of solute carriers → SLC27 family of fatty acid transporters
Overview: Fatty acid transporter proteins (FATPs) are a family
(SLC27) of six transporters (FATP1-6). They have at least one,
and possibly six [397, 557], transmembrane segments, and are
predicted on the basis of structural similarities to form dimers.
SLC27 members have several structural domains: integral mem-
brane associated domain, peripheral membrane associated do-
main, FATP signature, intracellular AMP binding motif, dimer-
ization domain, lipocalin motif, and an ER localization domain
(identiﬁed in FATP4 only) [190, 441, 481]. These transporters
are unusual in that they appear to express intrinsic very long-
chain acyl-CoA synthetase (EC 6.2.1.- , EC 6.2.1.7) enzyme activ-
ity. Within the cell, these transporters may associate with plasma
and peroxisomal membranes. FATP1-4 and -6 transport long- and
very long-chain fatty acids, while FATP5 transports long-chain
fatty acids as well as bile acids [439, 557].
Nomenclature Fatty acid transport protein 1 Fatty acid transport
protein 2
Fatty acid transport
protein 3
Fatty acid transport protein 4 Fatty acid transport
protein 5
Fatty acid transport
protein 6
Systematic nomenclature SLC27A1 SLC27A2 SLC27A3 SLC27A4 SLC27A5 SLC27A6
Common abbreviation FATP1 FATP2 FATP3 FATP4 FATP5 FATP6
HGNC, UniProt SLC27A1, Q6PCB7 SLC27A2, O14975 SLC27A3, Q5K4L6 SLC27A4, Q6P1M0 SLC27A5, Q9Y2P5 SLC27A6, Q9Y2P4
Endogenous substrates palmitic acid > oleic acid >
γ-linolenic acid > octanoic acid [238]
arachidonic acid > palmitic acid >
oleic acid > butyric acid [557]
– – palmitic acid , oleic acid > γ-linolenic acid
> octanoic acid [238]
palmitic acid > oleic acid > butyric acid,
γ-linolenic acid > arachidonic acid [586]
– palmitic acid >
oleic acid >
γ-linolenic acid >
octanoic acid [238]
Inhibitors – – – compound 1l (pIC50 7.1) [60] – –
Comments – – – FATP4 is genetically linked to
restrictive dermopathy.
– –
Comments: Although the stoichiometry of fatty acid transport
is unclear, it has been proposed to be facilitated by the coupling
of fatty acid transport to conjugation with coenzyme A to form
fatty acyl CoA esters. Small molecule inhibitors of FATP2 [398,
553] and FATP4 [60, 718], as well as bile acid inhibitors of FATP5
[718], have been described; analysis of the mechanism of action of
some of these inhibitors suggests that transport may be selectively
inhibited without altering enzymatic activity of the FATP.
C1-BODIPY-C12 accumulation has been used as a non-selective
index of fatty acid transporter activity.
FATP2 has two variants: Variant 1 encodes the full-length protein,
while Variant 2 encodes a shorter isoformmissing an internal pro-
tein segment. FATP6 also has two variants: Variant 2 encodes the
same protein as Variant 1 but has an additional segment in the 5’
UTR.
Further reading on SLC27 family of fatty acid transporters
Anderson CM et al. (2013) SLC27 fatty acid transport proteins. Mol. Aspects Med. 34: 516-28
[PMID:23506886]
Dourlen P et al. (2015) Fatty acid transport proteins in disease: New insights from invertebrate mod-
els. Prog. Lipid Res. 60: 30-40 [PMID:26416577]
Schwenk RW et al. (2010) Fatty acid transport across the cell membrane: regulation by fatty acid
transporters. Prostaglandins Leukot. Essent. Fatty Acids 82: 149-54 [PMID:20206486]
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SLC28 and SLC29 families of nucleoside transporters
Transporters → SLC superfamily of solute carriers → SLC28 and SLC29 families of nucleoside transporters
Overview: Nucleoside transporters are divided into two families, the sodium-dependent, concentrative solute carrier family 28 (SLC28) and the equilibrative, solute carrier family 29 (SLC29). The
endogenous substrates are typically nucleosides, although some family members can also transport nucleobases and organic cations.
SLC28 family
Transporters → SLC superfamily of solute carriers → SLC28 and SLC29 families of nucleoside transporters → SLC28 family
Overview: SLC28 family membersappear to have 13 TM segments with cytoplasmic N-termini and extracellular C-termini, and function as concentrative nucleoside transporters.
Nomenclature Sodium/nucleoside cotransporter 1 Sodium/nucleoside cotransporter 2 Solute carrier family 28 member 3
Systematic nomenclature SLC28A1 SLC28A2 SLC28A3
Common abbreviation CNT1 CNT2 CNT3
HGNC, UniProt SLC28A1, O00337 SLC28A2, O43868 SLC28A3, Q9HAS3
Substrates ribavirin [115], gemcitabine [114], zalcitabine, zidovudine cladribine [485], didanosine, vidarabine, ﬂudarabine [382],
formycin B [382]
zalcitabine, formycin B, cladribine, 5-ﬂuorouridine,
ﬂoxuridine, didanosine, zidovudine, zebularine,
gemcitabine
Endogenous substrates adenosine, uridine, cytidine, thymidine adenosine, guanosine, inosine, thymidine adenosine, uridine, guanosine, thymidine, inosine, cytidine
Stoichiometry 1 Na+ : 1 nucleoside (in) 1 Na+ : 1 nucleoside (in) 2 Na+/H+
Inhibitors – – compound 16 (pKi 5.5) [272]
Comments – – CNT3 forms cyclic homotrimers [588]. Genetic variants of
SLC28A3 are associated with increased risk of
anthracycline-induced cardiomyopathy [587].
Further reading on SLC28 family
Johnson ZL et al. (2014) Structural basis of nucleoside and nucleoside drug selectivity by concentra-
tive nucleoside transporters. Elife 3: e03604 [PMID:25082345]
Pastor-AngladaM et al. (2008) SLC28 genes and concentrative nucleoside transporter (CNT) proteins.
Xenobiotica 38: 972-94 [PMID:18668436]
Pastor-Anglada M et al. (2015) Nucleoside transporter proteins as biomarkers of drug responsiveness
and drug targets. Front Pharmacol 6: 13 [PMID:25713533]
Pastor-Anglada M et al. (2018) Who Is Who in Adenosine Transport. Front Pharmacol 9: 627
[PMID:29962948]
Young JD et al. (2013) The human concentrative and equilibrative nucleoside transporter families,
SLC28 and SLC29. Mol. Aspects Med. 34: 529-47 [PMID:23506887]
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SLC29 family
Transporters → SLC superfamily of solute carriers → SLC28 and SLC29 families of nucleoside transporters → SLC29 family
Overview: SLC29 family members appear to be composed of 11 TM segments with cytoplasmic N-termini and extracellular C-termini. ENT1, ENT2 and ENT4 are cell-surface transporters, while ENT3 is
intracellular, possibly lysosomal [38]. ENT1-3 are described as broad-spectrum equilibrative nucleoside transporters, while ENT4 is primarily a polyspeciﬁc organic cation transporter at neutral pH [293].
Nomenclature Equilibrative nucleoside transporter 1 Equilibrative nucleoside transporter 2
Systematic nomenclature SLC29A1 SLC29A2
Common abbreviation ENT1 ENT2
HGNC, UniProt SLC29A1, Q99808 SLC29A2, Q14542
Endogenous substrates in order of increasing Km: adenosine < inosine < uridine < guanosine < cytidine < hypoxanthine <
adenine < thymine
–
Substrates abacavir [96], atenolol [442], pentostatin, vidarabine, gemcitabine,
2-chloroadenosine, cytarabine, zalcitabine, didanosine, tubercidin, formycin B,
cladribine, ribavirin [115], ﬂoxuridine
formycin B, 2-chloroadenosine, cytarabine, tubercidin, cladribine,
gemcitabine, vidarabine, zidovudine
Endogenous substrates thymine [691], guanosine [691], hypoxanthine [691], uridine [691], inosine
[691], adenine [691], cytidine [691], thymidine [691], adenosine [691]
adenosine, guanine, thymine, uridine, guanosine, hypoxanthine, inosine,
thymidine, cytosine
Stoichiometry Equilibrative Equilibrative
Inhibitors nitrobenzylmercaptopurine ribonucleoside (pKi 9.7), draﬂazine (pKi 9.6)
[276], KF24345 (pKi 9.4) [277], NBTGR (pKi 9.3), dilazep (pKi 9),
dipyridamole (pKi 8.8) [277], ticagrelor (pKi 7.3) [26]
–
Labelled ligands [3H]nitrobenzylmercaptopurine ribonucleoside (pKd 9.3) –
Comments ENT1 has 100-1000-fold lower afﬁnity for nucleobases as compared with
nucleosides [691].
The afﬁnities of draﬂazine, dilazep, KF24345 and dipyridamole at ENT1
transporters are species dependent, exhibiting lower afﬁnity at rat transporters
than at human transporters [277, 593].
The loss of ENT1 activity in ENT1-null mice has been associated with a
hypermineralization disorder similar to human diffuse idiopathic skeletal
hyperostosis [661]. Lack of ENT1 also results in the Augustine-null blood type
[133].
–
Searchable database: http://www.guidetopharmacology.org/index.jsp SLC29 family S459
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14753/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology (2019) 176, S397–S493
Nomenclature Equilibrative nucleoside transporter 3 Plasma membrane monoamine transporter
Systematic nomenclature SLC29A3 SLC29A4
Common abbreviation ENT3 PMAT
HGNC, UniProt SLC29A3, Q9BZD2 SLC29A4, Q7RTT9
Substrates zidovudine [38], zalcitabine [38], didanosine [38], ﬂudarabine [38], cordycepin [38],
ﬂoxuridine [38], cladribine [38], tubercidin [38], zebularine [38]
tetraethylammonium [180, 655], MPP+ [180, 655], metformin [717], atenolol [442]
Endogenous substrates adenosine [38], inosine [38], uridine [38], thymidine [38], guanosine [38], adenine [38] histamine [180, 655], tyramine [180, 655], adenosine [716], 5-hydroxytryptamine [180,
655], dopamine [180, 655]
Stoichiometry Equilibrative Equilibrative
Inhibitors – decynium 22 (pKi 7) [180, 655], rhodamine123 (pKi 6) [180, 655], dipyridamole (pKi
5.9) [652], verapamil (pKi 4.7) [180, 655], ﬂuoxetine (pKi 4.6) [180, 655], quinidine (pKi
4.6) [180, 655], quinine (pKi 4.6) [180, 655], desipramine (pKi 4.5) [180, 655],
cimetidine (pKi <3.3) [180, 655]
Comments Defects in SLC29A3 have been implicated in histiocytosis-lymphadenopathy plus syndrome
(OMIM:602782) and lysosomal storage diseases [296, 342].
Uptake of substrates by PMAT is pH dependent, with greater uptake observed at acidic
extracellular pH [43, 717].
Further reading on SLC29 family
Boswell-Casteel RC et al. (2017) Equilibrative nucleoside transporters-A review. Nucleosides Nu-
cleotides Nucleic Acids 36: 7-30 [PMID:27759477]
Pastor-Anglada M et al. (2018) Who Is Who in Adenosine Transport. Front Pharmacol 9: 627
[PMID:29962948]
Wang J. (2016) The plasma membrane monoamine transporter (PMAT): Structure, function, and role
in organic cation disposition. Clin. Pharmacol. Ther. 100: 489-499 [PMID:27506881]
Further reading on SLC28 and SLC29 families of nucleoside transporters
Boswell-Casteel RC et al. (2017) Equilibrative nucleoside transporters-A review. Nucleosides Nu-
cleotides Nucleic Acids 36: 7-30 [PMID:27759477]
Pastor-Anglada M et al. (2015) Nucleoside transporter proteins as biomarkers of drug responsiveness
and drug targets. Front Pharmacol 6: 13 [PMID:25713533]
Young JD. (2016) The SLC28 (CNT) and SLC29 (ENT) nucleoside transporter families: a 30-year col-
laborative odyssey. Biochem. Soc. Trans. 44: 869-76 [PMID:27284054]
Young JD et al. (2013) The human concentrative and equilibrative nucleoside transporter families,
SLC28 and SLC29. Mol. Aspects Med. 34: 529-47 [PMID:23506887]
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SLC30 zinc transporter family
Transporters → SLC superfamily of solute carriers → SLC30 zinc transporter family
Overview: Along with the SLC39 family, SLC30 transporters reg-
ulate the movement of zinc ions around the cell. In particular,
these transporters remove zinc ions from the cytosol, allowing ac-
cumulation into intracellular compartments or efﬂux through the
plasma membrane. ZnT1 is thought to be placed on the plasma
membrane extruding zinc, while ZnT3 is associated with synap-
tic vesicles and ZnT4 and ZnT5 are linked with secretory granules.
Membrane topology predictions suggest a multimeric assembly,
potentially heteromultimeric [596], with subunits having six TM
domains, and both termini being cytoplasmic. Dityrosine cova-
lent linking has been suggested as a mechanism for dimerisation,
particularly for ZnT3 [551]. The mechanism for zinc transport is
unknown.
Information on members of this family may be found in the online database.
Comments: ZnT8/SLC30A8 is described as a type 1 diabetes susceptibility gene.
Zinc ﬂuxes may be monitored through the use of radioisotopic Zn-65 or the ﬂuorescent dye FluoZin 3.
Further reading on SLC30 zinc transporter family
Bouron A et al. (2014) Contribution of calcium-conducting channels to the transport of zinc ions.
Pﬂugers Arch. 466: 381-7 [PMID:23719866]
Hojyo S et al. (2016) Zinc transporters and signaling in physiology and pathogenesis. Arch. Biochem.
Biophys. 611: 43-50 [PMID:27394923]
Huang L et al. (2013) The SLC30 family of zinc transporters - a review of current understanding of
their biological and pathophysiological roles. Mol. Aspects Med. 34: 548-60 [PMID:23506888]
Kambe T et al. (2014) Current understanding of ZIP and ZnT zinc transporters in human health and
diseases. Cell. Mol. Life Sci. 71: 3281-95 [PMID:24710731]
Kambe T et al. (2015) The Physiological, Biochemical, and Molecular Roles of Zinc Transporters in
Zinc Homeostasis and Metabolism. Physiol. Rev. 95: 749-784 [PMID:26084690]
SLC31 family of copper transporters
Transporters → SLC superfamily of solute carriers → SLC31 family of copper transporters
Overview: SLC31 family members, alongside the Cu-ATPases are involved in the regulation of cellular copper levels. The CTR1 transporter is a cell-surface transporter to allow monovalent copper
accumulation into cells, while CTR2 appears to be a vacuolar/vesicular transporter [521]. Functional copper transporters appear to be trimeric with each subunit having three TM regions and an
extracellular N-terminus. CTR1 is considered to be a higher afﬁnity copper transporter compared to CTR2. The stoichiometry of copper accumulation is unclear, but appears to be energy-independent
[387].
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Nomenclature Copper transporter 1 Copper transporter 2
Systematic nomenclature SLC31A1 SLC31A2
Common abbreviation CTR1 CTR2
HGNC, UniProt SLC31A1, O15431 SLC31A2, O15432
Substrates cisplatin [317] cisplatin [61]
Endogenous substrates copper [387] copper
Stoichiometry Unknown Unknown
Comments: Copper accumulation through CTR1 is sensitive to silver ions, but not divalent cations [387].
Further reading on SLC31 family of copper transporters
Howell SB et al. (2010) Copper transporters and the cellular pharmacology of the platinum-
containing cancer drugs. Mol. Pharmacol. 77: 887-94 [PMID:20159940]
Kaplan JH et al. (2016) How Mammalian Cells Acquire Copper: An Essential but Potentially Toxic
Metal. Biophys. J. 110: 7-13 [PMID:26745404]
Kim H et al. (2013) SLC31 (CTR) family of copper transporters in health and disease. Mol. Aspects
Med. 34: 561-70 [PMID:23506889]
Monné M et al. (2014) Antiporters of the mitochondrial carrier family. Curr Top Membr 73: 289-320
[PMID:24745987]
SLC32 vesicular inhibitory amino acid transporter
Transporters → SLC superfamily of solute carriers → SLC32 vesicular inhibitory amino acid transporter
Overview: The vesicular inhibitory amino acid transporter,
VIAAT (also termed the vesicular GABA transporter VGAT),
which is the sole representative of the SLC32 family, trans-
ports GABA, or glycine, into synaptic vesicles [229, 230], and
is a member of the structurally-deﬁned amino acid-polyamine-
organocation/APC clan composed of SLC32, SLC36 and SLC38
transporter families (see [559]). VIAAT was originally suggested
to be composed of 10 TM segments with cytoplasmic N- and C-
termini [429]. However, an alternative 9TM structure with the N
terminus facing the cytoplasm and the C terminus residing in the
synaptic vesicle lumen has subsequently been reported [427]. VI-
AAT acts as an antiporter for inhibitory amino acids and protons.
The accumulation of GABA and glycine within vesicles is driven by
both the chemical (pH) and electrical (ψ) components of the
proton electrochemical gradient (μH+) established by a vacuolar
H+-ATPase [429]. However, one study, [334], presented evidence
that VIAAT is instead a Cl-/GABA co-transporter. VIAAT co-exists
with VGLUT1 (SLC17A7), or VGLUT2 (SLC17A6), in the synaptic
vesicles of selected nerve terminals [194, 701]. VIAAT knock out
mice die between embryonic day 18.5 and birth [671]. In cultures
of spinal cord neurones established from earlier embryos, the co-
release of of GABA and glycine from synaptic vesicles is drastically
reduced, providing direct evidence for the role of VIAAT in the se-
questration of both transmitters [547, 671].
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Nomenclature Vesicular inhibitory amino acid transporter
Systematic nomenclature SLC32A1
Common abbreviation VIAAT
HGNC, UniProt SLC32A1, Q9H598
Endogenous substrates β-alanine, γ-hydroxybutyric acid, GABA (Km 5×10−3M) [429], glycine
Stoichiometry 1 amino acid (in): 1 H+ (out) [229] or 1 amino acid: 2Cl- (in) [334]
Inhibitors vigabatrin (pIC50 2.1) [429]
Further reading on SLC32 vesicular inhibitory amino acid transporter
Anne C et al. (2014) Vesicular neurotransmitter transporters: mechanistic aspects. Curr Top Membr
73: 149-74 [PMID:24745982]
Schiöth HB et al. (2013) Evolutionary origin of amino acid transporter families SLC32, SLC36 and
SLC38 and physiological, pathological and therapeutic aspects. Mol. Aspects Med. 34: 571-85
[PMID:23506890]
SLC33 acetylCoA transporter
Transporters → SLC superfamily of solute carriers → SLC33 acetylCoA transporter
Overview: Acetylation of proteins is a post-translational modiﬁcation mediated by speciﬁc acetyltransferases, using the donor acetyl CoA. SLC33A1/AT1 is a putative 11 TM transporter present on the
endoplasmic reticulum, expressed in all tissues, but particularly abundant in the pancreas [341], which imports cytosolic acetyl CoA into these intracellular organelles.
Nomenclature AcetylCoA transporter
Systematic nomenclature SLC33A1
Common abbreviation ACATN1
HGNC, UniProt SLC33A1, O00400
Endogenous substrates acetyl CoA
Stoichiometry Unknown
Labelled ligands [14C]acetylCoA (Binding)
Comments: In heterologous expression studies, acetyl CoA transport through AT1 was inhibited by coenzyme A, but not acetic acid, ATP or UDP-galactose [330]. A loss-of-function mutation in
ACATN1/SLC33A1 has been associated with spastic paraplegia (SPG42, [401]), although this observation could not be replicated in a subsequent study [560].
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Further reading on SLC33 acetylCoA transporter
Hirabayashi Y et al. (2004) The acetyl-CoA transporter family SLC33. Pﬂugers Arch. 447: 760-2
[PMID:12739170]
Hirabayashi Y et al. (2013) The acetyl-CoA transporter family SLC33. Mol. Aspects Med. 34: 586-9
[PMID:23506891]
SLC34 family of sodium phosphate co-transporters
Transporters → SLC superfamily of solute carriers → SLC34 family of sodium phosphate co-transporters
Overview: The SLC34 family are sometimes referred to as Type II sodium-phosphate co-transporters, alongside Type I (SLC17 family) and Type III (SLC20 family) transporters. Topological modelling
suggests eight TM domains with C- and N- termini in the cytoplasm, and a re-entrant loop at TM7/8. SLC34 family members are expressed on the apical surfaces of epithelia in the intestine and kidneys
to regulate body phosphate levels, principally NaPi-IIa and NaPi-IIb, respectively. NaPi-IIa and NaPi-IIb are electrogenic, while NaPiIIc is electroneutral [18].
Nomenclature Sodium phosphate 1 Sodium phosphate 2 Sodium phosphate 3
Systematic nomenclature SLC34A1 SLC34A2 SLC34A3
Common abbreviation NaPi-IIa NaPi-IIb NaPi-IIc
HGNC, UniProt SLC34A1, Q06495 SLC34A2, O95436 SLC34A3, Q8N130
Stoichiometry 3 Na+ : 1 HPO42- (in) [210] 3 Na+ : 1 HPO42- (in) [18] 2 Na+ : 1 HPO42- (in) [18]
Antibodies – lifastuzumab vedotin (Binding) [146] –
Comments: These transporters can be inhibited by foscarnet, in contrast to type III sodium-phosphate cotransporters, the SLC20 family.
Further reading on SLC34 family of sodium phosphate co-transporters
Biber J et al. (2013) Phosphate transporters and their function. Annu. Rev. Physiol. 75: 535-50
[PMID:23398154]
Forster IC et al. (2013) Phosphate transporters of the SLC20 and SLC34 families. Mol. Aspects Med.
34: 386-95 [PMID:23506879]
Shobeiri N et al. (2014) Phosphate: an old bone molecule but new cardiovascular risk factor. Br J Clin
Pharmacol 77: 39-54 [PMID:23506202]
Wagner CA et al. (2014) The SLC34 family of sodium-dependent phosphate transporters. Pﬂugers
Arch. 466: 139-53 [PMID:24352629]
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SLC35 family of nucleotide sugar transporters
Transporters → SLC superfamily of solute carriers → SLC35 family of nucleotide sugar transporters
Overview: Glycoprotein formation in the Golgi and endoplasmic reticulum relies on the accumulation of nucleotide-conjugated sugars via the SLC35 family of transporters. These transporters have a
predicted topology of 10 TM domains, with cytoplasmic termini, and function as exchangers, swopping nucleoside monophosphates for the corresponding nucleoside diphosphate conjugated sugar. Five
subfamilies of transporters have been identiﬁed on the basis of sequence similarity, namely SLC35A1, SLC35A2, SLC35A3, SLC35A4 and SLC35A5; SLC35B1, SLC35B2, SLC35B3 and SLC35B4; SLC35C1
and SLC35C2; SLC35D1, SL35D1, SLC35D2 and SLC35D3, and the subfamily of orphan SLC35 transporters, SLC35E1-4 and SLC35F1-5.
Nomenclature CMP-sialic acid transporter UDP-galactose transporter UDP-N-acetylglucosamine
transporter
PAPS transporter 1 PAPS transporter 2
Systematic nomenclature SLC35A1 SLC35A2 SLC35A3 SLC35B2 SLC35B3
HGNC, UniProt SLC35A1, P78382 SLC35A2, P78381 SLC35A3, Q9Y2D2 SLC35B2, Q8TB61 SLC35B3, Q9H1N7
Substrates CMP-sialic acid [313] UDP-galactose [315, 445],
UDP N-acetyl-glucosamine [315,
445]
UDP N-acetyl-glucosamine [316] A3P5PS [336] A3P5PS [335]
Nomenclature YEA GDP-Fucose transporter UDP-glucuronic
acid/UDP-N-acetylgalactosamine dual
transporter
HFRC1
Systematic nomenclature SLC35B4 SLC35C1 SLC35D1 SLC35D2
HGNC, UniProt SLC35B4, Q969S0 SLC35C1, Q96A29 SLC35D1, Q9NTN3 SLC35D2, Q76EJ3
Substrates UDP-xylose [28], UDP N-acetyl-glucosamine
[28]
GDP-fucose [416] UDP-N-acetylgalactosamine [452],
UDP-glucuronic acid [452]
UDP-N-acetylgalactosamine [314]
Further reading on SLC35 family of nucleotide sugar transporters
Ishida N et al. (2004) Molecular physiology and pathology of the nucleotide sugar transporter family
(SLC35). Pﬂugers Arch. 447: 768-75 [PMID:12759756]
Orellana A et al. (2016) Overview of Nucleotide Sugar Transporter Gene Family Functions Across
Multiple Species. J. Mol. Biol. 428: 3150-3165 [PMID:27261257]
Song Z. (2013) Roles of the nucleotide sugar transporters (SLC35 family) in health and disease. Mol.
Aspects Med. 34: 590-600 [PMID:23506892]
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SLC36 family of proton-coupled amino acid transporters
Transporters → SLC superfamily of solute carriers → SLC36 family of proton-coupled amino acid transporters
Overview: Members of the SLC36 family of proton-coupled
amino acid transporters are involved in membrane transport of
amino acids and derivatives. The four transporters show variable
tissue expression patterns and are expressed in various cell types
at the plasma-membrane and in intracellular organelles. PAT1 is
expressed at the luminal surface of the small intestine and absorbs
amino acids and derivatives [3]. In lysosomes, PAT1 functions as
an efﬂuxmechanism for amino acids produced during intralysoso-
mal proteolysis [5, 542]. PAT2 is expressed at the apical membrane
of the renal proximal tubule [82] and at the plasma-membrane in
brown/beige adipocytes [633]. PAT1 and PAT4 are involved in reg-
ulation of the mTORC1 pathway [191]. More comprehensive lists
of substrates can be found within the reviews under Further Read-
ing and in the references.
Nomenclature Proton-coupled Amino acid Transporter 1 Proton-coupled Amino acid Transporter 2
Systematic nomenclature SLC36A1 SLC36A2
Common abbreviation PAT1 PAT2
HGNC, UniProt SLC36A1, Q7Z2H8 SLC36A2, Q495M3
Substrates muscimol [619], arecaidine [619], betaine [619], L-cycloserine [619], 5-aminolevulinic acid
[619], gaboxadol [383, 619], β-guanidinopropionic acid [619], D-cycloserine [619],
MeAIB [619], vigabatrin [1, 619], L-azetidine-2-carboxylate [619], THPO [619]
MeAIB [109], D-cycloserine, L-cycloserine, L-azetidine-2-carboxylate [350]
Endogenous substrates GABA [619], L-alanine [619], β-alanine [619], taurine [619], D-serine [619], D-proline
[619], trans-4-hydroxy-proline [619], sarcosine [619], D-cysteine [619], glycine [619],
D-alanine [619]
sarcosine, L-proline, glycine, L-alanine, trans-4-hydroxy-proline
Stoichiometry 1 H+ : 1 amino acid (symport) 1 H+ : 1 amino acid (symport)
Inhibitors 5-hydroxy-L-tryptophan (pKi 3) [434], L-tryptophan (pKi 2.3) [434],
indole-3-propionic acid (pKi 2.3) [434], 5-hydroxytryptamine (pKi 2.2) [434]
5-hydroxy-L-tryptophan (pIC50 2.8) [171], α-methyl-D,L-tryptophan (pIC50 2.5) [171]
Comments [3H] or [14C] labelled substrates as listed above are used as probes. PAT1 can also function
as an electroneutral transport system for protons and fatty acids including acetic acid,
propanoic acid and butyric acid [206]. In addition, forskolin, phosphodiesterase inhibitors,
amiloride analogues and SLC9A3 (NHE3) selective inhibitors all reduce PAT1 activity
indirectly (in intact mammalian intestinal epithelia such as human intestinal Caco-2 cells)
by inhibiting the Na+/H+ exchanger NHE3 which is required to maintain the
H+-electrochemical gradient driving force for H+/amino acid cotransport [14, 17, 619].
[3H] or [14C] labelled substrates as listed above are used as probes. Loss-of-function
mutations in PAT2 lead to iminoglycinuria and hyperglycinuria in man [82]. PAT2 can also
function as an electroneutral transport system for protons and fatty acids including acetic
acid, propanoic acid and butyric acid [206]. Replacement of a Phe residue in
transmembrane domain 3 with Cys (that has a smaller side-chain) broadens substrate
speciﬁcity to include larger substrates (e.g. methionine, leucine) [172].
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Nomenclature Proton-coupled Amino acid Transporter 3 Proton-coupled Amino acid Transporter 4
Systematic nomenclature SLC36A3 SLC36A4
Common abbreviation PAT3 PAT4
HGNC, UniProt SLC36A3, Q495N2 SLC36A4, Q6YBV0
Endogenous substrates – L-tryptophan [497], L-proline [497]
Stoichiometry Unknown Unknown
Comments The function of the testes-speciﬁc PAT3 remains unknown. PAT4 is not proton-coupled and functions by facilitated diffusion in an electroneutral,
Na+-independent, manner [497]. PAT4 is expressed ubiquitously and is predominantly
associated with the Golgi [192].. High PAT4 expression is associated with reduced
relapse-free survival after colorectal cancer surgery [192].
Further reading on SLC36 family of proton-coupled amino acid transporters
Schiöth HB et al. (2013) Evolutionary origin of amino acid transporter families SLC32, SLC36 and
SLC38 and physiological, pathological and therapeutic aspects. Mol. Aspects Med. 34: 571-85
[PMID:23506890]
Thwaites DT et al. (2011) The SLC36 family of proton-coupled amino acid transporters and their
potential role in drug transport. Br. J. Pharmacol. 164: 1802-16 [PMID:21501141]
Thwaites DT et al. (2007) Deciphering the mechanisms of intestinal imino (and amino)
acid transport: the redemption of SLC36A1. Biochim. Biophys. Acta 1768: 179-97
[PMID:17123464]
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SLC37 family of phosphosugar/phosphate exchangers
Transporters → SLC superfamily of solute carriers → SLC37 family of phosphosugar/phosphate exchangers
Overview: The family of sugar-phosphate exchangers pass particular phosphorylated sugars across intracellular membranes, exchanging for inorganic phosphate. Of the family of sugar phosphate
transporters, most information is available on SPX4, the glucose-6-phosphate transporter. This is a 10 TM domain protein with cytoplasmic termini and is associated with the endoplasmic reticulum,
with tissue-speciﬁc splice variation.
Nomenclature Glycerol-3-phosphate transporter Sugar phosphate exchanger 2 Glucose-6-phosphate transporter
Systematic nomenclature SLC37A1 SLC37A2 SLC37A4
Common abbreviation SPX1 SPX2 SPX4
HGNC, UniProt SLC37A1, P57057 SLC37A2, Q8TED4 SLC37A4, O43826
Endogenous substrates glycerol 3-phosphate, glucose 6-phosphate glucose 6-phosphate glucose 6-phosphate
Stoichiometry Glucose 6-phosphate (in): phosphate (out) [488]. Glucose 6-phosphate (in): phosphate (out) [488]. Glucose 6-phosphate (in): phosphate (out) [107].
Inhibitors – – S-4048 (pIC50 8.7) [101] – Rat
Comments – – Multiple polymorphisms have been described for the
SLC37A4 gene, some of which associate with a glycogen
storage disease [9].
Further reading on SLC37 family of phosphosugar/phosphate exchangers
Chou JY et al. (2014) The SLC37 family of sugar-phosphate/phosphate exchangers. Curr Top Membr
73: 357-82 [PMID:24745989]
Chou JY et al. (2013) The SLC37 family of phosphate-linked sugar phosphate antiporters. Mol. As-
pects Med. 34: 601-11 [PMID:23506893]
SLC38 family of sodium-dependent neutral amino acid transporters
Transporters → SLC superfamily of solute carriers → SLC38 family of sodium-dependent neutral amino acid transporters
Overview: The SLC38 family of transporters appears to be responsible for the functionally-deﬁned system A and system N mechanisms of amino acid transport and are mostly expressed in the CNS. Two
distinct subfamilies are identiﬁable within the SLC38 transporters. SNAT1, SNAT2 and SNAT4 appear to resemble system A transporters in accumulating neutral amino acids under the inﬂuence of the
sodium gradient. SNAT3 and SNAT5 appear to resemble system N transporters in utilizing proton co-transport to accumulate amino acids. The predicted membrane topology is of 11 TM domains with
an extracellular C-terminus and intracellular N-terminus [559].
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System A-like transporters
Transporters → SLC superfamily of solute carriers → SLC38 family of sodium-dependent neutral amino acid transporters → System A-like transporters
Nomenclature sodium-coupled neutral amino acid transporter 1 sodium-coupled neutral amino acid transporter 2 sodium-coupled neutral amino acid transporter 4
Systematic nomenclature SLC38A1 SLC38A2 SLC38A4
Common abbreviation SNAT1 SNAT2 SNAT4
HGNC, UniProt SLC38A1, Q9H2H9 SLC38A2, Q96QD8 SLC38A4, Q969I6
Substrates MeAIB
L-alanine > L-serine, L-glutamine, L-asparagine, L-histidine,
L-cysteine, L-methionine > glycine, L-threonine, L-proline,
L-tyrosine, L-valine [7]
MeAIB
L-alanine, L-methionine > L-asparagine, L-glutamine,
L-serine, L-proline, glycine > L-threonine, L-leucine,
L-phenylalanine [283]
MeAIB
L-histidine > L-arginine, L-alanine, L-asparagine, L-lysine >
glycine, L-glutamine, L-serine, L-proline, L-leucine,
L-phenylalanine [282]
Stoichiometry 1 Na+ : 1 amino acid (in) [7] 1 Na+ : 1 amino acid (in) [283] 1 Na+ : 1 neutral amino acid (in) [282]
Labelled ligands [14C]alanine, [3H]alanine [14C]alanine, [3H]alanine [14C]alanine, [14C]glycine, [3H]alanine, [3H]glycine
Comments – – Transport of cationic amino acids by SNAT4 was
sodium-independent [282].
System N-like transporters
Transporters → SLC superfamily of solute carriers → SLC38 family of sodium-dependent neutral amino acid transporters → System N-like transporters
Nomenclature Sodium-coupled neutral amino acid transporter 3 Sodium-coupled neutral amino acid transporter 5
Systematic nomenclature SLC38A3 SLC38A5
Common abbreviation SNAT3 SNAT5
HGNC, UniProt SLC38A3, Q99624 SLC38A5, Q8WUX1
Substrates MeAIB
L-histidine , L-glutamine > L-asparagine, L-alanine > L-glutamic acid [197]
MeAIB
L-asparagine, L-serine, L-histidine, L-glutamine > glycine, L-alanine [459]
Stoichiometry 1 Na+ : 1 amino acid (in) : 1 H+ (out) [75] 1 Na+ : 1 amino acid (in) : 1 H+ (out) [459]
Labelled ligands [14C]glutamine, [3H]glutamine [14C]histidine, [3H]histidine
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Orphan SLC38 transporters
Transporters → SLC superfamily of solute carriers → SLC38 family of sodium-dependent neutral amino acid transporters → Orphan SLC38 transporters
Nomenclature Putative sodium-coupled neutral amino acid transporter 7
Systematic nomenclature SLC38A7
Common abbreviation SNAT7
HGNC, UniProt SLC38A7, Q9NVC3
Comments SNAT7/SLC38A7 has been described to be a system N-like transporter allowing preferential accumulation of glutamine (e.g. L-glutamine), histidine (e.g. L-histidine) and asparagine
(e.g. L-asparagine) [302].
Further reading on SLC38 family of sodium-dependent neutral amino acid transporters
Bhutia YD et al. (2016) Glutamine transporters in mammalian cells and their functions in physiology
and cancer. Biochim. Biophys. Acta 1863: 2531-9 [PMID:26724577]
Bröer S. (2014) The SLC38 family of sodium-amino acid co-transporters. Pﬂugers Arch. 466: 155-72
[PMID:24193407]
Bröer S et al. (2011) The role of amino acid transporters in inherited and acquired diseases. Biochem.
J. 436: 193-211 [PMID:21568940]
Hägglund MG et al. (2011) Identiﬁcation of SLC38A7 (SNAT7) protein as a glutamine transporter
expressed in neurons. J. Biol. Chem. 286: 20500-11 [PMID:21511949]
Schiöth HB et al. (2013) Evolutionary origin of amino acid transporter families SLC32, SLC36 and
SLC38 and physiological, pathological and therapeutic aspects. Mol. Aspects Med. 34: 571-85
[PMID:23506890]
SLC39 family of metal ion transporters
Transporters → SLC superfamily of solute carriers → SLC39 family of metal ion transporters
Overview: Along with the SLC30 family, SLC39 family members regulate zinc movement in cells. SLC39 metal ion transporters accumulate zinc into the cytosol. Membrane topology modelling suggests
the presence of eight TM regions with both termini extracellular or in the lumen of intracellular organelles. The mechanism for zinc transport for many members is unknown but appears to involve
co-transport of bicarbonate ions [240, 407].
Nomenclature Zinc transporter 8 Zinc transporter 14
Systematic nomenclature SLC39A8 SLC39A14
Common abbreviation ZIP8 ZIP14
HGNC, UniProt SLC39A8, Q9C0K1 SLC39A14, Q15043
Substrates Cd2+ [132, 407] Cd2+ [240], Mn2+ [240], Fe2+ [408]
Stoichiometry 1 Zn2+ (in) : 2 HCO3- (in) [407] –
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Comments: Zinc ﬂuxes may be monitored through the use of radioisotopic Zn-65 or the ﬂuorescent dye FluoZin 3.
The bicarbonate transport inhibitor DIDS has been reported to inhibit cation accumulation through ZIP14 [240].
Further reading on SLC39 family of metal ion transporters
Hojyo S et al. (2016) Zinc transporters and signaling in physiology and pathogenesis. Arch. Biochem.
Biophys. 611: 43-50 [PMID:27394923]
Jeong J et al. (2013) The SLC39 family of zinc transporters. Mol. Aspects Med. 34: 612-9
[PMID:23506894]
Kambe T et al. (2014) Current understanding of ZIP and ZnT zinc transporters in human health and
diseases. Cell. Mol. Life Sci. 71: 3281-95 [PMID:24710731]
Kambe T et al. (2015) The Physiological, Biochemical, and Molecular Roles of Zinc Transporters in
Zinc Homeostasis and Metabolism. Physiol. Rev. 95: 749-784 [PMID:26084690]
Marger L et al. (2014) Zinc: an underappreciated modulatory factor of brain function. Biochem.
Pharmacol. 91: 426-35 [PMID:25130547]
SLC40 iron transporter
Transporters → SLC superfamily of solute carriers → SLC40 iron transporter
Overview: Alongside the SLC11 family of proton-coupled metal
transporters, ferroportin allows the accumulation of iron from the
diet. Whilst SLC11A2 functions on the apical membrane, ferro-
portin acts on the basolateral side of the enterocyte, as well as
regulating macrophage and placental iron levels. The predicted
topology is of 12 TM domains, with intracellular termini [527],
with the functional transporter potentially a dimeric arrangement
[4, 140]. Ferroportin is essential for iron homeostasis [160]. Ferro-
portin is expressed on the surface of cells that store and transport
iron, such as duodenal enterocytes, hepatocytes, adipocytes and
reticuloendothelial macrophages. Levels of ferroportin are regu-
lated by its association with (binding to) hepcidin, a 25 amino
acid hormone responsive to circulating iron levels (amongst other
signals). Hepcidin binding targets ferroportin for internalisation
and degradation, lowering the levels of iron export to the blood.
Novel therapeutic agents which stabilise ferroportin or protect it
from hepcidin-induced degradation are being developed as anti-
anemia agents. Anti-ferroportin monoclonal antibodies are such
an agent.
Nomenclature Ferroportin
Systematic nomenclature SLC40A1
Common abbreviation IREG1
HGNC, UniProt SLC40A1, Q9NP59
Endogenous substrates Fe2+
Stoichiometry Unknown
Antibodies LY2928057 (Binding) [395]
Comments: Hepcidin (HAMP, P81172), cleaved into hepcidin-25 (HAMP, P81172) and hepcidin-20 (HAMP, P81172), is a small protein that increases upon inﬂammation, binds to ferroportin to regulate
its cellular distribution and degradation. Gene disruption in mice results in embryonic lethality [160], while loss-of-function mutations in man are associated with haemochromatosis [141].
Searchable database: http://www.guidetopharmacology.org/index.jsp SLC40 iron transporter S471
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14753/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology (2019) 176, S397–S493
Further reading on SLC40 iron transporter
McKie AT et al. (2004) The SLC40 basolateral iron transporter family (IREG1/ferroportin/MTP1).
Pﬂugers Arch. 447: 801-6 [PMID:12836025]
Montalbetti N et al. (2013) Mammalian iron transporters: families SLC11 and SLC40. Mol. Aspects
Med. 34: 270-87 [PMID:23506870]
SLC41 family of divalent cation transporters
Transporters → SLC superfamily of solute carriers → SLC41 family of divalent cation transporters
Overview: By analogy with bacterial orthologues, this family is probably magnesium transporters. The prokaryote orthologue, MgtE, is responsible for uptake of divalent cations, while the heterologous
expression studies of mammalian proteins suggest Mg2+ efﬂux [369], possibly as a result of co-expression of particular protein partners (see [543]). Topological modelling suggests 10 TM domains with
cytoplasmic C- and N- termini.
Nomenclature Solute carrier family 41 member 1 Solute carrier family 41 member 2
Systematic nomenclature SLC41A1 SLC41A2
Common abbreviation MgtE –
HGNC, UniProt SLC41A1, Q8IVJ1 SLC41A2, Q96JW4
Substrates Co2+ [252], Cu2+ [252], Ba2+ [252], Cd2+ [252], Zn2+ [252], Mg2+ [252], Sr2+ [252], Fe2+ [252] Ba2+ [253], Mg2+ [253], Co2+ [253], Ni2+ [253], Mn2+ [253], Fe2+ [253]
Stoichiometry Unknown Unknown
Further reading on SLC41 family of divalent cation transporters
Payandeh J et al. (2013) The structure and regulation of magnesium selective ion channels. Biochim.
Biophys. Acta 1828: 2778-92 [PMID:23954807]
Sahni J et al. (2013) The SLC41 family of MgtE-like magnesium transporters. Mol. Aspects Med. 34:
620-8 [PMID:23506895]
Schweigel-Röntgen M et al. (2014) SLC41 transporters–molecular identiﬁcation and functional role.
Curr Top Membr 73: 383-410 [PMID:24745990]
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SLC42 family of Rhesus glycoprotein ammonium transporters
Transporters → SLC superfamily of solute carriers → SLC42 family of Rhesus glycoprotein ammonium transporters
Overview: Rhesus is commonly deﬁned as a ‘factor’ that de-
termines, in part, blood type, and whether neonates suffer from
haemolytic disease of the newborn. These glycoprotein antigens
derive from two genes, RHCE (P18577) and RHD (Q02161), ex-
pressed on the surface of erythrocytes. On erythrocytes, RhAG
associates with these antigens and functions as an ammonium
transporter. RhBG and RhBG are non-erythroid related sequences
associated with epithelia. Topological modelling suggests the pres-
ence of 12TM with cytoplasmic N- and C- termini. The majority
of information on these transporters derives from orthologues in
yeast, plants and bacteria. More recent evidence points to family
members being permeable to carbon dioxide, leading to the term
gas channels.
Nomenclature Ammonium transporter Rh type A Ammonium transporter Rh type B Ammonium transporter Rh type C
Systematic nomenclature SLC42A1 SLC42A2 SLC42A3
Common abbreviation RhAG RhBG RhCG
HGNC, UniProt RHAG, Q02094 RHBG, Q9H310 RHCG, Q9UBD6
Substrates NH4+ [665], NH3 [528], CO2 [179] – NH3 [721]
Stoichiometry Unknown Unknown Unknown
Labelled ligands [14C]methylamine (Binding) [286] – [14C]methylamine (Binding) [423] – Mouse
Further reading on SLC42 family of Rhesus glycoprotein ammonium transporters
Nakhoul NL et al. (2013) Characteristics of mammalian Rh glycoproteins (SLC42 transporters) and
their role in acid-base transport. Mol. Aspects Med. 34: 629-37 [PMID:23506896]
Weiner ID et al. (2011) Role of NH3 and NH4+ transporters in renal acid-base transport. Am. J.
Physiol. Renal Physiol. 300: F11-23 [PMID:21048022]
Weiner ID et al. (2014) Ammonia transport in the kidney by Rhesus glycoproteins. Am. J. Physiol.
Renal Physiol. 306: F1107-20 [PMID:24647713]
SLC43 family of large neutral amino acid transporters
Transporters → SLC superfamily of solute carriers → SLC43 family of large neutral amino acid transporters
Overview: LAT3 (SLC43A1) and LAT4 (SLC43A2) are transporters
with system L amino acid transporter activity, along with the
structurally and functionally distinct transporters LAT1 and LAT2
that are members of the SLC7 family. LAT3 and LAT4 contain 12
put.ative TM domains with both N and C termini located intra-
cellularly. They transport neutral amino acids in a manner inde-
pendent of Na+ and Cl- and with two kinetic components [33,
64]. LAT3/SLC43A1 is expressed in human tissues at high levels
in the pancreas, liver, skeletal muscle and fetal liver [33] whereas
LAT4/SLC43A2 is primarily expressed in the placenta, kidney and
peripheral blood leukocytes [64]. SLC43A3 is expressed in vascular
endothelial cells [651] but remains to be characterised.
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Nomenclature L-type amino acid transporter 3 L-type amino acid transporter 4
Systematic nomenclature SLC43A1 SLC43A2
Common abbreviation LAT3 LAT4
HGNC, UniProt SLC43A1, O75387 SLC43A2, Q8N370
Substrates L-isoleucine [33], L-valinol [33], L-leucinol [33], L-phenylalaninol [33], L-leucine [33],
L-phenylalanine [33], L-valine [33], L-methionine [33]
L-isoleucine, L-valinol, L-leucinol, L-leucine, L-phenylalanine, L-valine, L-methionine
Stoichiometry Operates by facilitative diffusion Operates by facilitative diffusion
Comments: Covalent modiﬁcation of LAT3 by N-ethylmaleimide inhibits its function [33] and at LAT4 inhibits the low-, but not high-afﬁnity component of transport [64].
Further reading on SLC43 family of large neutral amino acid transporters
Bodoy S et al. (2013) The small SLC43 family: facilitator system l amino acid transporters and the
orphan EEG1. Mol. Aspects Med. 34: 638-45 [PMID:23268354]
SLC44 choline transporter-like family
Transporters → SLC superfamily of solute carriers → SLC44 choline transporter-like family
Overview: Members of the choline transporter-like family are en-
coded by ﬁve genes (CTL1-CTL5) with further diversity occurring
through alternative splicing of CTL1, 4 and 5 [622]. CTL fam-
ily members are putative 10TM domain proteins with extracel-
lular termini that mediate Na+-independent transport of choline
with an afﬁnity that is intermediate to that of the high afﬁnity
choline transporter CHT1 (SLC5A7) and the low afﬁnity organic-
cation transporters [OCT1 (SLC22A1) andOCT2 (SLC22A2)] [438].
CLT1 is expressed almost ubiquitously in human tissues [669] and
mediates choline transport across the plasma and mitochondrial
membranes [437]. Transport of choline by CTL2, which in rodents
is expressed as two isoforms (CTL2P1 and CLTP2; [370]) in lung,
colon, inner ear and spleen and to a lesser extent in brain, tongue,
liver, and kidney, has only recently been demonstrated [370, 458].
CTL3-5 remain to be characterized functionally.
Nomenclature Choline transporter-like 1
Systematic nomenclature SLC44A1
Common abbreviation CTL1
HGNC, UniProt SLC44A1, Q8WWI5
Substrates choline
Stoichiometry Unknown: uptake enhanced in the absence of extracellular Na+, reduced by membrane depolarization, extracellular acidiﬁcation and collapse of plasma membrane H+ electrochemical
gradient
Inhibitors hemicholinium-3 (pKi 3.5–4.5)
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Comments: Data tabulated are features observed for CLT1 endogenous to: rat astrocytes [308]; rat renal tubule epithelial cells [683]; human colon carcinoma cells [373]; human keratinocytes [630] and
human neuroblastoma cells [684]. Choline uptake by CLT1 is inhibited by numerous organic cations (e.g. [308, 683, 684]). In the guinea-pig, CTL2 is a target for antibody-induced hearing loss [454] and
in man, a polymorphism in CTL2 constitutes the human neutrophil alloantigen-3a (HNA-3a; [256]).
Further reading on SLC44 choline transporter-like family
Inazu M. (2014) Choline transporter-like proteins CTLs/SLC44 family as a novel molecular target for
cancer therapy. Biopharm Drug Dispos 35: 431-49 [PMID:24532461]
Traiffort E et al. (2013) The choline transporter-like family SLC44: properties and roles in human
diseases. Mol. Aspects Med. 34: 646-54 [PMID:23506897]
SLC45 family of putative sugar transporters
Transporters → SLC superfamily of solute carriers → SLC45 family of putative sugar transporters
Overview: Members of the SLC45 family remain to be fully characterised. SLC45A1 was initially identiﬁed in the rat brain, particularly predominant in the hindbrain, as a proton-associated sugar
transport, induced by hypercapnia [574]. The protein is predicted to have 12TM domains, with intracellular termini. The SLC45A2 gene is thought to encode a transporter protein that mediates melanin
synthesis. Mutations in SLC45A2 are a cause of oculocutaneous albinism type 4 (e.g. [463]), and polymorphisms in this gene are associated with variations in skin and hair color (e.g. [254]).
Nomenclature Proton-associated sugar transporter A
Systematic nomenclature SLC45A1
HGNC, UniProt SLC45A1, Q9Y2W3
Substrates L-glucose [574], Galactose [574]
Stoichiometry Unknown; increased at acid pH [574].
Further reading on SLC45 family of putative sugar transporters
Bartölke R et al. (2014) Proton-associated sucrose transport of mammalian solute carrier family 45:
an analysis in Saccharomyces cerevisiae. Biochem. J. 464: 193-201 [PMID:25164149]
Vitavska O et al. (2013) The SLC45 gene family of putative sugar transporters. Mol. Aspects Med. 34:
655-60 [PMID:23506898]
SLC46 family of folate transporters
Transporters → SLC superfamily of solute carriers → SLC46 family of folate transporters
Overview: Based on the proptypical member of this family, PCFT, this family includes proton-driven transporters with 11 TM segments. SLC46A1 has been described to act as an intestinal proton-coupled
high-afﬁnity folic acid transporter [510], with lower afﬁnity for heme. Folic acid accumulation is independent of Na+ or K+ ion concentrations, but driven by extracellular protons with an as yet undeﬁned
stoichiometry.
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Nomenclature Proton-coupled folate transporter
Systematic nomenclature SLC46A1
Common abbreviation PCFT
HGNC, UniProt SLC46A1, Q96NT5
Substrates pemetrexed, N-formyltetrahydrofolate, methotrexate [510] folic acid (1.3μM) > heme (>100 μM) [455]
Endogenous substrates N5-methyltetrafolate [510]
Labelled ligands [3H]N5-methylfolate (Binding), [3H]folic acid, [3H]folinic acid (Binding), [3H]methotrexate, [3H]pemetrexed (Binding)
Comments Loss-of-function mutations in PCFT (SLC46A1) are the molecular basis for hereditary folate maladsorption [552].
Further reading on SLC46 family of folate transporters
Hou Z et al. (2014) Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. Curr
Top Membr 73: 175-204 [PMID:24745983]
Matherly LH et al. (2014) The major facilitative folate transporters solute carrier 19A1 and solute
carrier 46A1: biology and role in antifolate chemotherapy of cancer. Drug Metab. Dispos. 42:
632-49 [PMID:24396145]
Wilson MR et al. (2015) Structural determinants of human proton-coupled folate transporter
oligomerization: role of GXXXG motifs and identiﬁcation of oligomeric interfaces at transmem-
brane domains 3 and 6. Biochem. J. 469: 33-44 [PMID:25877470]
Zhao R et al. (2011) Mechanisms of membrane transport of folates into cells and across epithelia.
Annu. Rev. Nutr. 31: 177-201 [PMID:21568705]
Zhao R et al. (2013) Folate and thiamine transporters mediated by facilitative carriers (SLC19A1-3
and SLC46A1) and folate receptors. Mol. Aspects Med. 34: 373-85 [PMID:23506878]
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SLC47 family of multidrug and toxin extrusion transporters
Transporters → SLC superfamily of solute carriers → SLC47 family of multidrug and toxin extrusion transporters
Overview: These proton:organic cation exchangers are predicted to have 13 TM segments [709] and are suggested to be responsible for excretion of many drugs in the liver and kidneys.
Nomenclature Multidrug and toxin extrusion MATE2
Systematic nomenclature SLC47A1 SLC47A2
Common abbreviation MATE1 MATE2-K
HGNC, UniProt SLC47A1, Q96FL8 SLC47A2, Q86VL8
Substrates quinidine [607], cephradine [607], metformin (Km 7.8×10−4M) [607], cephalexin
[607], cimetidine (Km 1.7×10−4M) [477, 607], paraquat [108]
guanidine [607], procainamide [428], metformin (Km 1.9×10−3M) [428, 607], aciclovir
[607], MPP+ [428], cimetidine (Km 1.2×10−4M) [428, 607], N1-methylnicotinamide
[428]
Endogenous substrates thiamine [607], creatine [607] creatine [607], thiamine [607]
Sub/family-selective inhibitors pyrimethamine (pKi 7.1) [320], cimetidine (pKi 6) [627] pyrimethamine (pKi 6.3) [320] – Mouse, cimetidine (pKi 5.1) [627]
Labelled ligands [14C]TEA [482, 611], [14C]metformin [607, 611] [14C]TEA [607], [14C]metformin [607]
Comments: DAPI has been used to allow quantiﬁcation of MATE1 and MATE2-mediated transport activity [693]. MATE2 and MATE2-B are inactive splice variants of MATE2-K [428].
Further reading on SLC47 family of multidrug and toxin extrusion transporters
Damme K et al. (2011) Mammalian MATE (SLC47A) transport proteins: impact on efﬂux of endoge-
nous substrates and xenobiotics. Drug Metab. Rev. 43: 499-523 [PMID:21923552]
Motohashi H et al. (2013) Multidrug and toxin extrusion family SLC47: physiological, pharma-
cokinetic and toxicokinetic importance of MATE1 and MATE2-K. Mol. Aspects Med. 34: 661-8
[PMID:23506899]
Nies AT et al. (2016) Structure and function of multidrug and toxin extrusion proteins (MATEs)
and their relevance to drug therapy and personalized medicine. Arch. Toxicol. 90: 1555-84
[PMID:27165417]
Wagner DJ et al. (2016) Polyspeciﬁc organic cation transporters and their impact on drug intracellular
levels and pharmacodynamics. Pharmacol. Res. 111: 237-246 [PMID:27317943]
Yonezawa A et al. (2011) Importance of the multidrug and toxin extrusion MATE/SLC47A family to
pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. Br. J. Pharma-
col. 164: 1817-25 [PMID:21457222]
SLC48 heme transporter
Transporters → SLC superfamily of solute carriers → SLC48 heme transporter
Overview: HRG1 has been identiﬁed as a cell surface and lysosomal heme transporter [517]. In addition, evidence suggests this 4TM-containing protein associates with the V-ATPase in lysosomes [474].
Recent studies conﬁrm its lysosomal location and demonstrate that it has an important physiological function in macrophages ingesting senescent red blood cells (erythrophagocytosis), recycling heme
(released from the red cell hemoglobin) from the phagolysosome into the cytosol, where the heme is subsequently catabolized to recycle the iron [666].
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Nomenclature Heme transporter
Systematic nomenclature SLC48A1
Common abbreviation HRG1
HGNC, UniProt SLC48A1, Q6P1K1
Further reading on SLC48 heme transporter
Khan AA et al. (2013) Heme and FLVCR-related transporter families SLC48 and SLC49. Mol. Aspects
Med. 34: 669-82 [PMID:23506900]
SLC49 family of FLVCR-related heme transporters
Transporters → SLC superfamily of solute carriers → SLC49 family of FLVCR-related heme transporters
Overview: FLVCR1 was initially identiﬁed as a cell-surface at-
tachment site for feline leukemia virus subgroup C [601], and
later identiﬁed as a cell surface accumulation which exports heme
from the cytosol [513]. A recent study indicates that an isoform of
FLVCR1 is located in the mitochondria, the site of the ﬁnal steps
of heme synthesis, and appears to transport heme into the cytosol
[113]. FLVCR-mediated heme transport is essential for erythro-
poiesis. Flvcr1 gene mutations have been identiﬁed as the cause
of PCARP (posterior column ataxia with retinitis pigmentosa
(PCARP) [516].There are three paralogs of FLVCR1 in the human
genome.
FLVCR2, most similar to FLVCR1 [403], has been reported to func-
tion as a heme importer [163]. In addition, a congenital syndrome
of proliferative vasculopathy and hydranencephaly, also known as
Fowler’s syndrome, is associated with a loss-of-function mutation
in FLVCR2 [435].
The functions of the other two members of the SLC49 family,
MFSD7 and DIRC2, are unknown, although DIRC2 has been im-
plicated in hereditary renal carcinomas [63].
Nomenclature Feline leukemia virus subgroup C cellular receptor family, member 1 Feline leukemia virus subgroup C cellular receptor family, member 2
Systematic nomenclature SLC49A1 SLC49A2
Common abbreviation FLVCR1 FLVCR2
HGNC, UniProt FLVCR1, Q9Y5Y0 FLVCR2, Q9UPI3
Substrates heme [513] heme [163]
Stoichiometry Unknown Unknown
Comments: Non-functional splice alternatives of FLVCR1 have been implicated as a cause of a congenital red cell aplasia, Diamond Blackfan anemia [525].
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Further reading on SLC49 family of FLVCR-related heme transporters
Khan AA et al. (2013) Heme and FLVCR-related transporter families SLC48 and SLC49. Mol. Aspects
Med. 34: 669-82 [PMID:23506900]
Khan AA et al. (2011) Control of intracellular heme levels: heme transporters and heme oxygenases.
Biochim. Biophys. Acta 1813: 668-82 [PMID:21238504]
SLC50 sugar transporter
Transporters → SLC superfamily of solute carriers → SLC50 sugar transporter
Overview: A mouse stromal cell cDNA library was used to clone C2.3 [598], later termed Rag1-activating protein 1, with a sequence homology predictive of a 4TM topology. The plant orthologues,
termed SWEETs, appear to be 7 TM proteins, with extracellular N-termini, and the capacity for bidirectional ﬂux of D-glucose [105]. Expression of mouse SWEET in the mammary gland was suggestive of
a role in Golgi lactose synthesis [105].
Nomenclature SLC50 sugar exporter
Systematic nomenclature SLC50A1
Common abbreviation RAG1AP1
HGNC, UniProt SLC50A1, Q9BRV3
Further reading on SLC50 sugar transporter
Wright EM. (2013) Glucose transport families SLC5 and SLC50. Mol. Aspects Med. 34: 183-96
[PMID:23506865]
Wright EM et al. (2011) Biology of human sodium glucose transporters. Physiol. Rev. 91: 733-94
[PMID:21527736]
SLC51 family of steroid-derived molecule transporters
Transporters → SLC superfamily of solute carriers → SLC51 family of steroid-derived molecule transporters
Overview: The SLC51 organic solute transporter family of trans-
porters is a pair of heterodimeric proteins which regulate bile
salt movements in the small intestine, bile duct, and liver, as
part of the enterohepatic circulation [41, 137]. OSTα/OSTβ is
also expressed in steroidogenic cells of the brain and adrenal
gland, where it may contribute to steroid movement [193].
Bile acid transport is suggested to be facilitative and inde-
pendent of sodium, potassium, chloride ions or protons [41,
137]. OSTα/OSTβ heterodimers have been shown to trans-
port [3H]taurocholic acid, [3H]dehydroepiandrosterone sulphate,
[3H]estrone-3-sulphate, [3H]pregnenolone sulphate and
[3H]dehydroepiandrosterone sulphate [41, 137, 193].
OSTα/OSTβ-mediated transport of bile salts is inhibited by
clofazimine [635]. OSTα is suggested to be a seven TM pro-
tein, while OSTβ is a single TM ’ancillary’ protein, both of which
are thought to have intracellular C-termini [400]. Both pro-
teins function in solute transport and bimolecular ﬂuorescence
complementation studies suggest the possibility of OSTα homo-
oligomers, as well as OSTα/OSTβ hetero-oligomers [117, 400]. An
inherited mutation in OSTβ is associated with congenital diarrhea
in children [591].
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Nomenclature Organic solute transporter subunit α Organic solute transporter subunit β
Systematic nomenclature SLC51A1 SLC51B
Common abbreviation OSTα OSTβ
HGNC, UniProt SLC51A, Q86UW1 SLC51B, Q86UW2
Further reading on SLC51 family of steroid-derived molecule transporters
Ballatori N. (2011) Pleiotropic functions of the organic solute transporter Ostα-Ostβ. Dig Dis 29: 13-7
[PMID:21691099]
Ballatori N et al. (2013) The heteromeric organic solute transporter, OSTα-OSTβ/SLC51: a transporter
for steroid-derived molecules. Mol. Aspects Med. 34: 683-92 [PMID:23506901]
Dawson PA. (2011) Role of the intestinal bile acid transporters in bile acid and drug disposition.
Handb Exp Pharmacol 169-203 [PMID:21103970]
SLC52 family of riboﬂavin transporters
Transporters → SLC superfamily of solute carriers → SLC52 family of riboﬂavin transporters
Overview: Riboﬂavin, also known as vitamin B2, is a precursor of the enzyme cofactors ﬂavin mononucleotide (FMN) and ﬂavin adenine dinucleotide (FAD). Riboﬂavin transporters are predicted to
possess 10 or 11 TM segments.
Nomenclature solute carrier family 52 member 1 solute carrier family 52 member 2 solute carrier family 52 member 3
Systematic nomenclature SLC52A1 SLC52A2 SLC52A3
Common abbreviation RFVT1 RFVT2 RFVT3
HGNC, UniProt SLC52A1, Q9NWF4 SLC52A2, Q9HAB3 SLC52A3, Q9NQ40
Endogenous substrates riboﬂavin (Km 1.3×10−3M) [692] riboﬂavin (Km 9.8×10−4M) [692] riboﬂavin (Km 3.3×10−4M) [692]
Stoichiometry Unknown Unknown H+-dependent
Comments: Although expressed elsewhere, RFVT3 is found on the luminal surface of intestinal epithelium and is thought to mediate uptake of dietary riboﬂavin, while RFVT1 and RFVT2 are thought
to allow movement from the epithelium into the blood.
Further reading on SLC52 family of riboﬂavin transporters
Yonezawa A et al. (2013) Novel riboﬂavin transporter family RFVT/SLC52: identiﬁcation, nomen-
clature, functional characterization and genetic diseases of RFVT/SLC52. Mol. Aspects Med. 34:
693-701 [PMID:23506902]
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SLC53 Phosphate carriers
Transporters → SLC superfamily of solute carriers → SLC53 Phosphate carriers
Nomenclature xenotropic and polytropic retrovirus receptor 1
Systematic nomenclature SLC53A1
HGNC, UniProt XPR1, Q9UBH6
Substrates Phosphate [239]
Comments XPR1/SLC53A1 is a phosphate carrier which appears to play a role in bone and tooth mineralization. It is ubiquitously expressed [44, 600]. The pathological consequences of defective
SLC53A1 expression in the brain [393] and kidney [20] have been reported.
SLC54 Mitochondrial pyruvate carriers
Transporters → SLC superfamily of solute carriers → SLC54 Mitochondrial pyruvate carriers
Nomenclature mitochondrial pyruvate carrier 1 mitochondrial pyruvate carrier 2 mitochondrial pyruvate carrier 1 like
Systematic nomenclature SLC54A1 SLC54A2 SLC54A3
HGNC, UniProt MPC1, Q9Y5U8 MPC2, O95563 MPC1L, P0DKB6
Substrates Pyruvate [73, 289] Pyruvate [73] Pyruvate [642]
Comments SLC54A1 is ubiquitously expressed [642]. SLC54A2 is ubiquitously expressed [642]. SLC54A3 is expressed in testis, postmeiotic spermatids and
sperm cells [642].
Comments: SLC54 family transporters appear to function as mechanisms for accumulating pyruvate into mitochondria to link glycolysis with oxidative phosphorylation.
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SLC55 Mitochondrial cation/proton exchangers
Transporters → SLC superfamily of solute carriers → SLC55 Mitochondrial cation/proton exchangers
Nomenclature leucine zipper and EF-hand containing transmembrane
protein 1
leucine zipper and EF-hand containing transmembrane
protein 2
LETM1 domain containing 1
Systematic nomenclature SLC55A1 SLC55A2 SLC55A3
HGNC, UniProt LETM1, O95202 LETM2, Q2VYF4 LETMD1, Q6P1Q0
Transport type Exchanger / Ca2+:H+ [328, 569]
Exchanger / K+:H+ [154, 468]
– –
Substrates Ca2+, K+, H+ [154, 468, 469, 725] – –
Comments SLC55A1 is ubiquitously expressed [178]. Arguments
against SLC55A1’s role as a Ca2+ transporter are outlined
by Zotova et al. (2010) [725].
– –
Comments: The family of SLC55 mitochondrial transporters appear to regulate ion ﬂuxes and to maintain tubular networks.
SLC56 Sideroﬂexins
Transporters → SLC superfamily of solute carriers → SLC56 Sideroﬂexins
Nomenclature sideroﬂexin 1 sideroﬂexin 2 sideroﬂexin 3 sideroﬂexin 4 sideroﬂexin 5
Systematic nomenclature SLC56A1 SLC56A2 SLC56A3 SLC56A4 SLC56A5
HGNC, UniProt SFXN1, Q9H9B4 SFXN2, Q96NB2 SFXN3, Q9BWM7 – SFXN5, Q8TD22
Comments Sideroﬂexin 1 (SFXN1/SLC56A1) was probably
falsely identiﬁed as a tricarboxylate carrier in the
1993 article by Azzi et al. [32], as discussed several
years later in [205]. SFXN1 likely transports
pyridoxin or another heme precursor or the
5’-aminolevulinate synthase 2 (ALAS2; P22557)
cofactor [205, 694]. SFXN1 has recently been
suggested to be a mitochondrial serine transporter
[371]. It is mainly expressed in adult kidney and
liver (mouse) [205].
In mice sideroﬂexin 2
expression is mainly detected
in adult kidney and liver [205].
In human tissues it is detected
at highest levels in kidney, liver
and pancreas [694].
Sideroﬂexin 3 is ubiquitously
expressed in mouse tissues
[205].
Sideroﬂexin 4 is expressed in
mouse kidney, brain and heart
[205]. The SFXN4a isoform is
most highly expressed in
human kidney and pancreas,
and the SFXN4b isoform is
barely detectable in brain
[713].
Sideroﬂexin 5 is expressed in
mouse brain and liver [205].
Comments: These are a family of incompletely-characterised mitochondrial transporters.
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SLC57 NiPA-like magnesium transporter family
Transporters → SLC superfamily of solute carriers → SLC57 NiPA-like magnesium transporter family
Nomenclature NIPA magnesium transporter 1 NIPA magnesium transporter 2 NIPA like domain containing 1 NIPA like domain containing 3
Systematic nomenclature SLC57A1 SLC57A2 SLC57A3 SLC57A5
HGNC, UniProt NIPA1, Q7RTP0 NIPA2, Q8N8Q9 NIPAL1, Q6NVV3 NIPAL3, Q6P499
Substrates Sr2+, Fe2+ and Co2+ to a lesser extent [250],
Mg2+ [249]
Mg2+ [250] Mg2+, Sr2+, Ba2+, Fe2+, Cu2+ [250] –
Comments Human tissue expression: Constitutively
expressed at low levels, with signiﬁcant
enrichment in the brain [515].
Mouse tissue expression: Widely expressed,
including in the heart, kidney, liver, colon,
less in the brain, and not in the small
intestine [249].
– – –
SLC58 MagT-like magnesium transporter family
Transporters → SLC superfamily of solute carriers → SLC58 MagT-like magnesium transporter family
Nomenclature magnesium transporter 1 tumor suppressor candidate 3
Systematic nomenclature SLC58A1 SLC58A2
HGNC, UniProt MAGT1, Q9H0U3 TUSC3, Q13454
Transport type Channel-like [511] –
Substrates Mg2+ [251] Mg2+, Fe2+, Cu2+, Mn2+ [250, 511]
Comments Expressed in kidney, colon, heart and liver (the latter only at the mRNA level) [251];
universally expressed [714].
Expressed in placenta, pancreas, testis, ovary, heart, and prostate [418].
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SLC59 Sodium-dependent lysophosphatidylcholine symporter family
Transporters → SLC superfamily of solute carriers → SLC59 Sodium-dependent lysophosphatidylcholine symporter family
Nomenclature major facilitator superfamily domain containing 2A major facilitator superfamily domain containing 2B
Systematic nomenclature SLC59A1 SLC59A2
HGNC, UniProt MFSD2A, Q8NA29 MFSD2B, A6NFX1
Transport type Co-transporter: LPC:Na+, uptake –
Substrates LPC (lysophosphatidylcholine) form of DHA (docosahexaenoic acid) [464] –
Comments MFSD2B/SLC59A has been suggested to be a sphingosine 1-phosphate transporter in
erythropoietic cells [364]. It is expressed in brain, intestine, kidney, liver, lung, mammary
gland, and prostate [19]; relatively low expression in BAT (brown adipose tissue), but
upregulated during cold-induced thermogenesis [19]. Subcellular locations: plasma
membrane [656] and ER [19].
Expressed in the spleen, lung, testis and subcellularly in the ER [19].
SLC60 Glucose transporters
Transporters → SLC superfamily of solute carriers → SLC60 Glucose transporters
Nomenclature major facilitator superfamily domain containing 4A major facilitator superfamily domain containing 4B
Systematic nomenclature SLC60A1 SLC60A2
HGNC, UniProt MFSD4A, Q8N468 MFSD4B, Q5TF39
Transport type – Co-transporter / Na+ (1:1) uptake (Rat) [295]
Substrates – α-Me-glucose, D-glucose [295]
Inhibitors – phloretin [295] – Rat, phlorizin [295] – Rat, urea [460] – Rat
Comments – Expressed in rat kidney (cortex and medulla), brain, liver and lung [295].
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SLC61 Molybdate transporter family
Transporters → SLC superfamily of solute carriers → SLC61 Molybdate transporter family
Nomenclature major facilitator superfamily domain containing 5
Systematic nomenclature SLC61A1
HGNC, UniProt MFSD5, Q6N075
Substrates molybdate [610]
Comments MFSD5/SLC61 is a putative 12TM cell-surface protein which appears to allow the accumulation of molybdate, and where the neural expression appears to respond to changes in the
diet. It is expressed in cervix, stomach, nerve and skin [610]; ubiquitous but higher in skeletal muscle, olfactory bulb [212]; blood, cortex, hypothalamus, cerebellum and spinal cord
(mouse) [494].
SLC62 Pyrophosphate transporters
Transporters → SLC superfamily of solute carriers → SLC62 Pyrophosphate transporters
Nomenclature ANKH inorganic pyrophosphate transport regulator
Systematic nomenclature SLC62A1
HGNC, UniProt ANKH, Q9HCJ1
Substrates Pyrophosphate [292]
Comments ANKH/SLC62 is a putative 8TM membrane protein, also known as progressive ankylosis protein homolog. Mutations in this protein are associated with bone and joint abnormalities. It
is expressed in kidney and bone [92].
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SLC63 Sphingosine-phosphate transporters
Transporters → SLC superfamily of solute carriers → SLC63 Sphingosine-phosphate transporters
Overview: The SLC63 family of transporters has roles inside the cell (SLC63A1/SPNS1) or on the cell surface (SLC63A2/SPNS2) in sphingolipid transport.
Nomenclature sphingolipid transporter 1 (putative)
Systematic nomenclature SLC63A1
HGNC, UniProt SPNS1, Q9H2V7
Comments Expressed in mitochondria [690].
SLC64 Golgi Ca2+/H+ exchangers
Transporters → SLC superfamily of solute carriers → SLC64 Golgi Ca2+/H+ exchangers
Nomenclature transmembrane protein 165
Systematic nomenclature SLC64A1
HGNC, UniProt TMEM165, Q9HC07
Transport type Exchanger/ Ca2+:H+
Substrates Mn2+ [503, 504], Ca2+, H+ [144]
Comments TMEM165/SLC64 is a putative 6TM intracellular membrane protein. Mutations in the protein are associated with congenital disorder of glycosylation. It has been suggested to be
essential for milk production in the mammary gland [582]. TMEM165 deﬁciency (via siRNA knockdown) causes Golgi glycosylation defects in transfected HEK cells [211].
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SLC65 NPC-type cholesterol transporters
Transporters → SLC superfamily of solute carriers → SLC65 NPC-type cholesterol transporters
Overview: The SLC65 family of intracellular cholesterol transporters are 13TM membrane proteins. NPC1/SLC65A1 is an intracellular cholesterol transporter, which together with NPC2 (Uniprot ID
P61916), allows the accumulation into the cytosol of cholesterol acquired from low density lipoproteins.
Nomenclature NPC intracellular cholesterol transporter 1 NPC1 like intracellular cholesterol transporter 1
Systematic nomenclature SLC65A1 SLC65A2
HGNC, UniProt NPC1, O15118 NPC1L1, Q9UHC9
Substrates Cholesterol [309, 310, 496] Cholesterol [10]
Selective antagonists – ezetimibe (Inhibition) (pKd 6.7) [227]
Comments Expression is ubiquitous [10], with highest levels detected in liver, lung, and pancreas
[136]. NPC1 plays a critical role in the regulation of intracellular cholesterol trafﬁcking
[93]. Mutations in the NPC1 gene have been identiﬁed in patients with the lipid storage
disorder Niemann-Pick disease type C1 [62, 93, 255, 686].
Expressed in small intestine, gallbladder, liver, testis and stomach [10].
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SLCO family of organic anion transporting polypeptides
Transporters → SLC superfamily of solute carriers → SLCO family of organic anion transporting polypeptides
Overview: The SLCO superfamily is comprised of the organic an-
ion transporting polypeptides (OATPs). The 11 human OATPs are
divided into 6 families and ten subfamilies based on amino acid
identity. These proteins are located on the plasma membrane of
cells throughout the body. They have 12 TM domains and intra-
cellular termini, with multiple putative glycosylation sites. OATPs
mediate the sodium-independent uptake of a wide range of am-
phiphilic substrates, including many drugs and toxins. Due to
themultispeciﬁcity of these proteins, this guide lists classes of sub-
strates and inhibitors for each family member. More comprehen-
sive lists of substrates, inhibitors, and their relative afﬁnities may
be found in the review articles listed below.
Nomenclature OATP1A2 OATP1B1 OATP1B3 OATP1C1
Systematic nomenclature SLCO1A2 SLCO1B1 SLCO1B3 SLCO1C1
HGNC, UniProt SLCO1A2, P46721 SLCO1B1, Q9Y6L6 SLCO1B3, Q9NPD5 SLCO1C1, Q9NYB5
Substrates ﬂuoroquinolones, beta blockers, deltorphin II,
rosuvastatin, fexofenadine, bromsulphthalein,
anticancer drugs, antibiotics, HIV protease inhibitors,
talinolol, ouabain, microcystin-LR [204]
statins, opioids, β-lactam antibiotics, bile
acid derivatives and conjugates,
bromsulphthalein, anticancer drugs, HIV
protease inhibitors, fexofenadine,
antifungals, ACE inhibitors, rifampicin,
endothelin receptor antagonists, sartans
rifampicin, opioids, sartans, statins,
digoxin, anticancer drugs,
bromsulphthalein, bile acid derivatives
and conjugates, β-lactam antibiotics,
ouabain, amanitin, saquinavir,
fexofenadine, erythromycin, phalloidin
statins, bromsulphthalein
Endogenous substrates bile acids, thyroid hormones, steroid conjugates,
bilirubin, PGE2
leukotrienes, steroid conjugates, thyroid
hormones, bile acids, bilirubin
steroid conjugates, thyroid hormones,
bile acids, CCK-8 (CCK, P06307),
bilirubin, LTC4
thyroid hormones, steroid conjugates
Ligands – pravastatin (Binding) – –
Inhibitors rifamycin SV (pKi 5) [646], rifampicin (pKi 4.3) [646],
naringin [36]
cyclosporin A (pKi 7.3) [196, 344],
estrone-3-sulphate (pIC50 7.2) [267],
rifampicin (pKi 6) [344], rifamycin SV
(pKi 5.7) [646], gemﬁbrozil [471],
glycyrrhizin, indocyanine green
cyclosporin A (pIC50 6.1) [344, 623],
sildenaﬁl (pIC50 6.1) [623], rifampicin
(pIC50 5.8) [344, 623], gemﬁbrozil,
glycyrrhizin, rifamycin SV
DPDPE, probenecid, taurocholic acid
Labelled ligands [3H]BSP, [3H]DPDPE, [3H]estrone-3-sulphate [3H]estradiol-17β-glucuronide,
[3H]estrone-3-sulphate
[3H]BSP,
[3H]CCK-8 (human, mouse, rat),
[3H]estradiol-17β-glucuronide
[125I]thyroxine, [3H]BSP,
[3H]estrone-3-sulphate
Comments Although rat and mouse OATP1A4 are considered the
orthologs of human OATP1A2 we do not cross-link to
gene or protein databases for these since in reality
there are ﬁve genes in rodents that arose through gene
duplication in this family and it is not clear which one
of these is the "true" ortholog.
Other inhibitors include, ﬁbrates,
ﬂavonoids, glitazones and macrolide
antibiotics. Estrone-3-sulphate or the
drug substrates atorvastatin, pravastatin
and rosuvastatin are used as a probe.
Other inhibitors include, HIV protease
inhibitors, glitazones and macrolide
antibiotics. CCK-8 is used as an
OATP1B3-selective probe.
–
Searchable database: http://www.guidetopharmacology.org/index.jsp SLCO family of organic anion transporting polypeptides S488
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14753/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology (2019) 176, S397–S493
Nomenclature OATP2A1 OATP2B1 OATP3A1 OATP4A1 OATP4C1
Systematic nomenclature SLCO2A1 SLCO2B1 SLCO3A1 SLCO4A1 SLCO4C1
HGNC, UniProt SLCO2A1, Q92959 SLCO2B1, O94956 SLCO3A1, Q9UIG8 SLCO4A1, Q96BD0 SLCO4C1, Q6ZQN7
Substrates synthetic prostaglandin derivatives amiodarone, bromsulphthalein,
statins, glibenclamide, aliskiren,
fexofenadine, talinolol,
bosentan, telmisartan
– penicillin G dipeptidyl peptidase-4
inhibitors, anticancer drugs,
cardiac glycosides
Endogenous substrates prostaglandins, eicosanoids estrone-3-sulphate,
dehydroepiandrosterone
sulphate, T4
BQ123, vasopressin (AVP,
P01185), thyroid hormones,
prostaglandins
thyroid hormones,
prostaglandins, bile acids,
steroid conjugates
thyroid hormones, cyclic AMP,
steroid conjugates
Inhibitors bromocresol green (Inhibition of PGF2α
uptake in PGT-expressing HeLa cells) (pKi 5.4)
[337] – Rat, bromsulphthalein (Inhibition of
PGF2α uptake in PGT-expressing HeLa cells)
(pKi 5.2) [337] – Rat
erlotinib (pKi 6.3) [344],
verlukast (pKi 5.6) [344],
gemﬁbrozil, glibenclamide,
rifamycin SV, sildenaﬁl [623]
– – –
Labelled ligands [3H]PGE2 (Binding) [98] [3H]BSP, [3H]estrone-3-sulphate [3H]PGE2,
[3H]estrone-3-sulphate
[3H]estrone-3-sulphate [3H]digoxin
Comments Other inhibitors include NSAIDs Other inhibitors include
glitazones and citrus juices
– – –
Further reading on SLCO family of organic anion transporting polypeptides
Hagenbuch B et al. (2013) The SLCO (former SLC21) superfamily of transporters. Mol. Aspects Med.
34: 396-412 [PMID:23506880]
Hillgren KM et al. (2013) Emerging transporters of clinical importance: an update from the Interna-
tional Transporter Consortium. Clin. Pharmacol. Ther. 94: 52-63 [PMID:23588305]
International Transporter Consortium et al. (2010) Membrane transporters in drug development.
Nat Rev Drug Discov 9: 215-36 [PMID:20190787]
Lee HH et al. (2017) Interindividual and interethnic variability in drug disposition: polymorphisms
in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1). Br J Clin Pharmacol 83:
1176-1184 [PMID:27936281]
Roth M et al. (2012) OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO
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